CA1242664A - COVALENTLY ATTACHED COMPLEX OF .alpha.-1-PROTEINASE INHIBITOR WITH A WATER SOLUBLE POLYMER - Google Patents
COVALENTLY ATTACHED COMPLEX OF .alpha.-1-PROTEINASE INHIBITOR WITH A WATER SOLUBLE POLYMERInfo
- Publication number
- CA1242664A CA1242664A CA000465464A CA465464A CA1242664A CA 1242664 A CA1242664 A CA 1242664A CA 000465464 A CA000465464 A CA 000465464A CA 465464 A CA465464 A CA 465464A CA 1242664 A CA1242664 A CA 1242664A
- Authority
- CA
- Canada
- Prior art keywords
- alpha
- proteinase inhibitor
- water soluble
- soluble polymer
- complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0023—Heat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
ABSTRACT OF THE DISCLOSURE
There is disclosed a process for producing a covalently attached alpha-1-proteinase inhibitor - water soluble polymer complex useful for pulmonary emphysema therapy, a covalently attached alpha-1-proteinase inhibitor - water soluble polymer complex produced by the process, a composition thereof in a pharmaceutically acceptable carrier, and a method for treating pulmonary emphysema by administering to a human patient a therapeutically effec-tive amount of the complex or preparation.
There is disclosed a process for producing a covalently attached alpha-1-proteinase inhibitor - water soluble polymer complex useful for pulmonary emphysema therapy, a covalently attached alpha-1-proteinase inhibitor - water soluble polymer complex produced by the process, a composition thereof in a pharmaceutically acceptable carrier, and a method for treating pulmonary emphysema by administering to a human patient a therapeutically effec-tive amount of the complex or preparation.
Description
SPECIFICATION
Background of the Invention Field of the Invention: This invention relates to a 5 chemical agent useful in the treatment of pulmonary emphysema. More particularly, this invention relates to a covalent complex (or conjugate) of a water soluble polymer which may be a polysaccharide or a polyol with human alpha-l-proteinase inhibitor, to a process for producing o the covalent complex (or conjugate) of a polysaccharide or a polyol with alpha-l-proteinase inhibitor, optionally in the presence of catalase enzyme, to a pharmaceutical preparation comprisiny the covalent complex (or conjugate) of a polysaccharide or a polyol with alpha-l-proteinase 15 inhibitor, and to a method for treating pulmonary emphysema comprising administering to a human patient a therapeutically effective amount of the complex (or conjugate) or pharmaceutical preparation according to the invention.
Alpha-l-proteinase inhibitor (abbreviated "alPI") is a glycoprotein having a molecular weight of 53,000 determined by sedimentation equilibrium centrifugation. The glyco-protein consists of a single polypeptide chain to which 25 several oligosaccharide units are covalently bonded. Human alpha-l-proteinase inhibitor has a role in controlling tissue destruction by endogenous serine proteinases. A
genetic deficiency of alpha-l-proteinase inhibitor, which accounts for 90% of the trypsin inhibitory capacity in 30 blood plasma, has been shown to be associated with the premature development of pulmonary emphysema. The degradation of elastin associated with emphysema probably results from a local imbalance of elastolytic enzymes and the naturally occurring tissue and plasma proteinase 3s inhibitors. Alpha-l proteinase inhibitor inhibits human pancreatic and leukocyte elastases. See Pannell et al, Biochemistry, 13, 5439 (19?4); Johnson et al, Biochem.
~L24~6~
Biophys. Res. Commun., 72, 33 (1976); Del Mar et al, Biochem, Biophys. Res. Commun., _ , 346 (1979); and Heimburger et al, Proc. Int. Res. Conf. Proteinase Inhibitors, 1st, 1 - 21 (1970).
Description_of the Prior Art: Coan et al, U.S. Patent -4,379,087, disclose a method for separating alpha-l-proteinase inhibitor from blood plasma or blood plasma fractions which contain the proteinase inhibitor. An lO aqueous solution of the blood plasma fraction is held at a pH of about 6.5 - 8.5 and at a temperature of about 2 - 50 C, and for a period of about 0.2 - 24 hours and then mixed with a polycondensed polyglycol (e.g. polyethylene glycol) in the proportion of about 10 - 15 grams of polyglycol per 1S 100 ml of aqueous solution containing the blood plasma fraction. The mixture may be held at temperature of about
Background of the Invention Field of the Invention: This invention relates to a 5 chemical agent useful in the treatment of pulmonary emphysema. More particularly, this invention relates to a covalent complex (or conjugate) of a water soluble polymer which may be a polysaccharide or a polyol with human alpha-l-proteinase inhibitor, to a process for producing o the covalent complex (or conjugate) of a polysaccharide or a polyol with alpha-l-proteinase inhibitor, optionally in the presence of catalase enzyme, to a pharmaceutical preparation comprisiny the covalent complex (or conjugate) of a polysaccharide or a polyol with alpha-l-proteinase 15 inhibitor, and to a method for treating pulmonary emphysema comprising administering to a human patient a therapeutically effective amount of the complex (or conjugate) or pharmaceutical preparation according to the invention.
Alpha-l-proteinase inhibitor (abbreviated "alPI") is a glycoprotein having a molecular weight of 53,000 determined by sedimentation equilibrium centrifugation. The glyco-protein consists of a single polypeptide chain to which 25 several oligosaccharide units are covalently bonded. Human alpha-l-proteinase inhibitor has a role in controlling tissue destruction by endogenous serine proteinases. A
genetic deficiency of alpha-l-proteinase inhibitor, which accounts for 90% of the trypsin inhibitory capacity in 30 blood plasma, has been shown to be associated with the premature development of pulmonary emphysema. The degradation of elastin associated with emphysema probably results from a local imbalance of elastolytic enzymes and the naturally occurring tissue and plasma proteinase 3s inhibitors. Alpha-l proteinase inhibitor inhibits human pancreatic and leukocyte elastases. See Pannell et al, Biochemistry, 13, 5439 (19?4); Johnson et al, Biochem.
~L24~6~
Biophys. Res. Commun., 72, 33 (1976); Del Mar et al, Biochem, Biophys. Res. Commun., _ , 346 (1979); and Heimburger et al, Proc. Int. Res. Conf. Proteinase Inhibitors, 1st, 1 - 21 (1970).
Description_of the Prior Art: Coan et al, U.S. Patent -4,379,087, disclose a method for separating alpha-l-proteinase inhibitor from blood plasma or blood plasma fractions which contain the proteinase inhibitor. An lO aqueous solution of the blood plasma fraction is held at a pH of about 6.5 - 8.5 and at a temperature of about 2 - 50 C, and for a period of about 0.2 - 24 hours and then mixed with a polycondensed polyglycol (e.g. polyethylene glycol) in the proportion of about 10 - 15 grams of polyglycol per 1S 100 ml of aqueous solution containing the blood plasma fraction. The mixture may be held at temperature of about
2 - 10 C for a period of about 1 - 24 hours. Next, the pH
of the mixture is adjusted to about 4.6 - 5.7 to selectively precipitate unwanted proteins from the solution 20 without precipitation of alpha-l-proteinase inhibitor.
Finally, alpha-l-proteinase inhibitor is separated from solution and purified further.
Other processes for the production of alpha-l-proteinase 25 inhibitor have been reported. Pannell et al, Biochemistry, 13, 5439 (1974), mentioned above, disclose a process wherein albumin-poor blood plasma was pooled and fractionated with solid ammonium sulfate. The resulting precipitate was purified in a four-ste~ procedure involving 30 albumin removal using a Sepharose-Blue Dextran adsorption column, ammonium sulfate fractionation of the most active fractions from the first step, and two DEAE-cellulose chromatography separations.
3s Saklatvala et al, Biochem. J., 157, 339 (1976) disclose a process to obtain alpha-l-proteinase inhibitor by fractionating human plasma using ammonium sulfate and ~ G/~ ~n~ ~k ~ ~266~
chromatographing the resulting precipitate on DEAE-cellulose. The 0.5 M NaCl extract therefrom was applied to a concanavalin A-Sepharose column and eluted with alpha-D-methyl glucopyranoside. The eluate was again applied to a s DEAE-cellulose column and an eluate containing alpha-l-proteinase inhibitor was obtained using 0.0 - 0.2 M NaCl.
Musiani et al, Biochemistry, 15, 798 (1976) disclose the use of 50~ aqueous ammonium sulfate to separate a alpha-o l-proteinase inhibitor from blood plasma which was solubilized and subjected to successive chromatographic separations using DEAE in exchanger, concanavalin A-Sepharose, Sephadex G-100 and an immuno adsorbent columns to yield purified alpha-l-proteinase lnhibitor.
Kress et al, Preparative Biochemistry, 3 (6), 541 (1973), disclose the large scale purification of alpha-l-proteinase inhibitor from human plasma using 80~ ammonium sulfate aqueous solution~ the precipitate from which treatment was 20 solubilized, dialyzed and chromatographed on DEAE-cellulose. The resulting concentrate was again dlalyzed and gel-filtered on Sephadex G-100 and the alpha-1-proteinase inhibitor containing fractions were chromatographed twice on DE-52 cellulose.
Glaser et al, Preparative Biochemistry, 5 (4), 333 (1975), isolated alpha-l-proteinase inhibitor from Cohn Fraction IV-l in 30~ overall yield by chromatographing the Cohn Fraction IV-l on DEAE-cellulose, QAE-Sephadex, concanavalin 30 A-Sepharose and Sephadex G-150.
Hao et al, Proceedings of the International Workshop on Technology for Proteln Separation and Improvement of Blood Plasma Fractionation, 1977, Reston, Virginia, disclosed an 35 integrated plasma fractionation system based on the use of polyethylene glycol ~PEG) to obtain proteins distributed in ~aC~ ~c~
6~
four PEG fractions using 0 - 4% PEG, 4 - 10~ PEG, 10 - 20%
PEG and 20% PEG. Alpha-l-proteinase inhibitor was among the several proteins isolated in the 20% PEG fraction.
s Stabilization and modification of enzymes and other proteins by covalent attachment to carbohydrates and polyethylene glycol has been reported. Marshall and Rabinowitz, Arch. Biochem. BiophYs., 167, 77 (1975) and J.
Biol. Chem., 251, 1081 (1976), noting earlier reports that 10 glycoproteins ~mostly enzymes) often show unusual stability characteristics compared with carbohydrate-free proteins, the former being less sensitive to heat and other denaturing conditions and more resistant to proteolysis, disclose the preparation of soluble enzyme-carbohydrate 15 conjugates by coupling (by means of covalent attachment) trypsin, ~-amylase and ~-amylase to cyanogen bromide activated dextran. The resulting covalent conjugates displayed marked resistance to heat inactivation and denaturation, increased half-life, and reduction in loss of 20 activity under conditions favoring antolysis.
Vegarud et al, Biotechnol. Bioeng., 17, 1391 (1975) and Christensen et al, Process Biochemistry, 25 (July/August 1976), report the results of experiments carried out with 2s "natural" glycoproteins as well as the "artificial"
protein-glycoconjugates (produced by the cyanogen bromide method which have shown that glycosated enzymes are more stable towards heat inactivation by heat and proteases than the corresponding non-glycosated preparations.
Chaplin et al, Biotech. Bioeng., XXIV, 2627 (1982), dis-close soluble conjugates of pepsin and carboxypeptidase A
prepared by covalent linkage of the enzyme to an amino derivative of dextran having specific activities close to 35 those of the native enzymes and having increased tempera-ture and pH stabilitles.
~L2~266~L
~j Tam et alt Proc. Natl. Acad. Sci., 73 (6), 2128 (1976), disclose a complex between soluble dextran and human hemoglobin, produced by two alternative methods involving cyanogen bromide (alkylation) and dialdehyde coupling s chemistry, which is cleared through the kidneys and removed from circulation much more slowly than free hemoglobin in rabbits.
Hoylaerts et al, Thromb. Haemostas, (Stuttgart), 49 (2), 109 (1983), and Ceustermans et al, J. Biol. Chem., 257 (7), 3401 (1982), disclose covalent complexes of high affinity heparin fragments of low molecular weight and high affinity heparin with antithrombin-III having increased half-life compared with the uncomplexed heparin fragments and heparin and resulting in a 30-fold longer life time of Factor Xa inhibitory activity in plasma as compared with that of free intact heparin.
Bjork et al, FEBS Letters, 143 (1), 96 (1982), disclose covalent complexes formed by covalent attachment of antithrombin to high affinity heparin oligosaccharides r obtained by vitrous acid treatment of heparin, wherein the heparin oligosaccharide components have reactive aldehyde functions which form a Schi~f's base with the amino group 2s of any neighboring lysine residue of the protein.
Abuchowski et al, J. Biol. Chem., 252 (11), 3578 and 3582 (1977), disclose the modification of proteins, specifi-cally, bovine serum albumin and bovine liver catalase, by the covalent attachment thereto of nonimmunogenic methoxypropylene glycols of 1900 daltons (PEG-1900, Union Carbide Corp.) and 500 daltons (PEG-5000, Union Carbide Corp.) using cyanuric chloride (2,4,6-trichloro-s-triazine) as the coupling agent. The modified bovine serum albumin exhibited a blood circulating life in rabbits similar to native bovine serum albumin except that it was not removed from circulation by the eventual development of antibodies.
*polyethylene glycol 66~
Also, the modified bovine serum albumin exhibited sub-stantial changes in properties, such as solubility, electrophoretic mobility in acrylamide gel, ion exchange chromatography, and sedimentation, as compared with the s unmodified protein. Rabbits were immunized by the intra-venous administration of PEG-l900-catalase. The intra-venous antiserum/antibodies did not yield detectable antibodies against PEG-1900-catalase or native catalase whereas the intramuscular antiserum contained antibodies to o PEG-l900-catalase and native catalase. PEG-5000-catalase did not react with either antiserum. PEG-l900-catalase and PEG-5000-catalase retained 93~ and 95~, respectively, of their enzymatic activity and PEG-5000-catalase resisted digestion by trypsin, chymotrypsin and a protease from Streptoenyces griseus. PEG-1500-catalase and PEG-5000-catalase exhibited enhanced circulating lives in the blood of acatalasemic mice during repetitive intravenous injection and no evidence was seen of an immune response to injections of the modified enzymes.
Ashihara et al, Biochem. Biophys. Res. Commun., _ (2), 385 (1978), disclose the modification of E. coli L-asparginase with activated polyethylene glycol (PEG-5000, PEG-l900, and PEG-750) to obtain products having varying levels of enzyme 2s amino group substitution by means of covalent attachment of the polyethylene glycol to the enzyme amino groups. The modification of asparginase to 73 amino groups out of the total 92 amino groups in the molecule with PEG-5000 gave rise to a complete loss of the binding ability towards anti-asparginase serum from rabbits and retained the enzymatic activity (72) and hand versitivity against trypsin.
Koide et al, FEBS Letters, 143 (1), 73 (1982), disclose the 3s preparation of polyethylene glycol-modified streptokinase by covalently attaching the glycol and the enzyme. The resulting modified streptokinase had a complete loss of antigenicity but had retention of its enzymatic activity.
O'Neill et al, Biotechnol. Bioen~, 13, 319 (1971~ disclose 5 the covalent attachment of the enzyme, chymotrypsin, to dextran and to DEAE-cellulose using 2-amino-4,6-dichloro-s-triazine as the coupling agènt. Determination of the activity of the preparations showed that chymotrypsin attached to the soluble substrate had a considerably higher 0 activity towards both casein and anti-tyrosine ethyl ester than did chymotrypsin attached to DEAE-cellulose. Both of the conjugates had increased relative stability compared with native chymotrypsin as determined by incubating at 40 C followed by assaying with acetyl-tyrosine ethyl ester 15 (ATEE).
DESCRIPTION OF THE INVENTION
Summary of the Invention This invention is the discovery that stable, water soluble, covalently attached complexes, also referred to as covalent conjugates, can be formed by the chemical coupling reaction 25 of the blood plasma glycoprotein, alpha-l-proteinase inhibitor (abbreviated "~lPI") with an "activated" water soluble polymer. The "activated" water soluble polymer is a polysaccharide (or a carbohydrate) or a polyalkylene glycol produced by reacting the hydroxy groups thereof with 30 a polyfunctional coupling compound having functional groups which are reactive with the polysaccharide or polyalkylene glycol pendant hydroxy groups to provide an intermediate which is reactive with NH2 groups pendant to the protein, alpha-l-proteinase inhibitor.
Accordingly, in one aspect, this invention is a process for producing a covalently attached complex of alpha-l-.
~2~ 6~
proteinase inhibitor with an "activated" water soluble polymer. In another aspect, this invention is a covalent complex of alpha-l-proteinase inhibitor with an "activated"
water soluble polymer produced by the process of the 5 invention. In still another aspect, this invention is a pharmaceutical preparation of the covalent complex of alpha-l-proteinase inhibitor with an "activated" water soluble polymer and a pharmaceutically acceptable carrier.
In yet another aspect, this invention is a method for o treating pulmonary emphysema and respiratory distress syndrome by administering to a patient the covalent complex of alpha-l-proteinase inhibitor with an "activated" water soluble polymer. In a further aspect, this invention is the covalent complex of alpha-l-proteinase inhibitor with a 15 water soluble polymer having bound thereto, by covalent attachment or by ionic association, an antioxidant catalase enzyme, and pharmaceutical preparations thereof.
Detailed Description of the Invention The process for producing the covalently attached complex of alpha-l-proteinase inhibitor with an "activated" water soluble polymer having hydroxy groups pendant to the 25 polymer backbone, which hydroxy groups and amino groups pendant to alpha-l-proteinase inhibitor are chemically reactive with a polyfunctional coupling compound, comprises the steps of:
(a) contacting the water soluble polymer having hydroxy groups pendant to the polymer backbone, which hydroxy groups are chemically reactive with a polyfunctional coupling compound, with a polyfunctional coupling compound having functional groups which are reactive with said hydroxy groups in a CL-g2 ~2~6~
chemical activation rea~tion to obtain an activated intermediate which is reactive with amino groups pen~ant to the protein, alpha~l-proteinase s inhibitor; and (b) contacting the activated intermediate from step (a) with alpha-l-proteinase inhibitor in a chemical lo coupling reaction to effect covalent attachment and to thereby obtain a covalently attached complex of alpha-l-proteinase inhibitor with the water soluble polymer.
In another aspect, the process of the invention comprises the additional step of:
(c) isolating the covalently zo attached complex of alpha-l-proteinase inhibitor with the water soluble polymer obtained in step (b) from . residual uncoupled alpha-l-proteinase ~- inhibitor and water soluble polymer and undesirable compounds in the chemical coupling reaction mixture.
In a further aspect, the process of the invention comprises the addition of the antioxidant catalase enzyme (i) along 30 with the alpha-l-proteinase inhibitor in step (b) above to provide a covalently attached complex of alpha-l-proteinase inhibitor, water soluble polymer and antioxidant catalase enzyme, or (ii) following step (b), above to provide an ionic association or complex of the covalently attached 3s complex of alpha-l-proteinase inhibitor and water soluble polymer with the antioxidant catalase enzyme.
~. , The water soluble polymer having hydroxy groups pendant to the polymer backbone which is used in the present invention may be selected from known water soluble and water solubi-lizable polymers including (a) dextran and dextran deriva-5 tives including dextran sulfate, ~-aminoethyl cross linked dextran, and carboxymethyl dextran; (b) cellulose and cellulose derivatives including methyl cellulose and carboxymethyl cellulose; (c) starch and dextrines derived from starch; (d) polyalkylene glycols and derivatives thereof including polyethylene glycols and methoxypoly-ethene glycols; (e) heparin; (f) polyvinyl alcohol; and (g) polyvinylpyrrolidone. Preferably, the water soluble polymer is selected from dextran and dextran derivatives, dextrine and dextrine derivatives, cellulose and cellulose derivatives, and polyethylene glycols and derivatives thereof. More preferably, the water soluble polymer is selected from dextran and dextran derivatives, dextrine and dextrine derivatives, and polyethylene glycols and deriva-tives thereof. Most preferably, the water soluble polymer 20 iS selected from dextran and dextran derivatives. In an especially preferred embodiment, the water soluble polymer is dextran.
The expression "activated" as applied to the water soluble 25 polymer means that the water soluble polymer has been reacted with a polyfunctional coupling compound, which is reactive with the hydroxy groups pendant to the polymer backbone, to obtain an intermediate which is reactive, through the available functional group on the polyfunc-30 tional compound moiety or through a reactive intermediatefunctional group resulting from the chemical reaction of the polymer with the polyfunctional compound, with the amino groups pendant to the protein, alpha~l-proteinase inhibitor, which is believed to be attached through a lysine residue pendant to the protein.
~2~
The polyfunctional coupling compound which is used in the present invention may be selected from (a) a cyanogen halide wherein the halide is bromide, chloride or iodide;
(b) cyanuric chloride (2,4,6-trichloro-s-1,3,5-triazine) and 2-amino-4,6-dichloro-s-1,3,5-triazine; (c) tolylene diisocyanate; (d) tolylene diisothiocyanate; and (e) 1,4~diaminobenzene in combination with CNBr.
Preferably, the polyfunctional coupling compound is selected from a cyanogen halide and cyanuric chloride or o the 2-amino derivative thereof. More preferably, the polyfunctional coupling compound is a cyanogen halide, most preferably, cyanogen bromide.
The chemical activation reaction may be carried out by 1S known procedures such as those disclosed in the following:
Tam et al, Proc. Natl. Acad. Sci. (U.S.A.), 73 (6), 2128 (1976), Marshall et al, Arch. Biochem. Biophys., _ , 777 (1975) and J. Biol. Chem., 251, 1081 (1976) and Christensen 20 et al, Int. Res. Commun. Svst. (Biochem.), 2, 1311 (1974) concernlng CNBr activation of dextran; O'Neill et al Biotechnol. Bioeng., 13, 319 (1971) concerning 2-amino-4,6-dichloro-s-1,3,5-triazine activation of dextran and DEAE-cellulose; Chaplin et al, Biotechnol. Bioeng., 24, 2s 2627 (1982) concerning CNBr and diaminobenzene activation of dextran; Abuchowski et al, J. Biol. Chem., 252, 3578 and 3582 (1977) concerning cyanuric chloride activation of methoxypolyethylene glycols; Hoylaerts et al, Thromb.
Haemostas. (Stuttgart), 49 (2), 109 (1983) and Ceustermans 30 et al, J. Biol. Chem., 257 (7), 3401 (1982) concerning the tolylene diisothiocyanate activation of heparin; and Rogers et al, Biochem. Biophys. Res. Commun., _ , 662 (1971) concerning the tolylene diisocyanate activation of glyco-peptide from fetuin.
In the especially preferred embodiment of the process of thls invention, dextrans of average molecular welght :.
ranging from about 1 x 104 to about 2 x 106 are activated using CNBr as described in Marshall et al, supra.
Alpha-1-proteinase inhibitor for use in the process of the invention may be produced by any of the several processes mentioned above. Alpha-l-proteinase inhibitor produced by intracellular recombinant DNA technology is also intended to be within the scope-of the process according to this invention. Preferred processes to obtain ~lPI are the processes described in Coan et al, U.S. Patent 4,379,087 and U.S. Patent 4,439,358 concerning a method for separa-ting dlPI from a blood plasma frac-tion, fraction IV-l, obtained by the Cohn ethanol fractionation technique (Cohn et al, J. Chem. Soc., 68, 459 (1946) and U.S.
Patent 2,390,074) using a polycondensed polyglycol such as polyethylene glycol of molecular weight of about 2 x 103 to 1 x 104 under conditions which effect precipita-tion of unwanted proteins which are removed. The alpha-l-proteinase inhibitor is then separated from the remain-ing solution by contacting the solution with a suitable ion exchange medium and then eluting from the medium the alpha-1-proteinase inhibitor.
In the especially preferred embodiment of the process herein, the alpha-1-proteinase inhibitor is then contacted with the activated dextran by a modification of the method disclosed in Marshall et al, supra.
In the following description, emphasis is directed to the especially preferred process of the invention. Following the methods described in Marshall et al, J. Biol. Chem., 251 (4), 1081 (1976), to a stirred aqueous solution of dextran in water adjusted -to pH of about 9.0 to 13.0 pre-ferably 10.0 to 12.0, there is added cyanogen bromicle to obtain an activated dex-tran intermediate. Usually, about 1 to 2 parts of dextran are used per 0.05 to 1 part of ~ .
.i ~ .
i6~
cyanogen bromide. Preferably, about l to 2 parts of dextran are used per 0.2 to 0.5 part of cyanogen bromide.
The activation step is carried out at a temperature of from s about 2 to 35 C, preferably about 5 to 20 C, for a reaction period of about 5 - 60 minutes, preferably about 15 - 30 minutes. Unreacted cyanogen bromide is then removed by dialysis.
10 The solution of the activated dextran intermediate, adjusted to a pH of about 8 - 10.5, preferably about 9.0 -9.8, is then mixed with a solution containing about l to 2 parts of purified alpha-l-proteinase inhibitor (~1PI) per lO to 30 parts of dextran in the activated dextran inter-mediate, the residual active groups being neutralized with glycine.
The temperature of this coupling reaction is about 2 - 35 C, preferably about 5 - 20 C, and the coupling reaction 20 time is about 0.5 - 24 hours, preferably about 3 - 12 hours.
The coupling reaction product mixture containing the covalently bound alpha-l-proteinase inhibitor - dextran 2s complex may then be processed to put it in condition for use. Generally, the product mixture is concentrated to reduce its water content by conventional means. Also, if desired although not required, uncoupled ~1PI and dextran remaining in solution in the product mixture may then be 30 removed by conventional means, for example, dialysis, diafiltration, chromatography, etc. The resulting concentrates containing the covalently bound alpha-l-proteinase inhibitor - dextran complex can be formulated into pharmaceutical preparations for therapeutic use. The 3s resulting covalently bound alpha-l-proteinase inhibitor -dextran complex concentrate and pharmaceutical compositions containing the complex may be sterilized by conventional ~Z~6~,~
means, sterile-filtered, and treated to render them non-hepatitis infective. As used herein, the expression "sterilize" is meant to embrace those means which will inactivate or destroy microorganisms, including viruses and s especially hepatitis virus, so as to reduce or eliminate the microorganisms to render them non-infective.
Pharmaceutical preparations comprising the covalently bound, or covalently chemically coupled, alpha-l-proteinase inhibitor - dextran complex may be sterilized to render the preparations non-microorganism and non-hepatitis infective by conventional, known procedures, for example, heat treatment, chemical treatment using for example, ~-propiolactone or chloroform or Tween~ R0 to name but a few 15 representative chemical viral inactivating agents, ultra~
violet radiation treatment and colloidal silica. For example, the preparations, in wet or dry state, may be heated at temperatures of about 60 - 85 for a period of several minutes to several days. Optionally, the heat treatment procedure may be advantageously carried out in the presence of a heat stabillzing amount of at least one heat stabilizing agent. Suitable stabilizing agents include citrate ions, nonpolar anions with molecular weights greater than 80, sugars, reduced sugars, and amino 2s acids. Examples o~- suitable nonpolar anions include salts of carboxylates, hydroxycarboxylates and amino acids such as sodium or potassium caprylate, caprate, oleate, laurate, valerate, acetylphenylalaninate, acetyleucinate, and acetyltryptophanate. Examples of suitable sugars include glucose, sucrose and maltose to name but a few, and examples of suitable reduced sugars include erythritol and mannitol. Examples of suitable amino acids include lysine, glysine, proline and glutamic acid to name but a few. By way of example without limitation, suitable conventional known sterilization processes include those disclosed in U.S. Patents 3,041,242, 3,057,781, 3,227,626, 4,061,735, 4,137,307, 4,297,344, 2,705,230, 2,897,123, 3,284,301,
of the mixture is adjusted to about 4.6 - 5.7 to selectively precipitate unwanted proteins from the solution 20 without precipitation of alpha-l-proteinase inhibitor.
Finally, alpha-l-proteinase inhibitor is separated from solution and purified further.
Other processes for the production of alpha-l-proteinase 25 inhibitor have been reported. Pannell et al, Biochemistry, 13, 5439 (1974), mentioned above, disclose a process wherein albumin-poor blood plasma was pooled and fractionated with solid ammonium sulfate. The resulting precipitate was purified in a four-ste~ procedure involving 30 albumin removal using a Sepharose-Blue Dextran adsorption column, ammonium sulfate fractionation of the most active fractions from the first step, and two DEAE-cellulose chromatography separations.
3s Saklatvala et al, Biochem. J., 157, 339 (1976) disclose a process to obtain alpha-l-proteinase inhibitor by fractionating human plasma using ammonium sulfate and ~ G/~ ~n~ ~k ~ ~266~
chromatographing the resulting precipitate on DEAE-cellulose. The 0.5 M NaCl extract therefrom was applied to a concanavalin A-Sepharose column and eluted with alpha-D-methyl glucopyranoside. The eluate was again applied to a s DEAE-cellulose column and an eluate containing alpha-l-proteinase inhibitor was obtained using 0.0 - 0.2 M NaCl.
Musiani et al, Biochemistry, 15, 798 (1976) disclose the use of 50~ aqueous ammonium sulfate to separate a alpha-o l-proteinase inhibitor from blood plasma which was solubilized and subjected to successive chromatographic separations using DEAE in exchanger, concanavalin A-Sepharose, Sephadex G-100 and an immuno adsorbent columns to yield purified alpha-l-proteinase lnhibitor.
Kress et al, Preparative Biochemistry, 3 (6), 541 (1973), disclose the large scale purification of alpha-l-proteinase inhibitor from human plasma using 80~ ammonium sulfate aqueous solution~ the precipitate from which treatment was 20 solubilized, dialyzed and chromatographed on DEAE-cellulose. The resulting concentrate was again dlalyzed and gel-filtered on Sephadex G-100 and the alpha-1-proteinase inhibitor containing fractions were chromatographed twice on DE-52 cellulose.
Glaser et al, Preparative Biochemistry, 5 (4), 333 (1975), isolated alpha-l-proteinase inhibitor from Cohn Fraction IV-l in 30~ overall yield by chromatographing the Cohn Fraction IV-l on DEAE-cellulose, QAE-Sephadex, concanavalin 30 A-Sepharose and Sephadex G-150.
Hao et al, Proceedings of the International Workshop on Technology for Proteln Separation and Improvement of Blood Plasma Fractionation, 1977, Reston, Virginia, disclosed an 35 integrated plasma fractionation system based on the use of polyethylene glycol ~PEG) to obtain proteins distributed in ~aC~ ~c~
6~
four PEG fractions using 0 - 4% PEG, 4 - 10~ PEG, 10 - 20%
PEG and 20% PEG. Alpha-l-proteinase inhibitor was among the several proteins isolated in the 20% PEG fraction.
s Stabilization and modification of enzymes and other proteins by covalent attachment to carbohydrates and polyethylene glycol has been reported. Marshall and Rabinowitz, Arch. Biochem. BiophYs., 167, 77 (1975) and J.
Biol. Chem., 251, 1081 (1976), noting earlier reports that 10 glycoproteins ~mostly enzymes) often show unusual stability characteristics compared with carbohydrate-free proteins, the former being less sensitive to heat and other denaturing conditions and more resistant to proteolysis, disclose the preparation of soluble enzyme-carbohydrate 15 conjugates by coupling (by means of covalent attachment) trypsin, ~-amylase and ~-amylase to cyanogen bromide activated dextran. The resulting covalent conjugates displayed marked resistance to heat inactivation and denaturation, increased half-life, and reduction in loss of 20 activity under conditions favoring antolysis.
Vegarud et al, Biotechnol. Bioeng., 17, 1391 (1975) and Christensen et al, Process Biochemistry, 25 (July/August 1976), report the results of experiments carried out with 2s "natural" glycoproteins as well as the "artificial"
protein-glycoconjugates (produced by the cyanogen bromide method which have shown that glycosated enzymes are more stable towards heat inactivation by heat and proteases than the corresponding non-glycosated preparations.
Chaplin et al, Biotech. Bioeng., XXIV, 2627 (1982), dis-close soluble conjugates of pepsin and carboxypeptidase A
prepared by covalent linkage of the enzyme to an amino derivative of dextran having specific activities close to 35 those of the native enzymes and having increased tempera-ture and pH stabilitles.
~L2~266~L
~j Tam et alt Proc. Natl. Acad. Sci., 73 (6), 2128 (1976), disclose a complex between soluble dextran and human hemoglobin, produced by two alternative methods involving cyanogen bromide (alkylation) and dialdehyde coupling s chemistry, which is cleared through the kidneys and removed from circulation much more slowly than free hemoglobin in rabbits.
Hoylaerts et al, Thromb. Haemostas, (Stuttgart), 49 (2), 109 (1983), and Ceustermans et al, J. Biol. Chem., 257 (7), 3401 (1982), disclose covalent complexes of high affinity heparin fragments of low molecular weight and high affinity heparin with antithrombin-III having increased half-life compared with the uncomplexed heparin fragments and heparin and resulting in a 30-fold longer life time of Factor Xa inhibitory activity in plasma as compared with that of free intact heparin.
Bjork et al, FEBS Letters, 143 (1), 96 (1982), disclose covalent complexes formed by covalent attachment of antithrombin to high affinity heparin oligosaccharides r obtained by vitrous acid treatment of heparin, wherein the heparin oligosaccharide components have reactive aldehyde functions which form a Schi~f's base with the amino group 2s of any neighboring lysine residue of the protein.
Abuchowski et al, J. Biol. Chem., 252 (11), 3578 and 3582 (1977), disclose the modification of proteins, specifi-cally, bovine serum albumin and bovine liver catalase, by the covalent attachment thereto of nonimmunogenic methoxypropylene glycols of 1900 daltons (PEG-1900, Union Carbide Corp.) and 500 daltons (PEG-5000, Union Carbide Corp.) using cyanuric chloride (2,4,6-trichloro-s-triazine) as the coupling agent. The modified bovine serum albumin exhibited a blood circulating life in rabbits similar to native bovine serum albumin except that it was not removed from circulation by the eventual development of antibodies.
*polyethylene glycol 66~
Also, the modified bovine serum albumin exhibited sub-stantial changes in properties, such as solubility, electrophoretic mobility in acrylamide gel, ion exchange chromatography, and sedimentation, as compared with the s unmodified protein. Rabbits were immunized by the intra-venous administration of PEG-l900-catalase. The intra-venous antiserum/antibodies did not yield detectable antibodies against PEG-1900-catalase or native catalase whereas the intramuscular antiserum contained antibodies to o PEG-l900-catalase and native catalase. PEG-5000-catalase did not react with either antiserum. PEG-l900-catalase and PEG-5000-catalase retained 93~ and 95~, respectively, of their enzymatic activity and PEG-5000-catalase resisted digestion by trypsin, chymotrypsin and a protease from Streptoenyces griseus. PEG-1500-catalase and PEG-5000-catalase exhibited enhanced circulating lives in the blood of acatalasemic mice during repetitive intravenous injection and no evidence was seen of an immune response to injections of the modified enzymes.
Ashihara et al, Biochem. Biophys. Res. Commun., _ (2), 385 (1978), disclose the modification of E. coli L-asparginase with activated polyethylene glycol (PEG-5000, PEG-l900, and PEG-750) to obtain products having varying levels of enzyme 2s amino group substitution by means of covalent attachment of the polyethylene glycol to the enzyme amino groups. The modification of asparginase to 73 amino groups out of the total 92 amino groups in the molecule with PEG-5000 gave rise to a complete loss of the binding ability towards anti-asparginase serum from rabbits and retained the enzymatic activity (72) and hand versitivity against trypsin.
Koide et al, FEBS Letters, 143 (1), 73 (1982), disclose the 3s preparation of polyethylene glycol-modified streptokinase by covalently attaching the glycol and the enzyme. The resulting modified streptokinase had a complete loss of antigenicity but had retention of its enzymatic activity.
O'Neill et al, Biotechnol. Bioen~, 13, 319 (1971~ disclose 5 the covalent attachment of the enzyme, chymotrypsin, to dextran and to DEAE-cellulose using 2-amino-4,6-dichloro-s-triazine as the coupling agènt. Determination of the activity of the preparations showed that chymotrypsin attached to the soluble substrate had a considerably higher 0 activity towards both casein and anti-tyrosine ethyl ester than did chymotrypsin attached to DEAE-cellulose. Both of the conjugates had increased relative stability compared with native chymotrypsin as determined by incubating at 40 C followed by assaying with acetyl-tyrosine ethyl ester 15 (ATEE).
DESCRIPTION OF THE INVENTION
Summary of the Invention This invention is the discovery that stable, water soluble, covalently attached complexes, also referred to as covalent conjugates, can be formed by the chemical coupling reaction 25 of the blood plasma glycoprotein, alpha-l-proteinase inhibitor (abbreviated "~lPI") with an "activated" water soluble polymer. The "activated" water soluble polymer is a polysaccharide (or a carbohydrate) or a polyalkylene glycol produced by reacting the hydroxy groups thereof with 30 a polyfunctional coupling compound having functional groups which are reactive with the polysaccharide or polyalkylene glycol pendant hydroxy groups to provide an intermediate which is reactive with NH2 groups pendant to the protein, alpha-l-proteinase inhibitor.
Accordingly, in one aspect, this invention is a process for producing a covalently attached complex of alpha-l-.
~2~ 6~
proteinase inhibitor with an "activated" water soluble polymer. In another aspect, this invention is a covalent complex of alpha-l-proteinase inhibitor with an "activated"
water soluble polymer produced by the process of the 5 invention. In still another aspect, this invention is a pharmaceutical preparation of the covalent complex of alpha-l-proteinase inhibitor with an "activated" water soluble polymer and a pharmaceutically acceptable carrier.
In yet another aspect, this invention is a method for o treating pulmonary emphysema and respiratory distress syndrome by administering to a patient the covalent complex of alpha-l-proteinase inhibitor with an "activated" water soluble polymer. In a further aspect, this invention is the covalent complex of alpha-l-proteinase inhibitor with a 15 water soluble polymer having bound thereto, by covalent attachment or by ionic association, an antioxidant catalase enzyme, and pharmaceutical preparations thereof.
Detailed Description of the Invention The process for producing the covalently attached complex of alpha-l-proteinase inhibitor with an "activated" water soluble polymer having hydroxy groups pendant to the 25 polymer backbone, which hydroxy groups and amino groups pendant to alpha-l-proteinase inhibitor are chemically reactive with a polyfunctional coupling compound, comprises the steps of:
(a) contacting the water soluble polymer having hydroxy groups pendant to the polymer backbone, which hydroxy groups are chemically reactive with a polyfunctional coupling compound, with a polyfunctional coupling compound having functional groups which are reactive with said hydroxy groups in a CL-g2 ~2~6~
chemical activation rea~tion to obtain an activated intermediate which is reactive with amino groups pen~ant to the protein, alpha~l-proteinase s inhibitor; and (b) contacting the activated intermediate from step (a) with alpha-l-proteinase inhibitor in a chemical lo coupling reaction to effect covalent attachment and to thereby obtain a covalently attached complex of alpha-l-proteinase inhibitor with the water soluble polymer.
In another aspect, the process of the invention comprises the additional step of:
(c) isolating the covalently zo attached complex of alpha-l-proteinase inhibitor with the water soluble polymer obtained in step (b) from . residual uncoupled alpha-l-proteinase ~- inhibitor and water soluble polymer and undesirable compounds in the chemical coupling reaction mixture.
In a further aspect, the process of the invention comprises the addition of the antioxidant catalase enzyme (i) along 30 with the alpha-l-proteinase inhibitor in step (b) above to provide a covalently attached complex of alpha-l-proteinase inhibitor, water soluble polymer and antioxidant catalase enzyme, or (ii) following step (b), above to provide an ionic association or complex of the covalently attached 3s complex of alpha-l-proteinase inhibitor and water soluble polymer with the antioxidant catalase enzyme.
~. , The water soluble polymer having hydroxy groups pendant to the polymer backbone which is used in the present invention may be selected from known water soluble and water solubi-lizable polymers including (a) dextran and dextran deriva-5 tives including dextran sulfate, ~-aminoethyl cross linked dextran, and carboxymethyl dextran; (b) cellulose and cellulose derivatives including methyl cellulose and carboxymethyl cellulose; (c) starch and dextrines derived from starch; (d) polyalkylene glycols and derivatives thereof including polyethylene glycols and methoxypoly-ethene glycols; (e) heparin; (f) polyvinyl alcohol; and (g) polyvinylpyrrolidone. Preferably, the water soluble polymer is selected from dextran and dextran derivatives, dextrine and dextrine derivatives, cellulose and cellulose derivatives, and polyethylene glycols and derivatives thereof. More preferably, the water soluble polymer is selected from dextran and dextran derivatives, dextrine and dextrine derivatives, and polyethylene glycols and deriva-tives thereof. Most preferably, the water soluble polymer 20 iS selected from dextran and dextran derivatives. In an especially preferred embodiment, the water soluble polymer is dextran.
The expression "activated" as applied to the water soluble 25 polymer means that the water soluble polymer has been reacted with a polyfunctional coupling compound, which is reactive with the hydroxy groups pendant to the polymer backbone, to obtain an intermediate which is reactive, through the available functional group on the polyfunc-30 tional compound moiety or through a reactive intermediatefunctional group resulting from the chemical reaction of the polymer with the polyfunctional compound, with the amino groups pendant to the protein, alpha~l-proteinase inhibitor, which is believed to be attached through a lysine residue pendant to the protein.
~2~
The polyfunctional coupling compound which is used in the present invention may be selected from (a) a cyanogen halide wherein the halide is bromide, chloride or iodide;
(b) cyanuric chloride (2,4,6-trichloro-s-1,3,5-triazine) and 2-amino-4,6-dichloro-s-1,3,5-triazine; (c) tolylene diisocyanate; (d) tolylene diisothiocyanate; and (e) 1,4~diaminobenzene in combination with CNBr.
Preferably, the polyfunctional coupling compound is selected from a cyanogen halide and cyanuric chloride or o the 2-amino derivative thereof. More preferably, the polyfunctional coupling compound is a cyanogen halide, most preferably, cyanogen bromide.
The chemical activation reaction may be carried out by 1S known procedures such as those disclosed in the following:
Tam et al, Proc. Natl. Acad. Sci. (U.S.A.), 73 (6), 2128 (1976), Marshall et al, Arch. Biochem. Biophys., _ , 777 (1975) and J. Biol. Chem., 251, 1081 (1976) and Christensen 20 et al, Int. Res. Commun. Svst. (Biochem.), 2, 1311 (1974) concernlng CNBr activation of dextran; O'Neill et al Biotechnol. Bioeng., 13, 319 (1971) concerning 2-amino-4,6-dichloro-s-1,3,5-triazine activation of dextran and DEAE-cellulose; Chaplin et al, Biotechnol. Bioeng., 24, 2s 2627 (1982) concerning CNBr and diaminobenzene activation of dextran; Abuchowski et al, J. Biol. Chem., 252, 3578 and 3582 (1977) concerning cyanuric chloride activation of methoxypolyethylene glycols; Hoylaerts et al, Thromb.
Haemostas. (Stuttgart), 49 (2), 109 (1983) and Ceustermans 30 et al, J. Biol. Chem., 257 (7), 3401 (1982) concerning the tolylene diisothiocyanate activation of heparin; and Rogers et al, Biochem. Biophys. Res. Commun., _ , 662 (1971) concerning the tolylene diisocyanate activation of glyco-peptide from fetuin.
In the especially preferred embodiment of the process of thls invention, dextrans of average molecular welght :.
ranging from about 1 x 104 to about 2 x 106 are activated using CNBr as described in Marshall et al, supra.
Alpha-1-proteinase inhibitor for use in the process of the invention may be produced by any of the several processes mentioned above. Alpha-l-proteinase inhibitor produced by intracellular recombinant DNA technology is also intended to be within the scope-of the process according to this invention. Preferred processes to obtain ~lPI are the processes described in Coan et al, U.S. Patent 4,379,087 and U.S. Patent 4,439,358 concerning a method for separa-ting dlPI from a blood plasma frac-tion, fraction IV-l, obtained by the Cohn ethanol fractionation technique (Cohn et al, J. Chem. Soc., 68, 459 (1946) and U.S.
Patent 2,390,074) using a polycondensed polyglycol such as polyethylene glycol of molecular weight of about 2 x 103 to 1 x 104 under conditions which effect precipita-tion of unwanted proteins which are removed. The alpha-l-proteinase inhibitor is then separated from the remain-ing solution by contacting the solution with a suitable ion exchange medium and then eluting from the medium the alpha-1-proteinase inhibitor.
In the especially preferred embodiment of the process herein, the alpha-1-proteinase inhibitor is then contacted with the activated dextran by a modification of the method disclosed in Marshall et al, supra.
In the following description, emphasis is directed to the especially preferred process of the invention. Following the methods described in Marshall et al, J. Biol. Chem., 251 (4), 1081 (1976), to a stirred aqueous solution of dextran in water adjusted -to pH of about 9.0 to 13.0 pre-ferably 10.0 to 12.0, there is added cyanogen bromicle to obtain an activated dex-tran intermediate. Usually, about 1 to 2 parts of dextran are used per 0.05 to 1 part of ~ .
.i ~ .
i6~
cyanogen bromide. Preferably, about l to 2 parts of dextran are used per 0.2 to 0.5 part of cyanogen bromide.
The activation step is carried out at a temperature of from s about 2 to 35 C, preferably about 5 to 20 C, for a reaction period of about 5 - 60 minutes, preferably about 15 - 30 minutes. Unreacted cyanogen bromide is then removed by dialysis.
10 The solution of the activated dextran intermediate, adjusted to a pH of about 8 - 10.5, preferably about 9.0 -9.8, is then mixed with a solution containing about l to 2 parts of purified alpha-l-proteinase inhibitor (~1PI) per lO to 30 parts of dextran in the activated dextran inter-mediate, the residual active groups being neutralized with glycine.
The temperature of this coupling reaction is about 2 - 35 C, preferably about 5 - 20 C, and the coupling reaction 20 time is about 0.5 - 24 hours, preferably about 3 - 12 hours.
The coupling reaction product mixture containing the covalently bound alpha-l-proteinase inhibitor - dextran 2s complex may then be processed to put it in condition for use. Generally, the product mixture is concentrated to reduce its water content by conventional means. Also, if desired although not required, uncoupled ~1PI and dextran remaining in solution in the product mixture may then be 30 removed by conventional means, for example, dialysis, diafiltration, chromatography, etc. The resulting concentrates containing the covalently bound alpha-l-proteinase inhibitor - dextran complex can be formulated into pharmaceutical preparations for therapeutic use. The 3s resulting covalently bound alpha-l-proteinase inhibitor -dextran complex concentrate and pharmaceutical compositions containing the complex may be sterilized by conventional ~Z~6~,~
means, sterile-filtered, and treated to render them non-hepatitis infective. As used herein, the expression "sterilize" is meant to embrace those means which will inactivate or destroy microorganisms, including viruses and s especially hepatitis virus, so as to reduce or eliminate the microorganisms to render them non-infective.
Pharmaceutical preparations comprising the covalently bound, or covalently chemically coupled, alpha-l-proteinase inhibitor - dextran complex may be sterilized to render the preparations non-microorganism and non-hepatitis infective by conventional, known procedures, for example, heat treatment, chemical treatment using for example, ~-propiolactone or chloroform or Tween~ R0 to name but a few 15 representative chemical viral inactivating agents, ultra~
violet radiation treatment and colloidal silica. For example, the preparations, in wet or dry state, may be heated at temperatures of about 60 - 85 for a period of several minutes to several days. Optionally, the heat treatment procedure may be advantageously carried out in the presence of a heat stabillzing amount of at least one heat stabilizing agent. Suitable stabilizing agents include citrate ions, nonpolar anions with molecular weights greater than 80, sugars, reduced sugars, and amino 2s acids. Examples o~- suitable nonpolar anions include salts of carboxylates, hydroxycarboxylates and amino acids such as sodium or potassium caprylate, caprate, oleate, laurate, valerate, acetylphenylalaninate, acetyleucinate, and acetyltryptophanate. Examples of suitable sugars include glucose, sucrose and maltose to name but a few, and examples of suitable reduced sugars include erythritol and mannitol. Examples of suitable amino acids include lysine, glysine, proline and glutamic acid to name but a few. By way of example without limitation, suitable conventional known sterilization processes include those disclosed in U.S. Patents 3,041,242, 3,057,781, 3,227,626, 4,061,735, 4,137,307, 4,297,344, 2,705,230, 2,897,123, 3,284,301,
3,454,929, 4,379,085 and 4,370,264, and European Patent Publication 0058993, and in references disclosed in the patents.
s In this respect the concentrates may be treated to reduce hepatitis infectivity by, for example, pasteurization, i.e., heating at a temperature and for a time, such as, for example, at about 60 C or more for a period up to about 10 hours, sufficient to render the alpha-l-proteinase inhibitor - dextran covalent complex hepatitis non-infective. To stabilize the alpha-l-proteinase inhibitor -dextran covalent complex during this heat treatment a source of citrate ions is added in an amount sufficient to stabilize the alpha-l-proteinase inhibitor - dextran S covalent complex during heating. Generally, if about 20 mg of total protein is present in the alpha-l-proteinase inhibitor - dextran covalent complex concentrate, then the solution is made about 0.25 - 0.5 M in citrate ion. The pH
of the mixture during this heating step should preferably be about 6.0 - 7Ø
To achieve maximum stabilization of alpha-l-proteinase inhibitor - dextran covalent complex during heating it is desirable to use a carbohydrate as the stabilization agent 2s either alone or with sodium citrate. For this purpose one may use as the carbohydrate a mono-, di-, and trisaccharide such as arabinose, glucose, galactose, maltose, fructose, fibose, mannose, rhammose, sucrose, etc., or a sugar alcohol such as sorbitol and mannitol, etc., in an amount of about 0.5 - 2.4 g/ml of alpha-l-proteinase inhibitor -dextran covalent complex solution.
The covalent alpha-l-proteinase inhibitor - dextran complex product and concentrates thereof can be formulated into pharmaceutical preparations containing the complex and a pharmaceutically acceptable carrier. The term "pharma-ceutical preparation" is intended in a broad sense herein ~2~266~
to include preparations used for therapeutic purposes, for reagent purposes, for diagnostic purposes, for tissue culture purposes, and so forth. The pharmaceutical preparation intended for therapeutic use should contain a s pharmaceutically acceptable and useful concentration of the complex to provide a therapeutically effective amount of the complex, i.e., that arnount necessary for preventative or curative health measures. If the pharmaceutical prepar-ation is to be employed as a reagent, then it should lO contain reagent amounts of complex. Similarly, when used in tissue culture or as a culture medium the pharmaceutical preparation should contain an amount of complex sufficient to obtain the desired growth.
15 It is a characteristic of compositions comprising the alpha-l-proteinase inhibitor - dextran complex prepared in accordance with the present invention that they contain the complex in pharmaceutically useful amounts to provide therapeutically effective amounts.
To prepare them for intravenous administration the compo-sitions are constituted usually ln water containing physio-logically compatible substances such as sodium chloride, glycine, sugar and the like in physiologically compatible 25 concentrations and having a buffered pH compatible with physioloyical conditions. Generally, guidelines for intravenously administered compositions are established by governmental regulations.
30 The following examples are illustrative of but a few embodiments of the invention described above and are not to be construed as limiting in scope. All parts and percent-ages are by weight and all temperatures are in degrees Celsius unless otherwise indicated.
~L242~64 ' MATERIALS AND METHODS
Cohn Fraction IV-l, the source of alpha-l-proteinase inhibitor, was obtained by means of the Cohn fractiona-tion scheme mentioned above in Cohn et al, J. Amer. Chem.
Soc., 68, 459 (1946). Purification of alpha-l-proteinase inhibitor was initiated by sequential fractionation with polyethylene glycol (PEG 4000~ , Union Carbide Corpora-tion) at pH 5.0 - 5.5, as described in U.S. Patents
s In this respect the concentrates may be treated to reduce hepatitis infectivity by, for example, pasteurization, i.e., heating at a temperature and for a time, such as, for example, at about 60 C or more for a period up to about 10 hours, sufficient to render the alpha-l-proteinase inhibitor - dextran covalent complex hepatitis non-infective. To stabilize the alpha-l-proteinase inhibitor -dextran covalent complex during this heat treatment a source of citrate ions is added in an amount sufficient to stabilize the alpha-l-proteinase inhibitor - dextran S covalent complex during heating. Generally, if about 20 mg of total protein is present in the alpha-l-proteinase inhibitor - dextran covalent complex concentrate, then the solution is made about 0.25 - 0.5 M in citrate ion. The pH
of the mixture during this heating step should preferably be about 6.0 - 7Ø
To achieve maximum stabilization of alpha-l-proteinase inhibitor - dextran covalent complex during heating it is desirable to use a carbohydrate as the stabilization agent 2s either alone or with sodium citrate. For this purpose one may use as the carbohydrate a mono-, di-, and trisaccharide such as arabinose, glucose, galactose, maltose, fructose, fibose, mannose, rhammose, sucrose, etc., or a sugar alcohol such as sorbitol and mannitol, etc., in an amount of about 0.5 - 2.4 g/ml of alpha-l-proteinase inhibitor -dextran covalent complex solution.
The covalent alpha-l-proteinase inhibitor - dextran complex product and concentrates thereof can be formulated into pharmaceutical preparations containing the complex and a pharmaceutically acceptable carrier. The term "pharma-ceutical preparation" is intended in a broad sense herein ~2~266~
to include preparations used for therapeutic purposes, for reagent purposes, for diagnostic purposes, for tissue culture purposes, and so forth. The pharmaceutical preparation intended for therapeutic use should contain a s pharmaceutically acceptable and useful concentration of the complex to provide a therapeutically effective amount of the complex, i.e., that arnount necessary for preventative or curative health measures. If the pharmaceutical prepar-ation is to be employed as a reagent, then it should lO contain reagent amounts of complex. Similarly, when used in tissue culture or as a culture medium the pharmaceutical preparation should contain an amount of complex sufficient to obtain the desired growth.
15 It is a characteristic of compositions comprising the alpha-l-proteinase inhibitor - dextran complex prepared in accordance with the present invention that they contain the complex in pharmaceutically useful amounts to provide therapeutically effective amounts.
To prepare them for intravenous administration the compo-sitions are constituted usually ln water containing physio-logically compatible substances such as sodium chloride, glycine, sugar and the like in physiologically compatible 25 concentrations and having a buffered pH compatible with physioloyical conditions. Generally, guidelines for intravenously administered compositions are established by governmental regulations.
30 The following examples are illustrative of but a few embodiments of the invention described above and are not to be construed as limiting in scope. All parts and percent-ages are by weight and all temperatures are in degrees Celsius unless otherwise indicated.
~L242~64 ' MATERIALS AND METHODS
Cohn Fraction IV-l, the source of alpha-l-proteinase inhibitor, was obtained by means of the Cohn fractiona-tion scheme mentioned above in Cohn et al, J. Amer. Chem.
Soc., 68, 459 (1946). Purification of alpha-l-proteinase inhibitor was initiated by sequential fractionation with polyethylene glycol (PEG 4000~ , Union Carbide Corpora-tion) at pH 5.0 - 5.5, as described in U.S. Patents
4,379,087 and 4,439,358, both of which are owned by the assignee of the present application, followed by treat-ment by means of ion exchange chromatography techniques on DEAE Sepharose CL-6B using a conventional phosphate buffer tO.l M sodium phosphates, pH 6.5) as the eluent.
The protein was determined to be at least 90~ pure by means of sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) techniques as described by Weber et al, J. Biol. Chem., 244, 4406 (1969).
Cyanogen bromide was obtained from Aldrich Chemical Co.
Dextran of average molecular weight 17,700 and 10,300 daltons was obtained from Sigma Chemical Co. (St. Louis, MO.).
Porcine pancreatic elastase type III and chromogenic substrate N-succinyl-L-anlanyl-L-alanyl-L-alanyl-p-nitroanilide (SA3pNA) were obtained from Sigma Chemicals Co. (St. Louis, MO). Hydrolysis of the chromogenic sub-strate by the elastase liberates ~-nitroaniline which gives a yellow color whose absorbance is measurable spectrophotometrically (Model 1084 UV Spectrophotometer, Gilford Instruments, Oberlin, OH) at 405 nm. Alpha-l-proteinase inhibitor inhibits this hydrolysis reactionand the extent of elastase inhibition is proportional to the amount of alpha-l-proteinase inhibitor present.
- O
~;
-~Z~6~
Comparisons of the linear changes of absorbance with time both in the presence and in the absence of sample alpha-l-proteinase inhibitor and of sample alpha-l-proteinase inhibitor - dextran covalent complex were made. The amount s of inhibitor was then calculated based on the known molecular weights of the elastase and alpha-l-protelnase inhibitor, on the known 1:1 stoichrometry, and on the known amount of elastase used. A pool of normal human plasma (> 1000 donors) was used as the standard and assigned a 10 value of 1 ~/ml of ~lPI.
Antiserum (rabbit anti-human) to alpha-l-proteinase inhibitor was obtained from Miles Laboratories (Elkhart, IN). Comparison to purified alpha-l-proteinase inhibitor showed that 1 unit of alpha-l-proteinase inhibitor activity was equivalent to 1.3 mg.
Association constants (kaSSoC) between the enzyme (E) and the inhibitor (I) were determined as follows: 25 ~1 each 20 of equimolar amounts of the enzyme and the inhibitor were incubated at 37 C with 1950 ~1 of buffer (0.05 M TRIS, 0.15 M NaCl, pH 7.4) (TRISo is tris(hydroxymethyl)amino methane, supplied by Sigma, St. Louis, Missouri) to obtain a resultant concentration of 3.37 x 10 . At various 25 times, a 200 ~1 aliquot of the enzyme-inhibitor solution was added to 780 ~1 buffer and 20 ~1 substrate (SA3pNA) (60 n~l) and the hydrolysis rate followed in the temperature controlled (37 C~ cuvette with a recorder (Model 6051, Gilford Instruments, Oberlin, Ohio) attachment. During 30 hydrolysis no further enzyme-inhibitor association was assumed (5 fold dilution compared to preincubation) and the initial reaction rate (v) was indicative of the free enzyme (E) present at the end of the respective preincubation times. Enzyme inhibitor association is represented as:
66~
assoc E ~ I EI (1) kdi s soc for kdiSsoc ~ & equimolar concentrations of E & I we get -dE 2 dt kassoc E (2) With initial conditions t = 0, E = Eo (all free enzyme) equation (2) integrates to -- ~ -- = kassoc ( ) o By defining half life of the reaction to 5 to be at E = 0.5Eo we get t = (4) o.5 k E
assoc o Excluslon Chromatography: High performance liquid chroma-tography (HPLC) runs were made wlth a Varian Spherogel TSK
2s 3000 column (Varian Instruments, Palo Alto, CA) of size 7.5 x 300 mm. The buffer used was 0.05 M phosphate, 0.1 M KCl (pH 6.8) at a flow rate of 1 ml/min; 60 ~1 of the sample was applied. A Hitachi model 100-300 (Allen Scientific, Berkeley, CA) UV (280 nm) director with a Hewlett Packard (Hewlett Packard, Palo Alto, CA) Model 3388 computing integrator was used to identify the protein peaks. A Bio Rad (Richmond, CA) molecular weight standard was run for the purpo~se of calibration.
35 Studies Related to Heating_and Oxidation: Alpha-l-proteinase inhibitor and its dextran conjugates, with and without added beef liver catalase as antioxidant, were - 20 ~ 6~
heated in closed tubes at 60 + 0.2 C. The tubes were preheated and due to large mass difference the samples reached the bath temperature in less than 60 seconds. At designated time intervals samples were withdrawn and
The protein was determined to be at least 90~ pure by means of sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) techniques as described by Weber et al, J. Biol. Chem., 244, 4406 (1969).
Cyanogen bromide was obtained from Aldrich Chemical Co.
Dextran of average molecular weight 17,700 and 10,300 daltons was obtained from Sigma Chemical Co. (St. Louis, MO.).
Porcine pancreatic elastase type III and chromogenic substrate N-succinyl-L-anlanyl-L-alanyl-L-alanyl-p-nitroanilide (SA3pNA) were obtained from Sigma Chemicals Co. (St. Louis, MO). Hydrolysis of the chromogenic sub-strate by the elastase liberates ~-nitroaniline which gives a yellow color whose absorbance is measurable spectrophotometrically (Model 1084 UV Spectrophotometer, Gilford Instruments, Oberlin, OH) at 405 nm. Alpha-l-proteinase inhibitor inhibits this hydrolysis reactionand the extent of elastase inhibition is proportional to the amount of alpha-l-proteinase inhibitor present.
- O
~;
-~Z~6~
Comparisons of the linear changes of absorbance with time both in the presence and in the absence of sample alpha-l-proteinase inhibitor and of sample alpha-l-proteinase inhibitor - dextran covalent complex were made. The amount s of inhibitor was then calculated based on the known molecular weights of the elastase and alpha-l-protelnase inhibitor, on the known 1:1 stoichrometry, and on the known amount of elastase used. A pool of normal human plasma (> 1000 donors) was used as the standard and assigned a 10 value of 1 ~/ml of ~lPI.
Antiserum (rabbit anti-human) to alpha-l-proteinase inhibitor was obtained from Miles Laboratories (Elkhart, IN). Comparison to purified alpha-l-proteinase inhibitor showed that 1 unit of alpha-l-proteinase inhibitor activity was equivalent to 1.3 mg.
Association constants (kaSSoC) between the enzyme (E) and the inhibitor (I) were determined as follows: 25 ~1 each 20 of equimolar amounts of the enzyme and the inhibitor were incubated at 37 C with 1950 ~1 of buffer (0.05 M TRIS, 0.15 M NaCl, pH 7.4) (TRISo is tris(hydroxymethyl)amino methane, supplied by Sigma, St. Louis, Missouri) to obtain a resultant concentration of 3.37 x 10 . At various 25 times, a 200 ~1 aliquot of the enzyme-inhibitor solution was added to 780 ~1 buffer and 20 ~1 substrate (SA3pNA) (60 n~l) and the hydrolysis rate followed in the temperature controlled (37 C~ cuvette with a recorder (Model 6051, Gilford Instruments, Oberlin, Ohio) attachment. During 30 hydrolysis no further enzyme-inhibitor association was assumed (5 fold dilution compared to preincubation) and the initial reaction rate (v) was indicative of the free enzyme (E) present at the end of the respective preincubation times. Enzyme inhibitor association is represented as:
66~
assoc E ~ I EI (1) kdi s soc for kdiSsoc ~ & equimolar concentrations of E & I we get -dE 2 dt kassoc E (2) With initial conditions t = 0, E = Eo (all free enzyme) equation (2) integrates to -- ~ -- = kassoc ( ) o By defining half life of the reaction to 5 to be at E = 0.5Eo we get t = (4) o.5 k E
assoc o Excluslon Chromatography: High performance liquid chroma-tography (HPLC) runs were made wlth a Varian Spherogel TSK
2s 3000 column (Varian Instruments, Palo Alto, CA) of size 7.5 x 300 mm. The buffer used was 0.05 M phosphate, 0.1 M KCl (pH 6.8) at a flow rate of 1 ml/min; 60 ~1 of the sample was applied. A Hitachi model 100-300 (Allen Scientific, Berkeley, CA) UV (280 nm) director with a Hewlett Packard (Hewlett Packard, Palo Alto, CA) Model 3388 computing integrator was used to identify the protein peaks. A Bio Rad (Richmond, CA) molecular weight standard was run for the purpo~se of calibration.
35 Studies Related to Heating_and Oxidation: Alpha-l-proteinase inhibitor and its dextran conjugates, with and without added beef liver catalase as antioxidant, were - 20 ~ 6~
heated in closed tubes at 60 + 0.2 C. The tubes were preheated and due to large mass difference the samples reached the bath temperature in less than 60 seconds. At designated time intervals samples were withdrawn and
5 instantaneously cooled down (by ice bath) to room temperature prior to assay.
Hydrogen peroxide (30% solution, Sigma Chemicals) was used as the oxidation agent to investigate the effect of 0 - 28 o mM H2O2 on the recovery of elastase inhibitory capacity (EIC) following incubation at 37 C ~or 1 hour.
Preparation of covalently bound dextran - alpha-l-~oteinase inhibitor complex: 1 g de~tran (average mol.
wt. 17,700, Sigma Chemicals, industrial grade) was covalently coupled to 209 mg of purified human alpha-l-20 proteinase inhibitor prepared from Cohn Fractlon IV-l (Elastase inhibitory capacity/mg total protein = 1.5) by first dissolving the dextran in 100 ml of water at pH 10.7 and 20 C and then adding to the solution 0.4 g of cyanogen bromide. The pH of the resulting solution of dextran and 25 cyanogen bromide was adjusted to 10.7 and maintained at 20 C for ~0 minutes. This solution was dialyzed against pH 9.6 water (pH adjusted with 1 M Na2CO3) for 3 hours at 20 C to remove spent reactants. Purified alpha-l-proteinase inhibitor, 209 mg, was added to the solution.
30 The pH of the resulting mixture was adjusted to, and maintained at, 9.6 and the temperature held at 5 C for 18 hours to permit the coupling reaction to proceed. At the end of the coupling step the solution was dialyzed against water at pH 7.6 (pH adjusted with 1 M Ha2CO3) for 3 hours 35 at 20 C. 0.7 g glycine was added to the dextran -alpha-l-proteinase inhibitor solution, the final pH of the solution was 7.10. The properties of the resulting ~.Z~6~
alpha-1-proteinase inhibitor - dextran covalent complex are summarized in Table I.
s EXAMPLES 2 - 5 By ~ollowing substantially the procedure described in Example 1 above except that the startiny amount of purified alpha-l-proteinase inhibitor (per gram of dextran) was o changed from 20g mg in Example 1 to 100 mg, 20 mg, 100 mg, 20 mg in Examples 2 - 5, respectively, there were prepared the additional alpha-l-proteinase inhibitor - dextran complexes of Examples 2 - 5 whose properties are summarized in Table I.
Biological Evaluation Table I
Alpha-l-Proteinase Inhibitor Recovery Across Covalent Coupling Example Dextran Moles Dextran % EIC
No. Mol. Wt. Moles ~lPI Recovered -2s 2 17,700 0.0681 52.42%
3 17,700 0.3404 32.14 4 10,300 0.117 28.8%
10,300 0.585 18.4%
30 Table 1 shows the activity, expressed in terms of the elastase inhibitory capacity tEIC), of the alpha-l-proteinase inhibitor - dextran complexes according to the invention having varying molar ratios. Recovery of EIC
appears inverse~y proportional to the dextran/molar ratio.
35 This observation is consistent with the hypotheses that increased amino group substitution results in changed ~- CL-92 ~26~
conformation of the reactive center resulting in decreased biologlcal activity. Subsequent experiments were all carried out with 10,300 mol. wt. dextran.
5 Table II shows the results of precipitin reactions of alpha-l-proteinase inhibitor and its dextran (mol. wt.
10,3000) conjugates with rabbit antiserum to the unmodified protein. For unmodified alpha-l-proteinase inhibitor, only 0.092 ~g of protein was sufficient to obtain a strong o precipitin reaction. For the 0.117 moles dextran/mole alpha-l proteinase inhibitor conjugate, 14.5 ~g of alpha-l-proteinase inhibitor was needed to elicit a siml].ar response -- a very significant increase of antigen concentration. For the 0.585 moles dextran/mole alpha-l-proteinase inhibitor conjugate increase of antigen concentration up to 29.0 ~g was not sufficient to obtain a strong precipitin reaction with the antiserum. These results suggest that increased dextran attachment vla amino group substitution results in masking of the antigenic 20 determinants of the native protein molecule.
~L2~
Table II
Precipitin Reactions oE Alpha l-Proteinase Inhibitor and Conjugates with Rabbit Antiserum (dil. 1:2) to Unmodified Protein Antigen Conc. Precipitin Sample (~g) Reaction Unmodified alpha-l- 0.092 Strong proteinase inhibitor 10 0.117 Moles Dextran 14.5 Strong Mole alPI
(Ex. No. 4) 0.585 Moles Dextran 1.95 Weak Moles lPI
(Ex. No. 5) 29.0 Weak Table III shows the calculation of the association constants (kaSsoc) between the inhibitors and the enzyme 20 according to equation (4). The initial reaction rate (~
absorbance/5 minutes) depicts the hydrolysis rate of the substrate by the free enzyme present following the respective preincubation time. Initial reaction rate, in the absence of the inhibitor, was determined and the time 25 required for this rate to decrease to half of its original value (to 5) was calculated. Equation (4) was subsequently used to calculate k for each of the 3 cases.
assoc Beatty et al, J. Biol. Chem., 255, 3931 (1980), reported 30 the kaSSoC value between native alpha-l-proteinase inhibitor and porclne elastase (each at 1.4 x 10 8 M) to be 1 x 10 M sec. . Our value (1.85 x 10 M 1 sec. 1) for the native protein is reasonably close to that of Beatty et al considering the variabilities in source/purity of the 35 protein, molarities of the protein and the enzyme and the alpha-l proteinase inhibitor standard used for the assays.
TABLE III
Rate Constant for the Association Between the Enzyme and the Inhibitor s Initial Preincubation Reac. Rate Time ~ Absorbance t 5 -1 -1 Sample(Secs.) 5 Minutes (segs.) (M Sec Control, No ~lPI -- 0.890 10 Native lRI 15 0.460 5 0.310 16.17 1.85 x 10 0.173 0.170 0.128 0.117~1oles Dextran 20 0.450 ole ~lPI 45 0.285 21.49 1.41 x 105 (Ex. No. 4) 75 0.195 120 0.130 0.585 Moles Dextran 25 0.495 ~lole ~lPI65 0.285 34.67 8.56 x 10 (Ex. No. 5) 100 0.205 145 0.135 2s A progressive decrease of kaSSoC is noted with increasing dextran concentrations. Conformational changes in the protein molecule and steric hindrances are probably involved during the formation of the covalent conjugates resulting in decreased association rates with the enzyme.
In order to investigate the pH stability of these prepara-tions, experimental samples were adjusted to pH 3.0 with controls at pH 7.40 and incubated for 24 hours at +5 C.
Following this, pH was adjusted back up to 7.40 for the 3s experimental samples and EIC assays carried out immediately. Samples were further incubated for 24 hours ~2~66~
at +5 C and reassayed. In Table IV the results are presented as percent of control at each assay point.
TABLE IV
pH Stability ~pH 3~0) of the Native Proteln and its Conjugates Recovery of EIC as % of Control After Adiustment to PH 7.4 Incubation Time Sample Immediate 24 hrs. (5 C) Native lPI 41 66 Con~ugate w 0.117 68 81 5 Moles Dextran Mole lPI
(Ex. No. 4) Conjugate w 0.585 55 93 Moles Dextran Mole lPI
(Ex. No. 5) The inactivation of alpha-l-proteinase inhibitor at acid pH
is believed to be attributable to formation of molecular aggregates. Reincubation at neutral pH results in recovery of EIC activity which is time dependent as depicted in 2s Table IV. The conjugates show improved recovery compared to the native protein.
Effects of heating at 60 C of these samples are shown in Figure 1. A significant difference here is observed 30 between the native protein and its conjugates. Within 60 minutes, native alpha-l-proteinase inhibitor loses >90~ of its initial activity whereas the conjugates do not show any significant reduction of EIC.
35 Oxidative inactivation of alpha-l-proteinase inhibitor has been related to its reactive center methionine according to Johnson et al, J. Biol. Chem., 254, 4022 (1979). Hydrogen perioxide and other agents (periodate, dimethyl sulfoxide, chloromine-T, N-chloros~ccinamide) have been used to oxidize methionine to inactive methionine sulfoxide.
Figure 2 (oxidation at pH 7.4) depicts the effects of various concentrations of H2O2 on the samples. Oxidation at pH 6.4 showed similar trends in the data. It is apparent from Figure 2 that only the alpha-l-proteinase inhibitor - dextran-catalase conjugate (lPI - dextran conjugate further complexed with bovine liver catalase 10 wherein 100 mg of catalase per g of dextran was added duriny the coupling reaction of lPI with dextran) showed resistance to oxidative degradation by H2O2. Native alpha-l-proteinase inhibitor as well as its dextran conju-gate showed significant progressive loss of EIC with increasing H2O2 concentration. It was experimentally determined that physical addition of equivalent amounts of catalase would also inhibit H2O2 oxidation. The advantage of covalently bound catalase might be that in an 1n vivo system close proximity of alpha-l-proteinase inhibitor and 20 catalase may be of importance. It is to be understood that any antioxidant enzyme may be used, e.g. catalase or an equivalent enzyme such as superoxide di.smutase.
HPLC scans of the various samples are shown in Figure 3.
2s As expected, the conjugates show a heterogenous molecular species distribution, the void volume fraction (retention time ~5.5 minutes) being <5~ of total protein. On the other end of the spectrum no significant portion of the protein had retention times >11.71 minutes, the retention time corresponding to that of horse myoglobin (m.w. 7,000).
The HPLC results were confirmed with SDS-PAGE which also determined the presence of higher molecular weight components.
35 Accordingly, the data set forth and described above illustrate the advantages of the covalent alpha-l-proteinase inhibitor complex with a water soluble polymer, 1.2~26~
particularly, such advantages including improved heat and pH stability and reduced antigenicity. Dextran, a polysaccharride which has been widely used as a blood plasma volume extender, has been selected as the water s soluble polymer of choice because of its ready avallability and the convenience by which it may undergo activation with the simple coupling agent, cyanoyen bromide.
In contrast to native alpha-l-proteinase inhibitor, the 10 alpha-l-proteinase inhibitor produced by intracellular recombinant DNA technology is non-glycosylated. The process of this invention may be advantageously employed to obtain a glycosylated form, that is, a chemically, covalently coupled alpha-l-proteinase inhibitor - dextran 15 conjugate, of the r-DNA-produced alpha-l-proteinase inhibitor which would be expeoted to possess the characteristics of improved heat and pH stability and reduced antigenicity possessed by the conjugate produced from native (that is, plasma) alpha-l-proteinase inhibitor.
Hydrogen peroxide (30% solution, Sigma Chemicals) was used as the oxidation agent to investigate the effect of 0 - 28 o mM H2O2 on the recovery of elastase inhibitory capacity (EIC) following incubation at 37 C ~or 1 hour.
Preparation of covalently bound dextran - alpha-l-~oteinase inhibitor complex: 1 g de~tran (average mol.
wt. 17,700, Sigma Chemicals, industrial grade) was covalently coupled to 209 mg of purified human alpha-l-20 proteinase inhibitor prepared from Cohn Fractlon IV-l (Elastase inhibitory capacity/mg total protein = 1.5) by first dissolving the dextran in 100 ml of water at pH 10.7 and 20 C and then adding to the solution 0.4 g of cyanogen bromide. The pH of the resulting solution of dextran and 25 cyanogen bromide was adjusted to 10.7 and maintained at 20 C for ~0 minutes. This solution was dialyzed against pH 9.6 water (pH adjusted with 1 M Na2CO3) for 3 hours at 20 C to remove spent reactants. Purified alpha-l-proteinase inhibitor, 209 mg, was added to the solution.
30 The pH of the resulting mixture was adjusted to, and maintained at, 9.6 and the temperature held at 5 C for 18 hours to permit the coupling reaction to proceed. At the end of the coupling step the solution was dialyzed against water at pH 7.6 (pH adjusted with 1 M Ha2CO3) for 3 hours 35 at 20 C. 0.7 g glycine was added to the dextran -alpha-l-proteinase inhibitor solution, the final pH of the solution was 7.10. The properties of the resulting ~.Z~6~
alpha-1-proteinase inhibitor - dextran covalent complex are summarized in Table I.
s EXAMPLES 2 - 5 By ~ollowing substantially the procedure described in Example 1 above except that the startiny amount of purified alpha-l-proteinase inhibitor (per gram of dextran) was o changed from 20g mg in Example 1 to 100 mg, 20 mg, 100 mg, 20 mg in Examples 2 - 5, respectively, there were prepared the additional alpha-l-proteinase inhibitor - dextran complexes of Examples 2 - 5 whose properties are summarized in Table I.
Biological Evaluation Table I
Alpha-l-Proteinase Inhibitor Recovery Across Covalent Coupling Example Dextran Moles Dextran % EIC
No. Mol. Wt. Moles ~lPI Recovered -2s 2 17,700 0.0681 52.42%
3 17,700 0.3404 32.14 4 10,300 0.117 28.8%
10,300 0.585 18.4%
30 Table 1 shows the activity, expressed in terms of the elastase inhibitory capacity tEIC), of the alpha-l-proteinase inhibitor - dextran complexes according to the invention having varying molar ratios. Recovery of EIC
appears inverse~y proportional to the dextran/molar ratio.
35 This observation is consistent with the hypotheses that increased amino group substitution results in changed ~- CL-92 ~26~
conformation of the reactive center resulting in decreased biologlcal activity. Subsequent experiments were all carried out with 10,300 mol. wt. dextran.
5 Table II shows the results of precipitin reactions of alpha-l-proteinase inhibitor and its dextran (mol. wt.
10,3000) conjugates with rabbit antiserum to the unmodified protein. For unmodified alpha-l-proteinase inhibitor, only 0.092 ~g of protein was sufficient to obtain a strong o precipitin reaction. For the 0.117 moles dextran/mole alpha-l proteinase inhibitor conjugate, 14.5 ~g of alpha-l-proteinase inhibitor was needed to elicit a siml].ar response -- a very significant increase of antigen concentration. For the 0.585 moles dextran/mole alpha-l-proteinase inhibitor conjugate increase of antigen concentration up to 29.0 ~g was not sufficient to obtain a strong precipitin reaction with the antiserum. These results suggest that increased dextran attachment vla amino group substitution results in masking of the antigenic 20 determinants of the native protein molecule.
~L2~
Table II
Precipitin Reactions oE Alpha l-Proteinase Inhibitor and Conjugates with Rabbit Antiserum (dil. 1:2) to Unmodified Protein Antigen Conc. Precipitin Sample (~g) Reaction Unmodified alpha-l- 0.092 Strong proteinase inhibitor 10 0.117 Moles Dextran 14.5 Strong Mole alPI
(Ex. No. 4) 0.585 Moles Dextran 1.95 Weak Moles lPI
(Ex. No. 5) 29.0 Weak Table III shows the calculation of the association constants (kaSsoc) between the inhibitors and the enzyme 20 according to equation (4). The initial reaction rate (~
absorbance/5 minutes) depicts the hydrolysis rate of the substrate by the free enzyme present following the respective preincubation time. Initial reaction rate, in the absence of the inhibitor, was determined and the time 25 required for this rate to decrease to half of its original value (to 5) was calculated. Equation (4) was subsequently used to calculate k for each of the 3 cases.
assoc Beatty et al, J. Biol. Chem., 255, 3931 (1980), reported 30 the kaSSoC value between native alpha-l-proteinase inhibitor and porclne elastase (each at 1.4 x 10 8 M) to be 1 x 10 M sec. . Our value (1.85 x 10 M 1 sec. 1) for the native protein is reasonably close to that of Beatty et al considering the variabilities in source/purity of the 35 protein, molarities of the protein and the enzyme and the alpha-l proteinase inhibitor standard used for the assays.
TABLE III
Rate Constant for the Association Between the Enzyme and the Inhibitor s Initial Preincubation Reac. Rate Time ~ Absorbance t 5 -1 -1 Sample(Secs.) 5 Minutes (segs.) (M Sec Control, No ~lPI -- 0.890 10 Native lRI 15 0.460 5 0.310 16.17 1.85 x 10 0.173 0.170 0.128 0.117~1oles Dextran 20 0.450 ole ~lPI 45 0.285 21.49 1.41 x 105 (Ex. No. 4) 75 0.195 120 0.130 0.585 Moles Dextran 25 0.495 ~lole ~lPI65 0.285 34.67 8.56 x 10 (Ex. No. 5) 100 0.205 145 0.135 2s A progressive decrease of kaSSoC is noted with increasing dextran concentrations. Conformational changes in the protein molecule and steric hindrances are probably involved during the formation of the covalent conjugates resulting in decreased association rates with the enzyme.
In order to investigate the pH stability of these prepara-tions, experimental samples were adjusted to pH 3.0 with controls at pH 7.40 and incubated for 24 hours at +5 C.
Following this, pH was adjusted back up to 7.40 for the 3s experimental samples and EIC assays carried out immediately. Samples were further incubated for 24 hours ~2~66~
at +5 C and reassayed. In Table IV the results are presented as percent of control at each assay point.
TABLE IV
pH Stability ~pH 3~0) of the Native Proteln and its Conjugates Recovery of EIC as % of Control After Adiustment to PH 7.4 Incubation Time Sample Immediate 24 hrs. (5 C) Native lPI 41 66 Con~ugate w 0.117 68 81 5 Moles Dextran Mole lPI
(Ex. No. 4) Conjugate w 0.585 55 93 Moles Dextran Mole lPI
(Ex. No. 5) The inactivation of alpha-l-proteinase inhibitor at acid pH
is believed to be attributable to formation of molecular aggregates. Reincubation at neutral pH results in recovery of EIC activity which is time dependent as depicted in 2s Table IV. The conjugates show improved recovery compared to the native protein.
Effects of heating at 60 C of these samples are shown in Figure 1. A significant difference here is observed 30 between the native protein and its conjugates. Within 60 minutes, native alpha-l-proteinase inhibitor loses >90~ of its initial activity whereas the conjugates do not show any significant reduction of EIC.
35 Oxidative inactivation of alpha-l-proteinase inhibitor has been related to its reactive center methionine according to Johnson et al, J. Biol. Chem., 254, 4022 (1979). Hydrogen perioxide and other agents (periodate, dimethyl sulfoxide, chloromine-T, N-chloros~ccinamide) have been used to oxidize methionine to inactive methionine sulfoxide.
Figure 2 (oxidation at pH 7.4) depicts the effects of various concentrations of H2O2 on the samples. Oxidation at pH 6.4 showed similar trends in the data. It is apparent from Figure 2 that only the alpha-l-proteinase inhibitor - dextran-catalase conjugate (lPI - dextran conjugate further complexed with bovine liver catalase 10 wherein 100 mg of catalase per g of dextran was added duriny the coupling reaction of lPI with dextran) showed resistance to oxidative degradation by H2O2. Native alpha-l-proteinase inhibitor as well as its dextran conju-gate showed significant progressive loss of EIC with increasing H2O2 concentration. It was experimentally determined that physical addition of equivalent amounts of catalase would also inhibit H2O2 oxidation. The advantage of covalently bound catalase might be that in an 1n vivo system close proximity of alpha-l-proteinase inhibitor and 20 catalase may be of importance. It is to be understood that any antioxidant enzyme may be used, e.g. catalase or an equivalent enzyme such as superoxide di.smutase.
HPLC scans of the various samples are shown in Figure 3.
2s As expected, the conjugates show a heterogenous molecular species distribution, the void volume fraction (retention time ~5.5 minutes) being <5~ of total protein. On the other end of the spectrum no significant portion of the protein had retention times >11.71 minutes, the retention time corresponding to that of horse myoglobin (m.w. 7,000).
The HPLC results were confirmed with SDS-PAGE which also determined the presence of higher molecular weight components.
35 Accordingly, the data set forth and described above illustrate the advantages of the covalent alpha-l-proteinase inhibitor complex with a water soluble polymer, 1.2~26~
particularly, such advantages including improved heat and pH stability and reduced antigenicity. Dextran, a polysaccharride which has been widely used as a blood plasma volume extender, has been selected as the water s soluble polymer of choice because of its ready avallability and the convenience by which it may undergo activation with the simple coupling agent, cyanoyen bromide.
In contrast to native alpha-l-proteinase inhibitor, the 10 alpha-l-proteinase inhibitor produced by intracellular recombinant DNA technology is non-glycosylated. The process of this invention may be advantageously employed to obtain a glycosylated form, that is, a chemically, covalently coupled alpha-l-proteinase inhibitor - dextran 15 conjugate, of the r-DNA-produced alpha-l-proteinase inhibitor which would be expeoted to possess the characteristics of improved heat and pH stability and reduced antigenicity possessed by the conjugate produced from native (that is, plasma) alpha-l-proteinase inhibitor.
Claims (46)
1. A process for producing a covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer having hydroxy groups pendant to the polymer backbone, which hydroxy groups and amino groups pendant to alpha-1-proteinase inhibitor are chemically reactive with a polyfunctional coupling compound, com-prising the steps of:
(a) contacting the water soluble polymer having hydroxy groups pendant to the polymer backbone, which hydroxy groups are chemically reactive with a polyfunctional coupling compound, with a polyfunctional coupling compound having functional groups which are reactive with said hydroxy groups in a chemical activation reaction to obtain an activated intermediate which is reactive with amino groups pendant to the protein, alpha-1-proteinase inhibitor; and (b) contacting the activated intermediate from step (a) with alpha-1-proteinase inhibitor in a chemical coupling reaction to effect covalent attachment and to thereby obtain a covalently attached complex of alpha-1-proteinase inhibitor with the water soluble polymer.
(a) contacting the water soluble polymer having hydroxy groups pendant to the polymer backbone, which hydroxy groups are chemically reactive with a polyfunctional coupling compound, with a polyfunctional coupling compound having functional groups which are reactive with said hydroxy groups in a chemical activation reaction to obtain an activated intermediate which is reactive with amino groups pendant to the protein, alpha-1-proteinase inhibitor; and (b) contacting the activated intermediate from step (a) with alpha-1-proteinase inhibitor in a chemical coupling reaction to effect covalent attachment and to thereby obtain a covalently attached complex of alpha-1-proteinase inhibitor with the water soluble polymer.
2. A process according to claim 1 including the 35 further step of:
(c) isolating the covalently attached complex of alpha-1-proteinase inhibitor with the water soluble polymer obtained in step (b) from residual uncoupled alpha-1-proteinase inhibitor and water soluble polymer and undesirable compounds in the chemical coupling reaction mixture.
(c) isolating the covalently attached complex of alpha-1-proteinase inhibitor with the water soluble polymer obtained in step (b) from residual uncoupled alpha-1-proteinase inhibitor and water soluble polymer and undesirable compounds in the chemical coupling reaction mixture.
3. A process according to claim 1 wherein the water soluble polymer having hydroxy groups pendant to the polymer backbone, which hydroxy groups are chemically reactive with a polyfunctional coupling compound, is selected from (a) dextran and dextran derivatives including dextran sulphate, P-aminoethyl cross-linked dextran, and carboxymethyl dextran; (b) cellulose and cellulose deriva-tives including methyl cellulose and carboxymethyl cellu-lose; (c) starch and dextrines derived from starch and dextrine derivatives; (d) polyalkylene glycols and deriva-tives thereof including polyethylene glycols and methoxy-polyethene glycols; (e) heparin; (f) polyvinyl alcohol; and (g) polyvinylpyrrolidone.
4. A process according to claim 3 wherein the polyfunctional coupling compound is selected from (a) a cyanogen halide wherein the halide is bromide, chloride or iodide; (b) cyanuric chloride (2,4,6-trichloro-s-1,3,5-triazine) and 2-amino-4,6-dichloro-s-1,3,5-triazine;
(c) tolylene diisocyanate; (d) tolylene diisothiocyanate;
and (e) 1,4-diaminobenzene combined with cyanogen bromide.
(c) tolylene diisocyanate; (d) tolylene diisothiocyanate;
and (e) 1,4-diaminobenzene combined with cyanogen bromide.
5. A process according to claim 4 including the further step of:
(c) isolating the covalently attached complex of alpha-1-proteinase inhibitor with the water soluble polymer obtained in step (b) from residual uncoupled alpha-1-proteinase inhibitor and water soluble polymer and undesirable compounds in the chemical coupling reaction mixture by means, effective to separate the complex from residual uncomplexed alpha-1-proteinase inhibitor and water soluble polymer and undesirable compounds in the chemical coupling reaction mixture obtained in step (b), selected from ion exchange chromatography, affinity chroma-tography, dialysis, ultrafiltration and electrophoresis techniques.
(c) isolating the covalently attached complex of alpha-1-proteinase inhibitor with the water soluble polymer obtained in step (b) from residual uncoupled alpha-1-proteinase inhibitor and water soluble polymer and undesirable compounds in the chemical coupling reaction mixture by means, effective to separate the complex from residual uncomplexed alpha-1-proteinase inhibitor and water soluble polymer and undesirable compounds in the chemical coupling reaction mixture obtained in step (b), selected from ion exchange chromatography, affinity chroma-tography, dialysis, ultrafiltration and electrophoresis techniques.
6. A process according to claim 4 comprising the steps of:
(a) contacting a water soluble polymer having hydroxy groups pendant to the polymer backbone, which hydroxy groups are chemically reactive with a polyfunctional coupling compound, selected from (i) dextran and dextran derivatives including dextran sulphate, p-aminoethyl cross-linked dextran, and carboxymethyl dextran, (ii) dextrines and dextrine derivatives, (iii) cellu-lose and cellulose derivatives including methyl cellulose and carboxy-methyl cellulose, and (iv) polyethylene glycols and derivatives thereof including methoxypolyethylene glycols, with a polyfunctional coupling compound selected from (i) cyanogen bromide and (ii) cyanuric chloride (2,4,6-tri-chloro-s-1,3,5-triazine) and 2-amino-4,6-dichloro-s-1,3,5-triazine in a chemical activation reaction to obtain an activated intermediate which is reactive with amino groups pendant to the protein, alpha-1-proteinase inhibitor; and (b) contacting the activated intermediate from step (a) with alpha-1-proteinase inhibitor in a chemical coupling reaction to effect covalent attachment and to thereby obtain a covalently attached complex of alpha-1-proteinase inhibitor with the water soluble polymer.
(a) contacting a water soluble polymer having hydroxy groups pendant to the polymer backbone, which hydroxy groups are chemically reactive with a polyfunctional coupling compound, selected from (i) dextran and dextran derivatives including dextran sulphate, p-aminoethyl cross-linked dextran, and carboxymethyl dextran, (ii) dextrines and dextrine derivatives, (iii) cellu-lose and cellulose derivatives including methyl cellulose and carboxy-methyl cellulose, and (iv) polyethylene glycols and derivatives thereof including methoxypolyethylene glycols, with a polyfunctional coupling compound selected from (i) cyanogen bromide and (ii) cyanuric chloride (2,4,6-tri-chloro-s-1,3,5-triazine) and 2-amino-4,6-dichloro-s-1,3,5-triazine in a chemical activation reaction to obtain an activated intermediate which is reactive with amino groups pendant to the protein, alpha-1-proteinase inhibitor; and (b) contacting the activated intermediate from step (a) with alpha-1-proteinase inhibitor in a chemical coupling reaction to effect covalent attachment and to thereby obtain a covalently attached complex of alpha-1-proteinase inhibitor with the water soluble polymer.
7. A process according to claim 6 including the further step of:
(c) isolating the covalently attached complex of alpha-1-proteinase inhibitor with the water soluble polymer obtained in step (b) from residual uncoupled alpha-1-proteinase inhibitor, water soluble polymer and undesirable compounds in the chemical coupling reaction mixture by ion exchange chromatography and ultra-filtration techniques.
(c) isolating the covalently attached complex of alpha-1-proteinase inhibitor with the water soluble polymer obtained in step (b) from residual uncoupled alpha-1-proteinase inhibitor, water soluble polymer and undesirable compounds in the chemical coupling reaction mixture by ion exchange chromatography and ultra-filtration techniques.
8. A process according to claim 6 wherein the water soluble polymer is selected from dextran and dextran derivatives and the polyfunctional coupling compound is cyanogen bromide.
9. A covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer pro-duced by the process of claim 1.
10. A covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer pro-duced by the process of claim 5.
11. A covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer pro-duced by the process of claim 6.
12. A covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer pro-duced by the process of claim 8.
13. A process according to claim 1, including a step of sterilizing the resulting covalently attached complex of alpha-1-proteinase inhibitor and water soluble polymer, to render the complex non-viral infective.
14. A process according to claim 5, including a step of sterilizing the resulting covalently attached complex of alpha-1-proteinase inhibitor and water soluble polymer, to render the complex non-viral infective.
15. A process according to claim 6, including a step of sterilizing the resulting covalently attached complex of alpha-1-proteinase inhibitor and water soluble polymer, to render the complex non-viral infective.
16. A process according to claim 8, including a step of sterilizing the resulting covalently attached complex of alpha-1-proteinase inhibitor and water soluble polymer, to render the complex non-viral infective.
17. A sterilized covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer produced by the process of claim 13.
18. A sterilized covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer produced by the process of claim 14.
19. A sterilized covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer produced by the process of claim 15.
20. A sterilized covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer produced by the process of claim 16.
21. A process according to claim 1, comprising the further addition of about 1.0 to 300 mg of antioxidant catalase enzyme per g of dextran (i) in step (b) along with the alpha-1-proteinase inhibitor to obtain a co-valently attached complex of alpha-1-proteinase inhibitor and water insoluble polymer and catalase, or (ii) follow-ing step (b) to obtain an ionic association of the co-valently attached complex of alpha-1-proteinase inhibitor and the water soluble polymer with catalase.
22. A process according to claim 2, comprising the further addition of about 1.0 to 300 mg of antioxidant catalase enzyme per g of dextran (i) in step (b) along with an alpha-1-proteinase inhibitor to obtain a co-valently attached complex of alpha-1-proteinase inhibitor and water insoluble polymer and catalase, or (ii) follow-ing step (b) to obtain an ionic association of the co-valently attached complex of alpha-1-proteinase inhibitor and the water soluble polymer with catalase.
23. A process according to claim 6, comprising the further addition of about 1.0 to 300 mg of antioxidant catalase enzyme per g of dextran (i) in step (b) along with the alpha-1-proteinase inhibitor to obtain a co-valently attached complex of alpha-1-proteinase inhibitor and water insoluble polymer and catalase, or (ii) follow-ing step (b) to obtain an ionic association of the co-valently attached complex of alpha-1-proteinase inhibitor and the water soluble polymer with catalase.
24. A process according to claim 7, comprising the further addition of about 1.0 to 300 mg of antioxidant catalase enzyme per g of dextran (i) in step (b) along with the alpha-1-proteinase inhibitor to obtain a co-valently attached complex of alpha-1-proteinase inhibitor and water insoluble polymer and catalase, or (ii) follow-ing step (b) to obtain an ionic association of the co-valently attached complex of alpha-1-proteinase inhibitor and the water soluble polymer with catalase.
25. A process according to claim 8, comprising the further addition of about 100 mg of antioxidant beef liver catalase enzyme per g of dextran (i) in step (b) along with the alpha-1-proteinase inhibitor to obtain a covalently attached complex of alpha-1-proteinase inhi-bitor and water insoluble polymer and catalase, or (ii) following step (b) to obtain an ionic association of the covalently attached complex of alpha-1-proteinase inhi-bitor and the water soluble polymer with catalase.
26. A covalently attached complex of alpha-1-proteinase inhibitor, a water soluble polymer, and antioxidant catalase produced according to claim 21.
27. A covalently attached complex of alpha-1-proteinase inhibitor, a water soluble polymer, and antioxidant catalase produced according to claim 22.
28. A covalently attached complex of alpha-1-proteinase inhibitor, a water soluble polymer, and antioxidant catalase produced according to claim 23.
29. A covalently attached complex of alpha-1-proteinase inhibitor, a water soluble polymer, and antioxidant catalase produced according to claim 24.
30. A covalently attached complex of alpha-1-proteinase inhibitor, a water soluble polymer, and antioxidant catalase produced according to claim 25.
31. A pharmaceutical preparation comprising a phar-maceutically acceptable and useful concentration of the complex of claim 9 and a pharmaceutically accept-able carrier.
32. A pharmaceutical preparation comprising a phar-maceutically acceptable and useful concentration of the complex of claim 10 and a pharmaceutically accept-able carrier.
33. A pharmaceutical preparation comprising a phar-maceutically acceptable and useful concentration of the complex of claim 11 and a pharmaceutically accept-able carrier.
34. A pharmaceutical preparation comprising a phar-maceutically acceptable and useful concentration of the complex of claim 12 and a pharmaceutically accept-able carrier.
35. A sterilized pharmaceutical preparation produced by sterilizing the pharmaceutical preparation of claim 31 to render the preparation non-viral infective.
36. A sterilized pharmaceutical preparation produced by sterilizing the pharmaceutical preparation of claim 32 to render the preparation non-viral infective.
37. A sterilized pharmaceutical preparation produced by sterilizing the pharmaceutical preparation of claim 33 to render the preparation non-viral infective.
38. A sterilized pharmaceutical preparation produced by sterilizing the pharmaceutical preparation of claim 34 to render the preparation non-viral infective.
39. A pharmaceutical preparation comprising a phar-maceutically acceptable and useful concentration of the complex of claim 26 and a pharmaceutically accept-able carrier.
40. A pharmaceutical preparation comprising a phar-maceutically acceptable and useful concentration of the complex of claim 27 and a pharmaceutically accept-able carrier.
41. A pharmaceutical preparation comprising a phar-maceutically acceptable and useful concentration of the complex of claim 30 and a pharmaceutically accept-able carrier.
42. A pharmaceutical preparation for treating pul-monary emphysema and respiratory distress syndrome which comprises a therapeutically effective amount of a covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer, as defined in claim 9, in association with a pharmaceutically acceptable carrier.
43. A sterilized pharmaceutical preparation pro-duced by sterilizing the pharmaceutical preparation of claim 42 to render the preparation non-viral infective.
44. A pharmaceutical preparation comprising an effective amount of the complex of claim 9 in asso-ciation with an acceptable carrier.
45. A preparation according to claim 44 in the form of a reagent for diagnostic purposes, containing an effective reagent amount of said complex.
46. A preparation according to claim 44 for tissue culture purposes containing a growth effective amount of said complex.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US565,810 | 1983-12-27 | ||
US06/565,810 US4496689A (en) | 1983-12-27 | 1983-12-27 | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1242664A true CA1242664A (en) | 1988-10-04 |
Family
ID=24260195
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000465464A Expired CA1242664A (en) | 1983-12-27 | 1984-10-15 | COVALENTLY ATTACHED COMPLEX OF .alpha.-1-PROTEINASE INHIBITOR WITH A WATER SOLUBLE POLYMER |
Country Status (7)
Country | Link |
---|---|
US (1) | US4496689A (en) |
EP (1) | EP0147761B1 (en) |
JP (1) | JPH0696541B2 (en) |
AT (1) | ATE56025T1 (en) |
CA (1) | CA1242664A (en) |
DE (1) | DE3483094D1 (en) |
ES (1) | ES8605826A1 (en) |
Families Citing this family (882)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3440988A1 (en) * | 1984-11-09 | 1986-07-10 | Hoechst Ag, 6230 Frankfurt | METHOD FOR CLEAVING PEPTIDES AND PROTEINS ON THE METHIONYL BOND |
GB8430252D0 (en) * | 1984-11-30 | 1985-01-09 | Beecham Group Plc | Compounds |
US4970300A (en) * | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
US4713240A (en) * | 1985-04-04 | 1987-12-15 | Research Corporation | Vaccines based on insoluble supports |
US5206344A (en) * | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
US4766106A (en) * | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4791192A (en) * | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4745180A (en) * | 1986-06-27 | 1988-05-17 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using heparin fragments |
US4894226A (en) * | 1986-11-14 | 1990-01-16 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polyproline conjugation |
FR2610633B1 (en) * | 1987-02-05 | 1992-09-18 | Lille Transfusion Sanguine | PROCESS FOR OBTAINING A 1-ANTITRYPSIN CONCENTRATE FROM HUMAN PLASMA AND THE USE THEREOF AS A MEDICAMENT |
US4847325A (en) * | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
JP2761881B2 (en) * | 1988-03-10 | 1998-06-04 | チッソ株式会社 | An antibody-immobilized carrier for affinity chromatography |
US5162307A (en) * | 1988-09-09 | 1992-11-10 | Board Of Trustees Of The University Of Kentucky | Polymer bound elastase inhibitors |
EP0403605A4 (en) * | 1988-09-09 | 1991-08-21 | Univ Kentucky Res Found | Elastase inhibiting polymers and methods |
US5162430A (en) * | 1988-11-21 | 1992-11-10 | Collagen Corporation | Collagen-polymer conjugates |
US5510418A (en) * | 1988-11-21 | 1996-04-23 | Collagen Corporation | Glycosaminoglycan-synthetic polymer conjugates |
US5306500A (en) * | 1988-11-21 | 1994-04-26 | Collagen Corporation | Method of augmenting tissue with collagen-polymer conjugates |
US5264214A (en) * | 1988-11-21 | 1993-11-23 | Collagen Corporation | Composition for bone repair |
US5166322A (en) * | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
JP2896580B2 (en) * | 1989-08-25 | 1999-05-31 | チッソ株式会社 | Amylose-lysozyme hybrid, activated sugar and its production |
US5179080A (en) * | 1989-08-31 | 1993-01-12 | Clinical Homecare, Corp. | Formulations containing growth hormone and nutritional supplements, and methods of treating malnutrition in chronic lung disease |
JP2978187B2 (en) * | 1989-11-02 | 1999-11-15 | 日本ケミカルリサーチ株式会社 | Method for producing modified superoxide dismutase |
JPH082917B2 (en) * | 1989-11-15 | 1996-01-17 | サンド・アクチエンゲゼルシヤフト | Polymyxin complex |
US5177059A (en) * | 1989-11-15 | 1993-01-05 | Sandoz Ltd. | Polymyxin B conjugates |
AU7681091A (en) * | 1990-04-05 | 1991-10-30 | John R Hoidal | Method and medicament for prevention or medication of human leucocyte elastase-mediated pulmonary diseases |
US5232984A (en) * | 1990-10-15 | 1993-08-03 | The Board Of The Regents The University Of Texas | Biocompatible microcapsules |
US5595732A (en) * | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
CA2108689A1 (en) * | 1991-04-18 | 1992-10-19 | Edward J. Miller | Compositions and methods for inhibiting elastase |
US5284934A (en) * | 1991-04-24 | 1994-02-08 | Health Research Inc. | Synthesis and utilization of carbohydrate-binding polymer-lectin conjugates |
US5169627A (en) * | 1991-10-28 | 1992-12-08 | Mount Sinai School Of Medicine Of The City University Of New York | Oral pharmaceutical composition containing a polyethylene glycol-immunoglobulin G conjugate for reconstitution of secretory immunity and method of reconstituting secretory immunity |
WO1994001483A1 (en) * | 1992-07-02 | 1994-01-20 | Collagen Corporation | Biocompatible polymer conjugates |
US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
US6090925A (en) * | 1993-03-09 | 2000-07-18 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
US5981719A (en) * | 1993-03-09 | 1999-11-09 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
US5554730A (en) * | 1993-03-09 | 1996-09-10 | Middlesex Sciences, Inc. | Method and kit for making a polysaccharide-protein conjugate |
US5514665A (en) * | 1993-12-30 | 1996-05-07 | University Of British Columbia | Method of preventing or reducing the risk of infection by bacterial pathogens utilizing simple and conjugated dextrans |
US5877016A (en) | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
US5708142A (en) | 1994-05-27 | 1998-01-13 | Genentech, Inc. | Tumor necrosis factor receptor-associated factors |
DE4423131A1 (en) * | 1994-07-01 | 1996-01-04 | Bayer Ag | New hIL-4 mutant proteins as antagonists or partial agonists of human interleukin 4 |
US5545553A (en) * | 1994-09-26 | 1996-08-13 | The Rockefeller University | Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them |
DK0885242T3 (en) | 1995-06-07 | 2008-07-14 | Glaxo Group Ltd | Peptides and compounds that bind to a thrombopoietin receptor |
US5869451A (en) | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
US6833408B2 (en) * | 1995-12-18 | 2004-12-21 | Cohesion Technologies, Inc. | Methods for tissue repair using adhesive materials |
US7883693B2 (en) | 1995-12-18 | 2011-02-08 | Angiodevice International Gmbh | Compositions and systems for forming crosslinked biomaterials and methods of preparation of use |
JP4193917B2 (en) * | 1995-12-18 | 2008-12-10 | アンジオデバイス インターナショナル ゲーエムベーハー | Crosslinked polymer composition and method of use thereof |
US6458889B1 (en) | 1995-12-18 | 2002-10-01 | Cohesion Technologies, Inc. | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use |
US6998116B1 (en) * | 1996-01-09 | 2006-02-14 | Genentech, Inc. | Apo-2 ligand |
US20050089958A1 (en) * | 1996-01-09 | 2005-04-28 | Genentech, Inc. | Apo-2 ligand |
US6030945A (en) * | 1996-01-09 | 2000-02-29 | Genentech, Inc. | Apo-2 ligand |
US6046048A (en) * | 1996-01-09 | 2000-04-04 | Genetech, Inc. | Apo-2 ligand |
US20020165157A1 (en) * | 1996-04-01 | 2002-11-07 | Genentech, Inc. | Apo-2LI and Apo-3 polypeptides |
CA2249206A1 (en) * | 1996-04-01 | 1997-10-09 | Genentech, Inc. | Apo-2li and apo-3 apoptosis polypeptides |
US7091311B2 (en) * | 1996-06-07 | 2006-08-15 | Smithkline Beecham Corporation | Peptides and compounds that bind to a receptor |
US5851984A (en) * | 1996-08-16 | 1998-12-22 | Genentech, Inc. | Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides |
US6159462A (en) * | 1996-08-16 | 2000-12-12 | Genentech, Inc. | Uses of Wnt polypeptides |
US6462176B1 (en) * | 1996-09-23 | 2002-10-08 | Genentech, Inc. | Apo-3 polypeptide |
DE69713517D1 (en) | 1996-10-15 | 2002-07-25 | Medical Analysis Systems Inc | Process for the stabilization of troponin I (CTnI) by conjugation with an active polymer |
US20040241645A1 (en) * | 1997-01-31 | 2004-12-02 | Genentech, Inc. | O-fucosyltransferase |
JP3394540B2 (en) | 1997-01-31 | 2003-04-07 | ジェネンテク・インコーポレイテッド | O-fucosyltransferase |
US20020102706A1 (en) * | 1997-06-18 | 2002-08-01 | Genentech, Inc. | Apo-2DcR |
EP3260468A1 (en) | 1997-04-07 | 2017-12-27 | Genentech, Inc. | Anti-vegf antibodies |
EP0973804B1 (en) | 1997-04-07 | 2006-12-27 | Genentech, Inc. | Anti-vegf antibodies |
PT1860187E (en) * | 1997-05-15 | 2011-10-04 | Genentech Inc | Apo-2 receptor |
US20100152426A1 (en) * | 1997-05-15 | 2010-06-17 | Ashkenazi Avi J | Apo-2 receptor fusion proteins |
US6342369B1 (en) * | 1997-05-15 | 2002-01-29 | Genentech, Inc. | Apo-2-receptor |
AU739350B2 (en) | 1997-06-05 | 2001-10-11 | University Of Texas System, The | APAF-1, the CED-4 human homolog, an activator of caspase-3 |
DE69833487T9 (en) | 1997-06-12 | 2007-03-01 | Innovata Plc, Ruddington | POLYMER-ACTIVE CONJUGATE FOR THE TREATMENT OF CANCER |
JP2002508663A (en) * | 1997-06-18 | 2002-03-19 | ジェネンテク,インコーポレイテッド | Apo-2DcR |
US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
CA2301847A1 (en) * | 1997-08-26 | 1999-03-04 | Genentech, Inc. | Rtd receptor |
US20030175856A1 (en) * | 1997-08-26 | 2003-09-18 | Genetech, Inc. | Rtd receptor |
CA2382495A1 (en) | 1997-09-17 | 1999-03-25 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20040231011A1 (en) * | 2001-06-28 | 2004-11-18 | Genentech, Inc. | DcR3 polypeptide, a TNFR homolog |
ATE393222T1 (en) * | 1997-09-18 | 2008-05-15 | Genentech Inc | DCR3 POLYPEPTIDE, A TNFR HOMOLOGUE |
JP2001522584A (en) | 1997-10-10 | 2001-11-20 | ジェネンテク・インコーポレイテッド | Apo-3 ligand polypeptide |
ATE406441T1 (en) | 1997-10-29 | 2008-09-15 | Genentech Inc | USE OF THE WNT-1 INDUCED SECRETED POLYPEPTIDE WISP-1 |
EP2033970A3 (en) | 1997-10-29 | 2009-06-17 | Genentech, Inc. | Polypeptides and nucleic acids encoding the same |
US7192589B2 (en) | 1998-09-16 | 2007-03-20 | Genentech, Inc. | Treatment of inflammatory disorders with STIgMA immunoadhesins |
ES2305608T3 (en) | 1997-11-21 | 2008-11-01 | Genentech, Inc. | ANTIGENS TYPE A-33 AND ITS PHARMACOLOGICAL USES. |
WO1999036535A1 (en) | 1998-01-15 | 1999-07-22 | Genentech, Inc. | Apo-2 ligand |
EP2050762A3 (en) | 1998-03-10 | 2009-07-08 | Genentech, Inc. | Human cornichon-like protein and nucleic acids encoding it |
EP1064382B1 (en) | 1998-03-17 | 2008-08-20 | Genentech, Inc. | Polypeptides homologous to vegf and bmp1 |
US20020086852A1 (en) * | 1998-05-14 | 2002-07-04 | Cantor Jerome O. | Method for treating respiratory disorders associated with pulmonary elastic fiber injury |
EP1865061A3 (en) | 1998-05-15 | 2007-12-19 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
EP2333069A3 (en) | 1998-05-15 | 2011-09-14 | Genentech, Inc. | Therapeutic uses of IL-17 homologous polypeptides |
PT1086138E (en) * | 1998-06-12 | 2010-01-04 | Genentech Inc | Monoclonal antibodies, cross-reactive antibodies and method for producing the same |
US20020172678A1 (en) | 2000-06-23 | 2002-11-21 | Napoleone Ferrara | EG-VEGF nucleic acids and polypeptides and methods of use |
CN1810832B (en) | 1998-10-23 | 2012-12-12 | 麒麟-安姆根有限公司 | Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity |
EP1950300A3 (en) | 1998-11-18 | 2011-03-23 | Genentech, Inc. | Antibody variants with higher binding affinity compared to parent antibodies |
AUPP785098A0 (en) * | 1998-12-21 | 1999-01-21 | Victor Chang Cardiac Research Institute, The | Treatment of heart disease |
EP2075335A3 (en) | 1998-12-22 | 2009-09-30 | Genentech, Inc. | Methods and compositions for inhibiting neoplastic cell growth |
JP5456222B2 (en) | 1998-12-23 | 2014-03-26 | ジェネンテック, インコーポレイテッド | IL-1 related polypeptides |
WO2000044390A1 (en) * | 1999-02-01 | 2000-08-03 | John Lezdey | Treatment of bladder and gastrointestinal mastocytosis |
EP1792989A1 (en) | 1999-04-12 | 2007-06-06 | Agensys, Inc. | 13 Transmembrane protein expressed in prostate cancer |
IL145775A0 (en) | 1999-04-12 | 2002-07-25 | Agensys Inc | 13 transmembrane protein expressed in prostate cancer |
US6635249B1 (en) | 1999-04-23 | 2003-10-21 | Cenes Pharmaceuticals, Inc. | Methods for treating congestive heart failure |
EP1956030B1 (en) | 1999-06-15 | 2009-11-11 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids endoding the same |
EP1200590B1 (en) | 1999-08-12 | 2009-01-07 | Agensys, Inc. | C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof |
US7459540B1 (en) * | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
US6723788B1 (en) | 1999-09-10 | 2004-04-20 | The Procter & Gamble Company | Enzyme inhibitors |
WO2001017565A2 (en) | 1999-09-10 | 2001-03-15 | The Procter & Gamble Company | Polyoxyalkylenes conjugates as enzyme inhibitors |
ATE417104T1 (en) | 1999-10-05 | 2008-12-15 | Agensys Inc | G PROTEIN-COUPLED RECEPTOR HIGHLY EXPRESSED IN PROSTATE CANCER AND ITS USES |
US7332275B2 (en) * | 1999-10-13 | 2008-02-19 | Sequenom, Inc. | Methods for detecting methylated nucleotides |
US6893818B1 (en) | 1999-10-28 | 2005-05-17 | Agensys, Inc. | Gene upregulated in cancers of the prostate |
RU2002113076A (en) | 1999-11-18 | 2004-03-10 | Корвас Интернэшнл, Инк. (Us) | Nucleic acids encoding endotheliases, endotheliases and their use |
US6703480B1 (en) | 1999-11-24 | 2004-03-09 | Palani Balu | Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use |
US6462180B1 (en) | 1999-11-24 | 2002-10-08 | Bayer Corporation | Method of preparing α-1 proteinase inhibitor |
EP2228446A1 (en) | 1999-12-01 | 2010-09-15 | Genentech, Inc. | Secreted and transmembrane polypeptieds and nucleic acids encoding the same |
US7109299B1 (en) | 1999-12-16 | 2006-09-19 | Affymax, Inc. | Peptides and compounds that bind to the IL-5 receptor |
EP2290081A3 (en) | 1999-12-23 | 2012-08-01 | Genentech, Inc. | IL-17 homologous polypeptide and therapeutic uses thereof |
EP1246917B1 (en) * | 2000-01-13 | 2009-03-04 | Genentech, Inc. | Human stra6 polypeptides |
US7700341B2 (en) | 2000-02-03 | 2010-04-20 | Dendreon Corporation | Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon |
DK1255558T3 (en) | 2000-02-16 | 2006-10-23 | Genentech Inc | Anti-April antibodies and hybridoma cells |
US7101974B2 (en) | 2000-03-02 | 2006-09-05 | Xencor | TNF-αvariants |
US6740520B2 (en) * | 2000-03-21 | 2004-05-25 | Genentech, Inc. | Cytokine receptor and nucleic acids encoding the same |
US20040086970A1 (en) * | 2000-03-22 | 2004-05-06 | Genentech, Inc. | Novel cytokine receptors and nucleic acids encoding the same |
US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
EP2042597B1 (en) | 2000-06-23 | 2014-05-07 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
EP2077276A1 (en) | 2000-06-23 | 2009-07-08 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogensis |
FR2811323B1 (en) * | 2000-07-07 | 2006-10-06 | Fuma Tech Gmbh | HYBRID MATERIAL, USE OF SAID HYBRID MATERIAL, AND METHOD OF MANUFACTURING THE SAME |
ATE412009T1 (en) | 2000-08-24 | 2008-11-15 | Genentech Inc | METHOD FOR INHIBITING IL-22 INDUCED PAP1 |
EP1313850B1 (en) | 2000-08-28 | 2008-08-06 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer |
EP1944317A3 (en) | 2000-09-01 | 2008-09-17 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20020115058A1 (en) * | 2000-09-22 | 2002-08-22 | Pedersen Finn Skou | Methods for diagnosis and treatment of diseases associated with altered expression of Pik3r1 |
US20020164576A1 (en) * | 2000-09-22 | 2002-11-07 | Pedersen Finn Skou | Methods for diagnosis and treatment of diseases associated with altered expression of Nrf2 |
US6576452B1 (en) | 2000-10-04 | 2003-06-10 | Genencor International, Inc. | 2,5-diketo-L-gluconic acid reductases and methods of use |
US6673580B2 (en) * | 2000-10-27 | 2004-01-06 | Genentech, Inc. | Identification and modification of immunodominant epitopes in polypeptides |
US7820447B2 (en) * | 2000-12-22 | 2010-10-26 | Sagres Discovery Inc. | Compositions and methods for cancer |
US20030232334A1 (en) * | 2000-12-22 | 2003-12-18 | Morris David W. | Novel compositions and methods for cancer |
US20030099963A1 (en) * | 2000-12-22 | 2003-05-29 | Morris David W. | Novel compositions and methods in cancer associated with altered expression of TBX21 |
US7892730B2 (en) | 2000-12-22 | 2011-02-22 | Sagres Discovery, Inc. | Compositions and methods for cancer |
US7645441B2 (en) * | 2000-12-22 | 2010-01-12 | Sagres Discovery Inc. | Compositions and methods in cancer associated with altered expression of PRLR |
US7700274B2 (en) * | 2000-12-22 | 2010-04-20 | Sagres Discovery, Inc. | Compositions and methods in cancer associated with altered expression of KCNJ9 |
US20030087252A1 (en) * | 2000-12-22 | 2003-05-08 | Morris David W. | Novel compositions and methods in cancer associated with altered expression of PRDM11 |
US20030165878A1 (en) * | 2000-12-22 | 2003-09-04 | Morris David W. | Novel compositions and methods in cancer associated with altered expression of MCM3AP |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
CA2438656A1 (en) * | 2001-02-14 | 2002-08-22 | The Trustees Of Columbia University In The City Of New York | Method for the prevention of tissue elastic fiber injury |
US7087726B2 (en) | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
US6924358B2 (en) | 2001-03-05 | 2005-08-02 | Agensys, Inc. | 121P1F1: a tissue specific protein highly expressed in various cancers |
WO2002072786A2 (en) | 2001-03-13 | 2002-09-19 | Corvas International, Inc. | Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon |
US7271240B2 (en) | 2001-03-14 | 2007-09-18 | Agensys, Inc. | 125P5C8: a tissue specific protein highly expressed in various cancers |
US7172892B2 (en) | 2001-03-22 | 2007-02-06 | Dendreon Corporation | Nucleic acid molecules encoding serine protease CVSP14, the encoded polypeptides and methods based thereon |
WO2002077267A2 (en) | 2001-03-27 | 2002-10-03 | Dendreon San Diego Llc | Nucleic acid molecules encoding a transmembran serine protease 9, the encoded polypeptides and methods based thereon |
WO2002083921A2 (en) | 2001-04-10 | 2002-10-24 | Agensys, Inc. | Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers |
US20030191073A1 (en) | 2001-11-07 | 2003-10-09 | Challita-Eid Pia M. | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer |
ES2527471T3 (en) | 2001-05-11 | 2015-01-26 | Amgen Inc. | Peptides and related molecules that bind to TALL-1 |
CA2447050A1 (en) | 2001-05-14 | 2002-11-21 | Dendreon San Diego Llc | Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon |
US20070160576A1 (en) | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
EP1992643A3 (en) | 2001-06-20 | 2008-12-10 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
WO2003014294A2 (en) * | 2001-08-03 | 2003-02-20 | Genentech, Inc. | Tacis and br3 polypeptides and uses thereof |
CN1575338B (en) | 2001-08-29 | 2012-05-16 | 杰南技术公司 | Bv8 nucleic acids and polypeptides with mitogenic activity |
US20040235068A1 (en) * | 2001-09-05 | 2004-11-25 | Levinson Arthur D. | Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders |
AU2002336446B2 (en) | 2001-09-06 | 2008-03-06 | Agensys, Inc. | Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer |
WO2003024392A2 (en) | 2001-09-18 | 2003-03-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US20070098728A1 (en) * | 2001-09-24 | 2007-05-03 | Pedersen Finn S | Novel compositions and methods in cancer |
US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
US7399613B2 (en) * | 2001-10-10 | 2008-07-15 | Neose Technologies, Inc. | Sialic acid nucleotide sugars |
CN105131104B (en) | 2001-10-10 | 2018-11-16 | 诺和诺德公司 | The reconstruct and sugar conjugation of peptide |
NZ532027A (en) * | 2001-10-10 | 2008-09-26 | Neose Technologies Inc | Remodeling and glycoconjugation of peptides |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
US7265084B2 (en) * | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
US7795210B2 (en) * | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
US7226903B2 (en) * | 2001-10-10 | 2007-06-05 | Neose Technologies, Inc. | Interferon beta: remodeling and glycoconjugation of interferon beta |
US7265085B2 (en) * | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycoconjugation methods and proteins/peptides produced by the methods |
US8008252B2 (en) * | 2001-10-10 | 2011-08-30 | Novo Nordisk A/S | Factor VII: remodeling and glycoconjugation of Factor VII |
US7696163B2 (en) | 2001-10-10 | 2010-04-13 | Novo Nordisk A/S | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7125843B2 (en) * | 2001-10-19 | 2006-10-24 | Neose Technologies, Inc. | Glycoconjugates including more than one peptide |
US7179617B2 (en) | 2001-10-10 | 2007-02-20 | Neose Technologies, Inc. | Factor IX: remolding and glycoconjugation of Factor IX |
US7439043B2 (en) * | 2001-10-10 | 2008-10-21 | Neose Technologies, Inc. | Galactosyl nucleotide sugars |
US7157277B2 (en) * | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7297511B2 (en) * | 2001-10-10 | 2007-11-20 | Neose Technologies, Inc. | Interferon alpha: remodeling and glycoconjugation of interferon alpha |
US7521053B2 (en) | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
WO2003088808A2 (en) | 2002-04-16 | 2003-10-30 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US20040126762A1 (en) * | 2002-12-17 | 2004-07-01 | Morris David W. | Novel compositions and methods in cancer |
US20040166490A1 (en) * | 2002-12-17 | 2004-08-26 | Morris David W. | Novel therapeutic targets in cancer |
AU2002357004A1 (en) * | 2001-11-20 | 2003-06-10 | Dendreon San Diego Llc | Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon |
US7473680B2 (en) * | 2001-11-28 | 2009-01-06 | Neose Technologies, Inc. | Remodeling and glycoconjugation of peptides |
US20040197778A1 (en) * | 2002-12-26 | 2004-10-07 | Sagres Discovery, Inc. | Novel compositions and methods in cancer |
US20040180344A1 (en) * | 2003-03-14 | 2004-09-16 | Morris David W. | Novel therapeutic targets in cancer |
US20060040262A1 (en) * | 2002-12-27 | 2006-02-23 | Morris David W | Novel compositions and methods in cancer |
AU2002314790A1 (en) * | 2001-12-05 | 2003-06-23 | Dow Global Technologies Inc. | Method for immobilizing a biologic in a polyurethane-hydrogel composition, a composition prepared from the method, and biomedical applications |
EP1575571A4 (en) | 2002-01-02 | 2008-06-25 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
WO2003072714A2 (en) | 2002-02-21 | 2003-09-04 | Wyeth | Follistatin domain containing proteins |
CA2476518A1 (en) | 2002-02-22 | 2003-09-04 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
EP2110434A1 (en) | 2002-02-25 | 2009-10-21 | Genentech, Inc. | Type-1 cytokine receptor GLM-R |
US20100311954A1 (en) * | 2002-03-01 | 2010-12-09 | Xencor, Inc. | Optimized Proteins that Target Ep-CAM |
DE10209822A1 (en) * | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Coupling of low molecular weight substances to a modified polysaccharide |
DE10209821A1 (en) * | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Coupling of proteins to a modified polysaccharide |
JP2005520543A (en) | 2002-03-21 | 2005-07-14 | サイグレス ディスカバリー, インコーポレイテッド | Novel compositions and methods in cancer |
WO2003093296A2 (en) * | 2002-05-03 | 2003-11-13 | Sequenom, Inc. | Kinase anchor protein muteins, peptides thereof, and related methods |
US7351542B2 (en) | 2002-05-20 | 2008-04-01 | The Regents Of The University Of California | Methods of modulating tubulin deacetylase activity |
AU2002304965A1 (en) | 2002-05-24 | 2003-12-12 | Zensun (Shanghai) Sci-Tech.Ltd | Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy |
EP2305710A3 (en) | 2002-06-03 | 2013-05-29 | Genentech, Inc. | Synthetic antibody phage libraries |
JP2005528905A (en) * | 2002-06-07 | 2005-09-29 | ジェネンテック・インコーポレーテッド | Compositions and methods for tumor diagnosis and treatment |
DE60336555D1 (en) * | 2002-06-21 | 2011-05-12 | Novo Nordisk Healthcare Ag | PEGYLATED GLYCO FORMS OF FACTOR VII |
AU2003247806B2 (en) | 2002-07-08 | 2009-11-12 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
CA2492447A1 (en) * | 2002-07-25 | 2004-02-05 | Genentech, Inc. | Taci antibodies and uses thereof |
AU2003258157A1 (en) * | 2002-08-12 | 2004-02-25 | Genencor International, Inc. | Mutant e. coli appa phytase enzymes |
US20040081653A1 (en) | 2002-08-16 | 2004-04-29 | Raitano Arthur B. | Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer |
AU2003265361A1 (en) * | 2002-08-28 | 2004-03-19 | Pharmacia Corporation | Stable ph optimized formulation of a modified antibody |
WO2004019860A2 (en) * | 2002-08-28 | 2004-03-11 | Pharmacia Corporation | Formulations of modified antibodies and methods of making the same |
WO2004024072A2 (en) | 2002-09-11 | 2004-03-25 | Genentech, Inc. | Novel compositions and methods for the treatment of immune related diseases |
BR0314107A (en) * | 2002-09-11 | 2005-07-19 | Fresenius Kabi De Gmbh | Production method of hydroxyalkyl starch derivatives |
JP5401001B2 (en) | 2002-09-11 | 2014-01-29 | ジェネンテック, インコーポレイテッド | Novel compositions and methods for the treatment of immune related diseases |
EP2444409A2 (en) | 2002-09-16 | 2012-04-25 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
CA2499625A1 (en) | 2002-09-18 | 2004-04-01 | Ortho-Mcneil Pharmaceutical, Inc. | Methods of increasing platelet and hematopoietic stem cell production |
EP1585482A4 (en) | 2002-09-25 | 2009-09-09 | Genentech Inc | Nouvelles compositions et methodes de traitement du psoriasis |
US20040149235A1 (en) * | 2002-10-04 | 2004-08-05 | Pogue Albert S. | Apparatus and method for removal of waste from animal production facilities |
EP2322202A3 (en) | 2002-10-29 | 2011-07-27 | Genentech, Inc. | Compositions and methods for the treatment of immune diseases |
WO2004110345A2 (en) * | 2002-10-29 | 2004-12-23 | Pharmacia Corporation | Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same |
CA2503748A1 (en) | 2002-11-08 | 2004-05-27 | Genentech, Inc. | Compositions and methods for the treatment of natural killer cell related diseases |
WO2004047728A2 (en) | 2002-11-26 | 2004-06-10 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
CA2503346C (en) | 2002-11-27 | 2014-03-18 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 24p4c12 useful in treatment and detection of cancer |
JP2006516548A (en) * | 2002-12-30 | 2006-07-06 | アンジオテック インターナショナル アクツィエン ゲゼルシャフト | Drug delivery from rapidly gelled polymer compositions |
WO2004060405A2 (en) * | 2002-12-30 | 2004-07-22 | Angiotech International Ag | Tissue reactive compounds and compositions and uses thereof |
US20060014248A1 (en) * | 2003-01-06 | 2006-01-19 | Xencor, Inc. | TNF super family members with altered immunogenicity |
US20050221443A1 (en) * | 2003-01-06 | 2005-10-06 | Xencor, Inc. | Tumor necrosis factor super family agonists |
US7553930B2 (en) * | 2003-01-06 | 2009-06-30 | Xencor, Inc. | BAFF variants and methods thereof |
US20050130892A1 (en) * | 2003-03-07 | 2005-06-16 | Xencor, Inc. | BAFF variants and methods thereof |
WO2004063963A2 (en) * | 2003-01-08 | 2004-07-29 | Xencor, Inc. | Novel proteins with altered immunogenicity |
JP2007524361A (en) | 2003-02-10 | 2007-08-30 | アジェンシス, インコーポレイテッド | 158P1D7 nucleic acid and corresponding protein useful for the treatment and detection of bladder cancer and other cancers |
US7767387B2 (en) * | 2003-06-13 | 2010-08-03 | Sagres Discovery, Inc. | Therapeutic targets in cancer |
CA2516138A1 (en) | 2003-02-14 | 2004-09-02 | Sagres Discovery, Inc. | Therapeutic gpcr targets in cancer |
US20040170982A1 (en) | 2003-02-14 | 2004-09-02 | Morris David W. | Novel therapeutic targets in cancer |
US20070218071A1 (en) * | 2003-09-15 | 2007-09-20 | Morris David W | Novel therapeutic targets in cancer |
JP4912144B2 (en) | 2003-03-12 | 2012-04-11 | ジェネンテック, インコーポレイテッド | Use of BV8 and / or EG-VEGF to promote hematopoiesis |
KR20060003862A (en) * | 2003-03-14 | 2006-01-11 | 네오스 테크놀로지스, 인크. | Branched water-soluble polymers and their eonjugates |
EP2184298A1 (en) * | 2003-03-14 | 2010-05-12 | Wyeth a Corporation of the State of Delaware | Antibodies against human IL-21 receptor and uses therefor |
WO2006127896A2 (en) * | 2005-05-25 | 2006-11-30 | Neose Technologies, Inc. | Glycopegylated factor ix |
US7691603B2 (en) * | 2003-04-09 | 2010-04-06 | Novo Nordisk A/S | Intracellular formation of peptide conjugates |
US20070026485A1 (en) * | 2003-04-09 | 2007-02-01 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
US20050025763A1 (en) | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
US7932364B2 (en) | 2003-05-09 | 2011-04-26 | Novo Nordisk A/S | Compositions and methods for the preparation of human growth hormone glycosylation mutants |
DK1629088T3 (en) | 2003-05-30 | 2012-05-07 | Agensys Inc | VARIABLES OF THE PROSTATASTIC CELL ANTIGEN (PSCA) AND ITS SEQUENCES |
MXPA05012723A (en) | 2003-05-30 | 2006-02-08 | Genentech Inc | Treatment with anti-vegf antibodies. |
US20050163775A1 (en) * | 2003-06-05 | 2005-07-28 | Genentech, Inc. | Combination therapy for B cell disorders |
KR20060027801A (en) * | 2003-06-05 | 2006-03-28 | 제넨테크, 인크. | Combination therapy for b cell disorders |
US7939058B2 (en) | 2003-07-03 | 2011-05-10 | University Of Southern California | Uses of IL-12 in hematopoiesis |
SI1641822T1 (en) | 2003-07-08 | 2013-08-30 | Genentech, Inc. | Il-17 a/f heterologous polypeptides and therapeutic uses thereof |
AR046071A1 (en) | 2003-07-10 | 2005-11-23 | Hoffmann La Roche | ANTIBODIES AGAINST RECEIVER I OF THE INSULINAL TYPE GROWTH FACTOR AND THE USES OF THE SAME |
JP5105874B2 (en) | 2003-07-18 | 2012-12-26 | アムジエン・インコーポレーテツド | Specific binding factor for hepatocyte growth factor |
WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
WO2005014655A2 (en) | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
SG145746A1 (en) * | 2003-08-08 | 2008-09-29 | Fresenius Kabi De Gmbh | Conjugates of hydroxyalkyl starch and g-csf |
WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
US20050043239A1 (en) * | 2003-08-14 | 2005-02-24 | Jason Douangpanya | Methods of inhibiting immune responses stimulated by an endogenous factor |
WO2005016349A1 (en) * | 2003-08-14 | 2005-02-24 | Icos Corporation | Methods of inhibiting leukocyte accumulation |
AR045614A1 (en) * | 2003-09-10 | 2005-11-02 | Hoffmann La Roche | ANTIBODIES AGAINST THE RECEIVER OF INTERLEUQUINA- 1 AND USES OF THE SAME |
US8883147B2 (en) | 2004-10-21 | 2014-11-11 | Xencor, Inc. | Immunoglobulins insertions, deletions, and substitutions |
US8399618B2 (en) | 2004-10-21 | 2013-03-19 | Xencor, Inc. | Immunoglobulin insertions, deletions, and substitutions |
US20060134105A1 (en) * | 2004-10-21 | 2006-06-22 | Xencor, Inc. | IgG immunoglobulin variants with optimized effector function |
US20070281896A1 (en) * | 2003-09-30 | 2007-12-06 | Morris David W | Novel compositions and methods in cancer |
EP1675871A2 (en) | 2003-10-10 | 2006-07-05 | Xencor Inc. | Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders |
US20070274988A1 (en) * | 2003-10-10 | 2007-11-29 | Five Prime Therapeautics, Inc. | Kiaa0779, Splice Variants Thereof, and Methods of Their Use |
EP1689432B1 (en) | 2003-11-17 | 2009-12-30 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
US20080305992A1 (en) * | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
EP1694347B1 (en) * | 2003-11-24 | 2013-11-20 | BioGeneriX AG | Glycopegylated erythropoietin |
US8633157B2 (en) * | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
US20070254836A1 (en) * | 2003-12-03 | 2007-11-01 | Defrees Shawn | Glycopegylated Granulocyte Colony Stimulating Factor |
US20060040856A1 (en) * | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
US20080318850A1 (en) * | 2003-12-03 | 2008-12-25 | Neose Technologies, Inc. | Glycopegylated Factor Ix |
US7956032B2 (en) * | 2003-12-03 | 2011-06-07 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
DK1704166T3 (en) | 2004-01-07 | 2015-06-01 | Novartis Vaccines & Diagnostic | M-CSF-SPECIFIC MONOCLONAL ANTIBODY AND APPLICATIONS THEREOF |
KR101439880B1 (en) * | 2004-01-08 | 2014-09-12 | 라티오팜 게엠베하 | O-linked glycosylation of peptides |
US20050169970A1 (en) * | 2004-02-02 | 2005-08-04 | Unilever Bestfoods, North America | Food composition with fibers |
WO2005092391A2 (en) * | 2004-03-11 | 2005-10-06 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
WO2005092928A1 (en) * | 2004-03-11 | 2005-10-06 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination |
MXPA06011199A (en) * | 2004-03-31 | 2007-04-16 | Genentech Inc | Humanized anti-tgf-beta antibodies. |
US7794713B2 (en) * | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
CA2885854C (en) | 2004-04-13 | 2017-02-21 | F. Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
BRPI0510477B1 (en) | 2004-04-28 | 2023-01-17 | Angiotech Biomaterials Corporation | METHOD FOR FORMING A GEL AND DEVICE FOR USE IN MEDICAL APPLICATIONS |
ATE455861T1 (en) | 2004-05-04 | 2010-02-15 | Novo Nordisk Healthcare Ag | O-LINKED GLYCOFORMS OF FACTOR VII AND METHOD FOR THE PRODUCTION THEREOF |
DK1761540T3 (en) | 2004-05-13 | 2016-11-21 | Icos Corp | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase DELTA |
EP1755609A1 (en) * | 2004-05-25 | 2007-02-28 | Icos Corporation | Methods for treating and/or preventing aberrant proliferation of hematopoietic cells |
WO2005118864A2 (en) | 2004-05-28 | 2005-12-15 | Agensys, Inc. | Antibodies and related molecules that bind to psca proteins |
US20060014680A1 (en) * | 2004-07-13 | 2006-01-19 | Caiding Xu | Peptides and compounds that bind to the IL-5 receptor |
EP1771066A2 (en) | 2004-07-13 | 2007-04-11 | Neose Technologies, Inc. | Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1 |
US20060024677A1 (en) | 2004-07-20 | 2006-02-02 | Morris David W | Novel therapeutic targets in cancer |
ZA200701183B (en) | 2004-07-20 | 2008-05-28 | Genentech Inc | Inhibitors of angiopoietin-like 4 protein, combinations, an their use |
US8268967B2 (en) * | 2004-09-10 | 2012-09-18 | Novo Nordisk A/S | Glycopegylated interferon α |
TWI380996B (en) * | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | Anti-ox40l antibodies |
US8303973B2 (en) | 2004-09-17 | 2012-11-06 | Angiotech Pharmaceuticals (Us), Inc. | Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use |
US20060204512A1 (en) | 2004-09-23 | 2006-09-14 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
US7442778B2 (en) | 2004-09-24 | 2008-10-28 | Amgen Inc. | Modified Fc molecules |
JP2008514215A (en) * | 2004-09-29 | 2008-05-08 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | Modified protein |
US7572771B1 (en) | 2004-10-15 | 2009-08-11 | The United States Of America As Represented By The Departments Of Health And Human Services | Multi-domain amphipathic helical peptides and methods of their use |
ES2572779T3 (en) | 2004-10-29 | 2016-06-02 | Ratiopharm Gmbh | Remodeling and glucopegilation of Fibroblast Growth Factor (FGF) |
CN102746404B (en) | 2004-11-12 | 2016-01-20 | 赞科股份有限公司 | To FcRn in conjunction with reformed Fc variant |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
CA2589374C (en) | 2004-11-30 | 2016-05-03 | Curagen Corporation | Antibodies directed to gpnmb and uses thereof |
US20060134698A1 (en) * | 2004-12-20 | 2006-06-22 | Evanston Northwestern Healthcare Research Institute | Methods for treating cardiac disease by modifying an N-terminal domain of troponin I |
JP2008526864A (en) * | 2005-01-06 | 2008-07-24 | ネオス テクノロジーズ インコーポレイテッド | Sugar linkage using sugar fragments |
ES2449195T3 (en) | 2005-01-10 | 2014-03-18 | Ratiopharm Gmbh | Glycopegylated granulocyte colony stimulating factor |
WO2006081171A1 (en) * | 2005-01-24 | 2006-08-03 | Amgen Inc. | Humanized anti-amyloid antibody |
WO2006089106A2 (en) * | 2005-02-17 | 2006-08-24 | Icos Corporation | Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation |
AU2006222187A1 (en) * | 2005-03-11 | 2006-09-14 | Fresenius Kabi Deutschland Gmbh | Production of bioactive glycoproteins from inactive starting material by conjugation with hydroxyalkylstarch |
US20060246544A1 (en) * | 2005-03-30 | 2006-11-02 | Neose Technologies,Inc. | Manufacturing process for the production of peptides grown in insect cell lines |
NZ562453A (en) | 2005-03-31 | 2010-04-30 | Agensys Inc | Antibodies and related molecules that bind to 161P2F10B proteins |
TW200720289A (en) | 2005-04-01 | 2007-06-01 | Hoffmann La Roche | Antibodies against CCR5 and uses thereof |
EP1865981A2 (en) | 2005-04-07 | 2007-12-19 | Chiron Corporation | Cacna1e in cancer diagnosis, detection and treatment |
EP1871911A2 (en) | 2005-04-07 | 2008-01-02 | Chiron Corporation | Cancer-related genes (prlr) |
EP2386571B1 (en) | 2005-04-08 | 2016-06-01 | ratiopharm GmbH | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
US20060271262A1 (en) * | 2005-05-24 | 2006-11-30 | Mclain Harry P Iii | Wireless agricultural network |
EP1888098A2 (en) * | 2005-05-25 | 2008-02-20 | Neose Technologies, Inc. | Glycopegylated erythropoietin formulations |
US8389469B2 (en) * | 2005-06-06 | 2013-03-05 | The Rockefeller University | Bacteriophage lysins for Bacillus anthracis |
US7858843B2 (en) | 2005-06-06 | 2010-12-28 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
US8252756B2 (en) | 2005-06-14 | 2012-08-28 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
US7582291B2 (en) * | 2005-06-30 | 2009-09-01 | The Rockefeller University | Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria |
WO2007008943A2 (en) | 2005-07-08 | 2007-01-18 | Xencor, Inc. | Optimized anti-ep-cam antibodies |
DK1912675T3 (en) | 2005-07-25 | 2014-03-24 | Emergent Product Dev Seattle | B-cell reduction using specific and cd37-cd20-specific binding molecules |
JP5457671B2 (en) * | 2005-07-28 | 2014-04-02 | ノバルティス アーゲー | M-CSF specific monoclonal antibody and use thereof |
JP5657862B2 (en) * | 2005-07-28 | 2015-01-21 | ノバルティス アーゲー | Use of antibodies against M-CSF |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
AU2006280321A1 (en) | 2005-08-15 | 2007-02-22 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
KR20080080081A (en) * | 2005-08-19 | 2008-09-02 | 네오스 테크놀로지스, 인크. | Glycopegylated factor vii and factor viia |
CA2620903A1 (en) | 2005-08-24 | 2007-03-01 | The Rockefeller University | Ply-gbs mutant lysins |
EP1762250A1 (en) * | 2005-09-12 | 2007-03-14 | Fresenius Kabi Deutschland GmbH | Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine |
WO2007044396A2 (en) * | 2005-10-04 | 2007-04-19 | The Research Foundation Of State University Of New York | Fibronectin polypeptides and methods of use |
US20090074720A1 (en) * | 2005-10-28 | 2009-03-19 | Sabbadini Roger A | Methods for decreasing immune response and treating immune conditions |
US20080213274A1 (en) * | 2005-10-28 | 2008-09-04 | Sabbadini Roger A | Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye |
US20090048440A1 (en) * | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
CN101360826B (en) | 2005-11-18 | 2014-04-30 | 格兰马克药品股份有限公司 | Anti-alpha2 integrin antibodies and their uses |
AU2006335053A1 (en) | 2005-11-21 | 2007-07-19 | Genentech, Inc. | Novel gene disruptions, compositions and methods relating thereto |
CA2629306A1 (en) * | 2005-11-23 | 2007-05-31 | Genentech, Inc. | Methods and compositions related to b cell assays |
US20070213264A1 (en) | 2005-12-02 | 2007-09-13 | Mingdong Zhou | Neuregulin variants and methods of screening and using thereof |
EP1981525B1 (en) * | 2005-12-30 | 2015-01-21 | Zensun (Shanghai) Science and Technology Limited | Extended release of neuregulin for improved cardiac function |
US9012605B2 (en) | 2006-01-23 | 2015-04-21 | Amgen Inc. | Crystalline polypeptides |
CA2638821A1 (en) | 2006-02-17 | 2007-10-11 | Genentech, Inc. | Gene disruptons, compositions and methods relating thereto |
TW200745163A (en) * | 2006-02-17 | 2007-12-16 | Syntonix Pharmaceuticals Inc | Peptides that block the binding of IgG to FcRn |
TWI417301B (en) | 2006-02-21 | 2013-12-01 | Wyeth Corp | Antibodies against human il-22 and uses therefor |
TW200744634A (en) | 2006-02-21 | 2007-12-16 | Wyeth Corp | Methods of using antibodies against human IL-22 |
EP2010569A4 (en) | 2006-03-20 | 2009-09-09 | Xoma Technology Ltd | Human antibodies specific for gastrin materials and methods |
ES2544957T3 (en) | 2006-03-21 | 2015-09-07 | Genentech, Inc. | Combined therapy involving alpha5beta1 antagonists |
SMP200800060B (en) | 2006-04-07 | 2009-07-14 | Procter & Gamble | Antibodies that bind the human protein tyrosine phosphatase beta (hptbeta) and their uses |
EP2082645A1 (en) | 2006-04-19 | 2009-07-29 | Genentech, Inc. | Novel gene disruptions, compositions and methods relating thereto |
TWI395754B (en) | 2006-04-24 | 2013-05-11 | Amgen Inc | Humanized c-kit antibody |
US7862812B2 (en) * | 2006-05-31 | 2011-01-04 | Lpath, Inc. | Methods for decreasing immune response and treating immune conditions |
JP2009539413A (en) * | 2006-06-12 | 2009-11-19 | トゥルビオン・ファーマシューティカルズ・インコーポレーテッド | Single-chain multivalent binding protein with effector function |
US20080199398A1 (en) * | 2006-06-16 | 2008-08-21 | Brewer H Bryan | Novel Peptides That Promote Lipid Efflux |
US20080206142A1 (en) * | 2006-06-16 | 2008-08-28 | Lipid Sciences, Inc. | Novel Peptides That Promote Lipid Efflux |
US20080227686A1 (en) * | 2006-06-16 | 2008-09-18 | Lipid Sciences, Inc. | Novel Peptides that Promote Lipid Efflux |
US7981425B2 (en) | 2006-06-19 | 2011-07-19 | Amgen Inc. | Thrombopoietic compounds |
EP2452683A3 (en) | 2006-06-26 | 2012-08-22 | Amgen Inc. | Methods for treating atherosclerosis |
US9187532B2 (en) | 2006-07-21 | 2015-11-17 | Novo Nordisk A/S | Glycosylation of peptides via O-linked glycosylation sequences |
CA2659820A1 (en) | 2006-08-04 | 2008-02-14 | Novartis Ag | Ephb3-specific antibody and uses thereof |
GEP20125612B (en) | 2006-08-18 | 2012-08-27 | Novartis Ag | Prlr-specific antibody and usage thereof |
CL2007002567A1 (en) | 2006-09-08 | 2008-02-01 | Amgen Inc | ISOLATED PROTEINS FROM LINK TO ACTIVINE TO HUMAN. |
WO2008039843A2 (en) * | 2006-09-26 | 2008-04-03 | Lipid Sciences, Inc. | Novel peptides that promote lipid efflux |
BRPI0717512A2 (en) | 2006-09-29 | 2013-11-19 | Hoffmann La Roche | CCR5 ANTIBODIES AND USES OF THE SAME |
US7767206B2 (en) | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
EP2054521A4 (en) * | 2006-10-03 | 2012-12-19 | Novo Nordisk As | Methods for the purification of polypeptide conjugates |
JP5457185B2 (en) * | 2006-10-04 | 2014-04-02 | ノヴォ ノルディスク アー/エス | Glycerol-linked PEGylated sugars and glycopeptides |
EP1914303A1 (en) * | 2006-10-09 | 2008-04-23 | Qiagen GmbH | Thermus eggertssonii DNA polymerases |
JP5795833B2 (en) | 2006-10-27 | 2015-10-14 | エルパス・インコーポレイテッドLpath, Inc. | Compositions and methods for binding sphingosine-1-phosphate |
WO2008055072A2 (en) | 2006-10-27 | 2008-05-08 | Lpath, Inc. | Compositions and methods for treating ocular diseases and conditions |
WO2008073620A2 (en) * | 2006-11-02 | 2008-06-19 | Neose Technologies, Inc. | Manufacturing process for the production of polypeptides expressed in insect cell-lines |
WO2008140477A2 (en) * | 2006-11-02 | 2008-11-20 | Capon Daniel J | Hybrid immunoglobulins with moving parts |
EP2097450A2 (en) | 2006-11-10 | 2009-09-09 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
CN101605797A (en) | 2006-11-13 | 2009-12-16 | 伊莱利利公司 | The Thienopyrimidinones of treatment inflammatory disease and cancer |
MX2009004757A (en) | 2006-11-14 | 2009-05-21 | Genentech Inc | Modulators of neuronal regeneration. |
AU2007325838B2 (en) | 2006-11-22 | 2013-09-19 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR |
WO2008070780A1 (en) | 2006-12-07 | 2008-06-12 | Novartis Ag | Antagonist antibodies against ephb3 |
US8183201B2 (en) * | 2006-12-26 | 2012-05-22 | National Cheng Kung University | Methods of treating αvβ3 integrin-associated diseases by administering polypeptides selective for αvβ3 integrin |
US7943728B2 (en) | 2006-12-26 | 2011-05-17 | National Cheng Kung University | Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases |
EP2125013A4 (en) * | 2007-01-26 | 2010-04-07 | Bioinvent Int Ab | Dll4 signaling inhibitors and uses thereof |
TW201206954A (en) * | 2007-02-02 | 2012-02-16 | Amgen Inc | Hepcidin, hepcidin antagonists and methods of use |
US20100144599A1 (en) | 2007-02-02 | 2010-06-10 | Bristol-Myers Squibb Company | Vegf pathway blockade |
MX2009008470A (en) * | 2007-02-09 | 2009-11-26 | Univ Northwestern | Particles for detecting intracellular targets. |
US8415453B2 (en) * | 2007-02-13 | 2013-04-09 | Academia Sinica | Lung cancer-targeted peptides and applications thereof |
US8088887B2 (en) * | 2007-02-13 | 2012-01-03 | Academia Sinica | Peptide-conjugates that bind to VEGF-stimulated or tumor vasculature and methods of treatment |
US7875431B2 (en) | 2007-02-22 | 2011-01-25 | Genentech, Inc. | Methods for detecting inflammatory bowel disease |
CA2682897C (en) * | 2007-04-03 | 2016-11-22 | Biogenerix Ag | Methods of treatment using glycopegylated g-csf |
US20090053167A1 (en) * | 2007-05-14 | 2009-02-26 | Neose Technologies, Inc. | C-, S- and N-glycosylation of peptides |
ES2585702T3 (en) * | 2007-05-30 | 2016-10-07 | Lpath, Inc | Compositions and methods for lysophosphatidic acid binding |
US9163091B2 (en) * | 2007-05-30 | 2015-10-20 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
AU2008259907B2 (en) * | 2007-05-30 | 2014-12-04 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
EP2162535A4 (en) * | 2007-06-04 | 2011-02-23 | Novo Nordisk As | O-linked glycosylation using n-acetylglucosaminyl transferases |
CN101778859B (en) * | 2007-06-12 | 2014-03-26 | 诺和诺德公司 | Improved process for the production of nucleotide sugars |
EP2167111A4 (en) * | 2007-06-14 | 2010-06-09 | Univ New York State Res Found | Polypeptides and methods of use |
US7625555B2 (en) | 2007-06-18 | 2009-12-01 | Novagen Holding Corporation | Recombinant human interferon-like proteins |
CN101990439A (en) * | 2007-07-06 | 2011-03-23 | 特鲁比昂药品公司 | Binding peptides having a c-terminally disposed specific binding domain |
JP5469600B2 (en) | 2007-07-16 | 2014-04-16 | ジェネンテック, インコーポレイテッド | Anti-CD79b antibody and immunoconjugate and method of use thereof |
TW200918089A (en) | 2007-07-16 | 2009-05-01 | Genentech Inc | Humanized anti-CD79b antibodies and immunoconjugates and methods of use |
KR20100040937A (en) | 2007-07-26 | 2010-04-21 | 암젠 인크 | Modified lecithin-cholesterol acyltransferase enzymes |
CN101361968B (en) | 2007-08-06 | 2011-08-03 | 健能隆医药技术(上海)有限公司 | Use of interleukin-22 in treating fatty liver |
AU2008284047A1 (en) * | 2007-08-09 | 2009-02-12 | Syntonix Pharmaceuticals, Inc. | Immunomodulatory peptides |
JOP20080381B1 (en) | 2007-08-23 | 2023-03-28 | Amgen Inc | Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9) |
EP2615114B1 (en) | 2007-08-23 | 2022-04-06 | Amgen Inc. | Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) |
CN104689333B (en) | 2007-08-27 | 2018-05-29 | 拉蒂奥法姆有限责任公司 | The liquid preparation of G-CSF conjugates |
US8207112B2 (en) * | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
CA2698203C (en) | 2007-08-29 | 2018-09-11 | Sanofi-Aventis | Humanized anti-cxcr5 antibodies, derivatives thereof and their use |
US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
US20090156488A1 (en) * | 2007-09-12 | 2009-06-18 | Zensun (Shanghai) Science & Technology Limited | Use of neuregulin for organ preservation |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
US8361465B2 (en) * | 2007-10-26 | 2013-01-29 | Lpath, Inc. | Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents |
PL2612868T3 (en) | 2007-11-01 | 2018-12-31 | Astellas Pharma Inc. | Immunosuppressive polypeptides and nucleic acids |
US8541543B2 (en) * | 2007-11-20 | 2013-09-24 | Academia Sinica | Peptides specific for hepatocellular carcinoma cells and applications thereof |
US8779088B2 (en) | 2007-12-17 | 2014-07-15 | Marfl Ab | Vaccine for the treatment of Mycobacterium related disorders |
US8414893B2 (en) | 2007-12-21 | 2013-04-09 | Amgen Inc. | Anti-amyloid antibodies and uses thereof |
SI2808343T1 (en) | 2007-12-26 | 2019-10-30 | Xencor Inc | Fc variants with altered binding to FcRn |
JP5647899B2 (en) * | 2008-01-08 | 2015-01-07 | ラツィオファルム ゲーエムベーハーratiopharm GmbH | Glycoconjugation of polypeptides using oligosaccharyltransferase |
KR20200075044A (en) | 2008-01-22 | 2020-06-25 | 아라임 파마슈티칼즈, 인크. | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
AU2009206306B2 (en) | 2008-01-25 | 2013-06-06 | Amgen Inc. | Ferroportin antibodies and methods of use |
ES2848323T3 (en) | 2008-01-31 | 2021-08-06 | Inst Nat Sante Rech Med | Antibodies against human CD39 and their use to inhibit the activity of regulatory T cells |
SI2657253T1 (en) | 2008-01-31 | 2017-10-30 | Genentech, Inc. | Anti-CD79b antibodies and immunoconjugates and methods of use |
JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof |
US20130189239A1 (en) | 2008-02-27 | 2013-07-25 | Novo Nordisk A/S | Conjugated Factor VIII Molecules |
WO2009126725A1 (en) * | 2008-04-09 | 2009-10-15 | The Regents Of The University Of Michigan | Method of modulating neovascularization |
SG10201402815VA (en) | 2008-04-09 | 2014-09-26 | Genentech Inc | Novel compositions and methods for the treatment of immune related diseases |
ES2368700T3 (en) * | 2008-04-11 | 2011-11-21 | Emergent Product Development Seattle, Llc | IMMUNOTHERAPEUTIC AGENT FOR CD37 AND COMBINATION WITH A BIFUNCTIONAL CHEMOTHERAPEUTIC AGENT OF THE SAME. |
US8921315B1 (en) | 2008-04-24 | 2014-12-30 | Neumedicines, Inc. | Method of increasing survival of a human subject having exposure to an acute exposure to non-therapeutic whole body ionization by administering a therapeutically effective dose of IL-12 |
EP2816059A1 (en) | 2008-05-01 | 2014-12-24 | Amgen, Inc | Anti-hepcidin antibodies and methods of use |
DK2279405T3 (en) | 2008-05-13 | 2014-01-13 | Advanced Liquid Logic Inc | Drip actuator devices, systems and methods |
JP2011524858A (en) | 2008-05-15 | 2011-09-08 | セレクシーズ ファーマスーティカルズ コーポレーション | Anti-PSGL-1 antibody and method for identification and use thereof |
US8093018B2 (en) | 2008-05-20 | 2012-01-10 | Otsuka Pharmaceutical Co., Ltd. | Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same |
AR071874A1 (en) | 2008-05-22 | 2010-07-21 | Bristol Myers Squibb Co | ARMAZON DOMAIN PROTEINS BASED ON MULTIVALENT FIBRONECTINE |
JOP20190083A1 (en) | 2008-06-04 | 2017-06-16 | Amgen Inc | Fgf21 mutant fusion polypeptides and uses thereof |
US8052970B2 (en) * | 2008-06-30 | 2011-11-08 | The Regents Of The University Of Michigan | Lysosomal phospholipase A2 (LPLA2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosis |
US20100048488A1 (en) * | 2008-08-01 | 2010-02-25 | Syntonix Pharmaceuticals, Inc. | Immunomodulatory peptides |
CA2735433C (en) | 2008-09-07 | 2016-02-16 | Glyconex Inc. | Anti-extended type i glycosphingolipid antibody, derivatives thereof and use |
NO2344540T3 (en) | 2008-10-02 | 2018-04-28 | ||
WO2010040766A1 (en) | 2008-10-07 | 2010-04-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Neutralizing antibodies and fragments thereof directed against platelet factor-4 variant 1 (pf4v1) |
EA032727B1 (en) | 2008-10-10 | 2019-07-31 | Амген Инк. | Fgf21 mutant proteolysis-resistant polypeptide and use thereof |
AU2009308293B2 (en) | 2008-10-22 | 2015-02-05 | Genentech, Inc. | Modulation of axon degeneration |
US8871202B2 (en) | 2008-10-24 | 2014-10-28 | Lpath, Inc. | Prevention and treatment of pain using antibodies to sphingosine-1-phosphate |
JP5775458B2 (en) * | 2008-11-06 | 2015-09-09 | グレンマーク ファーマシューティカルズ, エセ.アー. | Treatment using anti-α2 integrin antibody |
PT2355828T (en) | 2008-11-13 | 2018-07-02 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
US9492449B2 (en) | 2008-11-13 | 2016-11-15 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
AU2009316286B2 (en) | 2008-11-24 | 2016-05-26 | Northwestern University | Polyvalent RNA-nanoparticle compositions |
SI2379096T1 (en) * | 2008-12-19 | 2020-03-31 | Baxalta GmbH | Tfpi inhibitors and methods of use |
JP5801205B2 (en) * | 2009-01-08 | 2015-10-28 | ノースウェスタン ユニバーシティ | Inhibition of bacterial protein production by multivalent oligonucleotide modified nanoparticle conjugates |
US20100233270A1 (en) * | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
US20100294952A1 (en) * | 2009-01-15 | 2010-11-25 | Northwestern University | Controlled agent release and sequestration |
EP3002296B1 (en) | 2009-03-17 | 2020-04-29 | Université d'Aix-Marseille | Btla antibodies and uses thereof |
WO2010108153A2 (en) | 2009-03-20 | 2010-09-23 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
BRPI1012333A2 (en) | 2009-03-24 | 2016-03-29 | Gilead Calistoga Llc | atropisomers of 2-purinyl-3-tolyl-quinazolinones derivatives and methods of use |
NZ594343A (en) | 2009-03-25 | 2013-10-25 | Genentech Inc | Novel anti-alpha5beta1 antibodies and uses thereof |
UA105384C2 (en) | 2009-04-01 | 2014-05-12 | Дженентек, Инк. | Treatment of insulin-resistant disorders |
AU2010236787A1 (en) | 2009-04-01 | 2011-11-10 | Genentech, Inc. | Anti-FcRH5 antibodies and immunoconjugates and methods of use |
WO2010112034A2 (en) | 2009-04-02 | 2010-10-07 | Aarhus Universitet | Compositions and methods for treatment and diagnosis of synucleinopathies |
US8067201B2 (en) * | 2009-04-17 | 2011-11-29 | Bristol-Myers Squibb Company | Methods for protein refolding |
ES2548253T3 (en) * | 2009-04-20 | 2015-10-15 | Gilead Calistoga Llc | Methods for the treatment of solid tumors |
EP2248903A1 (en) | 2009-04-29 | 2010-11-10 | Universitat Autònoma De Barcelona | Methods and reagents for efficient and targeted gene transfer to monocytes and macrophages |
US20120052069A1 (en) | 2009-05-05 | 2012-03-01 | Amgen Inc | Fgf21 mutants and uses thereof |
HRP20240135T1 (en) | 2009-05-05 | 2024-04-12 | Amgen Inc. | Fgf21 mutants and uses thereof |
TW201102086A (en) | 2009-06-04 | 2011-01-16 | Hoffmann La Roche | Antibodies against human CCN1 and uses thereof |
WO2010148010A1 (en) | 2009-06-15 | 2010-12-23 | 4S3 Bioscience Inc. | Methods and compositions for treatment of myotubular myopathy using chimeric polypeptides comprising myotubularih 1 (mtm1) polypeptides |
WO2010148142A1 (en) | 2009-06-17 | 2010-12-23 | Amgen Inc. | Chimeric fgf19 polypeptides and uses thereof |
NZ597580A (en) * | 2009-07-20 | 2013-11-29 | Univ Nat Taiwan | Polypeptides selective for alpha.v.beta.3 integrin conjugated with a variant of human serum albumin (hsa) and pharmaceutical uses thereof |
WO2011011550A1 (en) | 2009-07-21 | 2011-01-27 | Calistoga Pharmaceuticals Inc. | Treatment of liver disorders with pi3k inhibitors |
NZ597531A (en) | 2009-07-31 | 2014-05-30 | Genentech Inc | Inhibition of tumor metastasis using bv8- or g-csf-antagonists |
US8926976B2 (en) | 2009-09-25 | 2015-01-06 | Xoma Technology Ltd. | Modulators |
US9885711B2 (en) | 2009-09-25 | 2018-02-06 | Xoma Technology Ltd. | Screening methods |
BR112012008665A2 (en) | 2009-10-12 | 2016-11-22 | Pfizer | cancer treatment |
TW201117824A (en) | 2009-10-12 | 2011-06-01 | Amgen Inc | Use of IL-17 receptor a antigen binding proteins |
US8535912B2 (en) * | 2009-10-15 | 2013-09-17 | Genentech, Inc. | Chimeric fibroblast growth factors with altered receptor specificity |
WO2011049625A1 (en) | 2009-10-20 | 2011-04-28 | Mansour Samadpour | Method for aflatoxin screening of products |
CN104043126A (en) | 2009-10-22 | 2014-09-17 | 霍夫曼-拉罗奇有限公司 | Modulation of axon degeneration |
BR112012009409A2 (en) | 2009-10-22 | 2017-02-21 | Genentech Inc | method of identifying an inhibitory substance, antagonist molecule, isolated nucleic acid, vector, host cell, method of making the molecule, composition, article of manufacture, method of inhibiting a biological activity, method of treating a pathological condition, method for detect msp in a sample and method to detect hepsin in a sample |
WO2011056497A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor type iib compositions and methods of use |
WO2011056494A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations |
WO2011056502A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Bone morphogenetic protein receptor type ii compositions and methods of use |
CN102666879B (en) | 2009-10-30 | 2016-02-24 | 西北大学 | Templated nanometer conjugate |
MX352661B (en) | 2009-11-05 | 2017-12-04 | Rhizen Pharmaceuticals S A Star | Novel benzopyran kinase modulators. |
CN102612374A (en) | 2009-11-12 | 2012-07-25 | 霍夫曼-拉罗奇有限公司 | A method of promoting dendritic spine density |
US9260517B2 (en) | 2009-11-17 | 2016-02-16 | Musc Foundation For Research Development | Human monoclonal antibodies to human nucleolin |
TW201129379A (en) | 2009-11-20 | 2011-09-01 | Amgen Inc | Anti-Orai1 antigen binding proteins and uses thereof |
AR079217A1 (en) | 2009-11-30 | 2012-01-04 | Genentech Inc | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TUMOR TREATMENT |
WO2011066511A1 (en) | 2009-11-30 | 2011-06-03 | The U.S.A., As Represented By The Secretary Department Of Health And Human Services | Synthetic apoa-1 mimetic amphipathic peptides and methods of use thereof |
JP2013512672A (en) * | 2009-12-02 | 2013-04-18 | アムジエン・インコーポレーテツド | Human FGFR1c, human β-croto-, and binding proteins that bind to both human FGFR1c and human β-croto- |
UA109888C2 (en) | 2009-12-07 | 2015-10-26 | ANTIBODY OR ANTIBODILITY ANTIBODY OR ITS BINDING TO THE β-CLOTE, FGF RECEPTORS AND THEIR COMPLEXES | |
TW201132353A (en) | 2009-12-18 | 2011-10-01 | Amgen Inc | WISE binding agents and epitopes |
DK2516469T3 (en) | 2009-12-22 | 2016-05-02 | Roche Glycart Ag | ANTI-HER3 antibodies and uses thereof |
EP2516467A2 (en) | 2009-12-23 | 2012-10-31 | Emergent Product Development Seattle, LLC | Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof |
RU2012131251A (en) | 2009-12-23 | 2014-01-27 | Нэйшнл Ченг Кунг Юниверсити | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISEASES RELATED TO ANGIOGENESIS |
SI2519543T1 (en) | 2009-12-29 | 2016-08-31 | Emergent Product Development Seattle, Llc | Heterodimer binding proteins and uses thereof |
WO2011097527A2 (en) | 2010-02-04 | 2011-08-11 | Xencor, Inc. | Immunoprotection of therapeutic moieties using enhanced fc regions |
US20110189178A1 (en) * | 2010-02-04 | 2011-08-04 | Xencor, Inc. | Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions |
CN104610454A (en) | 2010-02-16 | 2015-05-13 | 米迪缪尼有限公司 | HSA-related compositions and methods of use |
MX2012009215A (en) | 2010-02-23 | 2012-11-23 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor. |
JP5972176B2 (en) | 2010-02-23 | 2016-08-17 | サノフイ | Anti-alpha2 integrin antibodies and uses thereof |
US20110212088A1 (en) * | 2010-02-26 | 2011-09-01 | Sabbadini Roger A | Anti-paf antibodies |
US8642557B2 (en) | 2010-03-12 | 2014-02-04 | Abbvie Biotherapeutics Inc. | CTLA4 proteins and their uses |
EP3146977A1 (en) | 2010-03-19 | 2017-03-29 | Baxalta GmbH | Tfpi inhibitors and methods of use |
HUE038788T2 (en) | 2010-03-31 | 2018-11-28 | Boehringer Ingelheim Int | Anti-CD40 antibodies |
CA2794555A1 (en) | 2010-04-01 | 2011-10-06 | Oncorena Ab | Improved treatment of renal cell carcinoma |
AU2011239689A1 (en) | 2010-04-15 | 2012-11-08 | Amgen Inc. | Human FGF receptor and beta-Klotho binding proteins |
MA34291B1 (en) | 2010-05-03 | 2013-06-01 | Genentech Inc | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING A TUMOR |
WO2011145035A1 (en) | 2010-05-17 | 2011-11-24 | Indian Incozen Therapeutics Pvt. Ltd. | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases |
EP2571516B1 (en) | 2010-05-18 | 2017-11-15 | Neumedicines, Inc | Il-12 formulations for enhancing hematopoiesis |
ES2573108T3 (en) | 2010-05-26 | 2016-06-06 | Bristol-Myers Squibb Company | Fibronectin-based framework proteins that have improved stability |
JP2013530187A (en) | 2010-06-17 | 2013-07-25 | ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ シークレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Compositions and methods for treating inflammatory diseases. |
AR082163A1 (en) | 2010-07-15 | 2012-11-14 | Hoffmann La Roche | SPECIFICALLY BINDING ANTIBODIES OF THE HUMAN TSLPR AND METHODS OF USING THEMSELVES |
WO2012010696A1 (en) | 2010-07-23 | 2012-01-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for cancer management targeting co-029 |
JP5953303B2 (en) | 2010-07-29 | 2016-07-20 | ゼンコア インコーポレイテッド | Antibodies with modified isoelectric points |
EP2603526A1 (en) | 2010-08-13 | 2013-06-19 | Medimmune Limited | Monomeric polypeptides comprising variant fc regions and methods of use |
PE20140135A1 (en) | 2010-08-20 | 2014-02-20 | Wyeth Llc | OSTEOGENIC DESIGN PROTEIN |
US9688735B2 (en) | 2010-08-20 | 2017-06-27 | Wyeth Llc | Designer osteogenic proteins |
CN102380091A (en) | 2010-08-31 | 2012-03-21 | 健能隆医药技术(上海)有限公司 | Application of interleukin-22 in curing virus hepatitis |
EP2616487B1 (en) | 2010-09-14 | 2015-03-25 | F.Hoffmann-La Roche Ag | Serpin-finger fusion polypeptide |
EP2619226B1 (en) | 2010-09-22 | 2018-09-12 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
US9228023B2 (en) | 2010-10-01 | 2016-01-05 | Oxford Biotherapeutics Ltd. | Anti-ROR1 antibodies and methods of use for treatment of cancer |
US9445990B2 (en) | 2010-10-06 | 2016-09-20 | Medtronic, Inc. | TNF inhibitor formulation for use in implantable infusion devices |
WO2012061129A1 (en) | 2010-10-25 | 2012-05-10 | Genentech, Inc | Treatment of gastrointestinal inflammation and psoriasis a |
EA030436B1 (en) | 2010-11-04 | 2018-08-31 | Бёрингер Ингельхайм Интернациональ Гмбх | ANTI-IL-23p19 ANTIBODIES OR ANTIGEN-BINDING FRAGMENTS THEREOF, USE THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING THESE ANTIBODIES, METHOD FOR PRODUCING SAME, ISOLATED POLYNUCLEOTIDES, EXPRESSION VECTORS AND CELLS FOR PRODUCING ANTIBODIES |
US9023791B2 (en) | 2010-11-19 | 2015-05-05 | Novartis Ag | Fibroblast growth factor 21 mutations |
WO2012080769A1 (en) | 2010-12-15 | 2012-06-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-cd277 antibodies and uses thereof |
PT2654781T (en) | 2010-12-21 | 2018-05-02 | Oklahoma Med Res Found | Anti-p-selectin antibodies and methods of their use and identification |
US20130273062A1 (en) | 2010-12-22 | 2013-10-17 | Orega Biotech | Antibodies against human cd39 and use thereof |
JOP20210044A1 (en) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | Anti-cd38 antibodies |
WO2012102679A1 (en) | 2011-01-24 | 2012-08-02 | National University Of Singapore | Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins |
WO2012101125A1 (en) | 2011-01-24 | 2012-08-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Specific antibodies against human cxcl4 and uses thereof |
TW201238976A (en) | 2011-02-23 | 2012-10-01 | Hoffmann La Roche | Antibodies against human IL33R and uses thereof |
EP3235508B1 (en) | 2011-03-16 | 2020-12-30 | Sanofi | Compositions comprising a dual v region antibody-like protein |
EP3590969A1 (en) | 2011-03-31 | 2020-01-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies directed against icos and uses thereof |
CN103619881B (en) | 2011-04-07 | 2017-07-28 | 安姆根有限公司 | New EGFR associated proteins |
EP2699598B1 (en) | 2011-04-19 | 2019-03-06 | Pfizer Inc | Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer |
CA2833935C (en) | 2011-05-04 | 2020-09-15 | Dhanapalan Nagarathnam | Novel compounds as modulators of protein kinases |
JOP20200043A1 (en) | 2011-05-10 | 2017-06-16 | Amgen Inc | Methods of treating or preventing cholesterol related disorders |
KR102011924B1 (en) | 2011-05-18 | 2019-08-21 | 메더리스 다이어비티즈, 엘엘씨 | Improved peptide pharmaceuticals for insulin resistance |
CN108892709A (en) | 2011-05-18 | 2018-11-27 | 欧莫德里斯制药公司 | The peptide medicine of improvement |
US9127065B2 (en) | 2011-05-19 | 2015-09-08 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Anti-human HER3 antibodies and uses thereof |
WO2012166622A1 (en) | 2011-05-27 | 2012-12-06 | Baxter International Inc. | Therapeutic proteins with increased half-life and methods of preparing same |
SG10201902706VA (en) | 2011-06-03 | 2019-04-29 | Xoma Technology Ltd | Antibodies specific for tgf-beta |
PT3412305T (en) | 2011-06-10 | 2021-01-29 | Baxalta Inc | Treatment of coagulation disease by administration of recombinant vwf |
WO2012174056A1 (en) | 2011-06-13 | 2012-12-20 | Neumedicines, Inc. | Mitigation of cutaneous injury with il-12 |
WO2012178063A1 (en) | 2011-06-23 | 2012-12-27 | The Regents Of The University Of Michigan | Compound and method for modulating opioid receptor activity |
EP2543679A1 (en) | 2011-07-08 | 2013-01-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies for the treatment and prevention of thrombosis |
EP2543678A1 (en) | 2011-07-08 | 2013-01-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies for the treatment and prevention of thrombosis |
EP2543677A1 (en) | 2011-07-08 | 2013-01-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies for the treatment and prevention of thrombosis |
EP2734546A1 (en) | 2011-07-18 | 2014-05-28 | Amgen Inc. | Apelin antigen-binding proteins and uses thereof |
US20140234330A1 (en) | 2011-07-22 | 2014-08-21 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
WO2013022855A1 (en) | 2011-08-05 | 2013-02-14 | Xencor, Inc. | Antibodies with modified isoelectric points and immunofiltering |
EP2744828A4 (en) | 2011-08-16 | 2014-12-31 | Univ Emory | Jaml specific binding agents, antibodies, and uses related thereto |
CN103890008A (en) | 2011-08-17 | 2014-06-25 | 霍夫曼-拉罗奇有限公司 | Inhibition of angiogenesis in refractory tumors |
US20140213512A1 (en) | 2011-08-31 | 2014-07-31 | Amgen Inc. | Method of Treating or Ameliorating Type 1 Diabetes Using FGF21 |
AU2012308302A1 (en) | 2011-09-14 | 2014-03-20 | Northwestern University | Nanoconjugates able to cross the blood-brain barrier |
MX353958B (en) | 2011-09-22 | 2018-02-07 | Amgen Inc | Cd27l antigen binding proteins. |
TW201315742A (en) | 2011-09-26 | 2013-04-16 | Novartis Ag | Dual fuction proteins for treating metabolic disorders |
WO2013053076A1 (en) | 2011-10-10 | 2013-04-18 | Zensun (Shanghai)Science & Technology Limited | Compositions and methods for treating heart failure |
US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
JP6310394B2 (en) | 2011-10-10 | 2018-04-11 | ゼンコア インコーポレイテッド | Methods for purifying antibodies |
US8999325B2 (en) | 2011-10-13 | 2015-04-07 | Aerpio Therapeutics, Inc | Treatment of ocular disease |
WO2013056240A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome and cancer |
US9522951B2 (en) | 2011-10-31 | 2016-12-20 | Bristol-Myers Squibb Company | Fibronectin binding domains with reduced immunogenicity |
CN112812183A (en) | 2011-11-16 | 2021-05-18 | 勃林格殷格翰国际有限公司 | anti-IL-36R antibodies |
SG11201402619VA (en) | 2011-11-23 | 2014-10-30 | Igenica Biotherapeutics Inc | Anti-cd98 antibodies and methods of use thereof |
JP2015502368A (en) | 2011-12-16 | 2015-01-22 | カロス セラピューティクス,インコーポレーテッド | Methods and uses of ANP (atrial natriuretic peptide), BNP (brain natriuretic peptide) and CNP (C-type natriuretic peptide) -related peptides and their derivatives for the treatment of retinal disorders and diseases |
EP2793944A4 (en) | 2011-12-23 | 2015-09-02 | Nicholas B Lydon | Immunoglobulins and variants directed against pathogenic microbes |
US9988439B2 (en) | 2011-12-23 | 2018-06-05 | Nicholas B. Lydon | Immunoglobulins and variants directed against pathogenic microbes |
US9636381B2 (en) | 2012-01-18 | 2017-05-02 | Neumedicines, Inc. | Methods for radiation protection by administering IL-12 |
CA2861392C (en) | 2012-01-26 | 2021-08-17 | Christopher J. Soares | Peptide antagonists of the calcitonin cgrp family of peptide hormones and their use |
KR20140133590A (en) | 2012-03-05 | 2014-11-19 | 길리아드 칼리스토가 엘엘씨 | Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one |
JP6200437B2 (en) | 2012-03-16 | 2017-09-20 | ユニバーシティ ヘルス ネットワーク | Methods and compositions for modulating TOSO activity |
NZ629130A (en) | 2012-03-21 | 2016-10-28 | Baxalta Inc | Tfpi inhibitors and methods of use |
US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
CA2865719C (en) | 2012-03-30 | 2020-09-22 | Rhizen Pharmaceuticals Sa | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases |
CA2868883C (en) | 2012-03-30 | 2022-10-04 | Sorrento Therapeutics Inc. | Fully human antibodies that bind to vegfr2 |
WO2013151649A1 (en) | 2012-04-04 | 2013-10-10 | Sialix Inc | Glycan-interacting compounds |
US10385395B2 (en) | 2012-04-11 | 2019-08-20 | The Regents Of The University Of California | Diagnostic tools for response to 6-thiopurine therapy |
EP2838566A2 (en) | 2012-04-16 | 2015-02-25 | Cantab Biopharmaceuticals Patents Limited | Optimised subcutaneous therapeutic agents |
EA039663B1 (en) | 2012-05-03 | 2022-02-24 | Амген Инк. | Use of an anti-pcsk9 antibody for lowering serum cholesterol ldl and treating cholesterol related disorders |
CN109206516A (en) | 2012-05-03 | 2019-01-15 | 勃林格殷格翰国际有限公司 | Anti-il-23 p 19 antibodies |
US9441039B2 (en) | 2012-05-07 | 2016-09-13 | Amgen Inc. | Anti-erythropoietin antibodies |
CA2873511A1 (en) | 2012-05-17 | 2013-11-21 | Ra Pharmaceuticals, Inc. | Peptide and peptidomimetic inhibitors |
JO3623B1 (en) | 2012-05-18 | 2020-08-27 | Amgen Inc | St2 antigen binding proteins |
AU2013267161A1 (en) | 2012-05-31 | 2014-11-20 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
AU2013274347B2 (en) | 2012-06-11 | 2018-03-08 | Amgen Inc. | Dual receptor antagonistic antigen-binding proteins and uses thereof |
US10377827B2 (en) | 2012-06-21 | 2019-08-13 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind c-met |
JP6438391B2 (en) | 2012-06-22 | 2018-12-12 | ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. | Antigen binding protein that binds to CCR2 |
US9676847B2 (en) | 2012-06-25 | 2017-06-13 | Orega Biotech | IL-17 antagonist antibodies |
EP2877490B1 (en) | 2012-06-27 | 2018-09-05 | The Trustees of Princeton University | Split inteins, conjugates and uses thereof |
WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
ES2791778T3 (en) | 2012-08-01 | 2020-11-05 | Ikaika Therapeutics Llc | Mitigation of tissue damage and fibrosis through anti-LTBP4 antibodies |
WO2014022759A1 (en) | 2012-08-03 | 2014-02-06 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
WO2014033327A1 (en) | 2012-09-03 | 2014-03-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies directed against icos for treating graft-versus-host disease |
TWI595007B (en) | 2012-09-10 | 2017-08-11 | Neotope Biosciences Ltd | Anti-mcam antibodies and associated methods of use |
DK2892547T3 (en) | 2012-09-10 | 2020-10-26 | Xencor Inc | DOMINANT, NEGATIVE TNF-ALPHA INHIBITOR FOR USE IN THE TREATMENT OF NEUROLOGICAL CNS DISORDERS |
WO2014059028A1 (en) | 2012-10-09 | 2014-04-17 | Igenica, Inc. | Anti-c16orf54 antibodies and methods of use thereof |
WO2014079886A1 (en) | 2012-11-20 | 2014-05-30 | Sanofi | Anti-ceacam5 antibodies and uses thereof |
MX360816B (en) | 2012-11-20 | 2018-11-15 | Mederis Diabetes Llc | Improved peptide pharmaceuticals for insulin resistance. |
EP3444281B1 (en) | 2012-11-20 | 2021-11-03 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals |
TW201425336A (en) | 2012-12-07 | 2014-07-01 | Amgen Inc | BCMA antigen binding proteins |
EA201690004A1 (en) | 2012-12-27 | 2016-07-29 | Санофи | ANTIBODIES AGAINST LAMP1 AND CONJUGATES ANTIBODIES AND MEDICINES AND THEIR APPLICATION |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
AU2014205086B2 (en) | 2013-01-14 | 2019-04-18 | Xencor, Inc. | Novel heterodimeric proteins |
US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
EP2945969A1 (en) | 2013-01-15 | 2015-11-25 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
JO3519B1 (en) | 2013-01-25 | 2020-07-05 | Amgen Inc | Antibody constructs for CDH19 and CD3 |
ES2728936T3 (en) | 2013-01-25 | 2019-10-29 | Amgen Inc | Antibodies directed against CDH19 for melanoma |
EP2951206A2 (en) | 2013-02-01 | 2015-12-09 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins |
MX2015009901A (en) | 2013-02-01 | 2016-04-06 | Santa Maria Biotherapeutics Inc | Administration of an anti-activin-a compound to a subject. |
US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
JOP20140087B1 (en) | 2013-03-13 | 2021-08-17 | Amgen Inc | Proteins specific for baff and b7rp1 and uses thereof |
US9580486B2 (en) | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
TR201809571T4 (en) | 2013-03-15 | 2018-07-23 | Hoffmann La Roche | IL-22 polypeptides and IL-22 fc fusion proteins and methods of use. |
PT3611180T (en) | 2013-03-15 | 2022-03-15 | Biomolecular Holdings Llc | Hybrid immunoglobulin containing non-peptidyl linkage |
US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
US9505849B2 (en) | 2013-03-15 | 2016-11-29 | Amgen Research (Munich) Gmbh | Antibody constructs for influenza M2 and CD3 |
CN111138543A (en) | 2013-03-15 | 2020-05-12 | Xencor股份有限公司 | Heterodimeric proteins |
US9260527B2 (en) | 2013-03-15 | 2016-02-16 | Sdix, Llc | Anti-human CXCR4 antibodies and methods of making same |
EP3421495A3 (en) | 2013-03-15 | 2019-05-15 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
MX359794B (en) | 2013-03-15 | 2018-10-10 | Intrinsic Lifesciences Llc | Anti-hepcidin antibodies and uses thereof. |
US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
AR095596A1 (en) | 2013-03-15 | 2015-10-28 | Amgen Res (Munich) Gmbh | UNIQUE CHAIN UNION MOLECULES UNDERSTANDING N-TERMINAL ABP |
SG10201913751RA (en) | 2013-05-06 | 2020-03-30 | Scholar Rock Inc | Compositions and methods for growth factor modulation |
US10005839B2 (en) | 2013-05-17 | 2018-06-26 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Antagonist of the BTLA/HVEM interaction for use in therapy |
EA201592285A1 (en) | 2013-05-30 | 2016-05-31 | Байоджен Ма Инк. | ANTIGENSYCLING PROTEINS TO ONCOSTATIN M RECEPTOR |
TWI482782B (en) * | 2013-05-31 | 2015-05-01 | Univ Nat Chiao Tung | Antibody-conjugated double emulsion core-shell nano structure |
CN105683217B (en) | 2013-05-31 | 2019-12-10 | 索伦托治疗有限公司 | Antigen binding proteins that bind to PD-1 |
AU2013396206B2 (en) | 2013-06-28 | 2019-11-14 | Amgen Inc. | Methods for treating homozygous familial hypercholesterolemia |
AR097648A1 (en) | 2013-09-13 | 2016-04-06 | Amgen Inc | COMBINATION OF EPIGENETIC FACTORS AND BIESPECTIVE COMPOUNDS THAT HAVE LIKE DIANA CD33 AND CD3 IN THE TREATMENT OF MYELOID LEUKEMIA |
EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
WO2015049355A1 (en) | 2013-10-04 | 2015-04-09 | Roche Diagnostics Gmbh | Antibodies specifically binding to her3 |
PT3055331T (en) | 2013-10-11 | 2021-04-05 | Oxford Bio Therapeutics Ltd | Conjugated antibodies against ly75 for the treatment of cancer |
EP3057605A1 (en) | 2013-10-18 | 2016-08-24 | Novartis AG | Methods of treating diabetes and related disorders |
EP3733868A3 (en) | 2013-10-28 | 2021-01-13 | DOTS Technology Corp. | Allergen detection |
US10988745B2 (en) | 2013-10-31 | 2021-04-27 | Resolve Therapeutics, Llc | Therapeutic nuclease-albumin fusions and methods |
CN104623637A (en) | 2013-11-07 | 2015-05-20 | 健能隆医药技术(上海)有限公司 | Application of IL-22 dimer in preparation of intravenous injection drugs |
NZ736970A (en) | 2013-12-20 | 2018-11-30 | Gilead Calistoga Llc | Process methods for phosphatidylinositol 3-kinase inhibitors |
AU2014364414A1 (en) | 2013-12-20 | 2016-06-30 | Gilead Calistoga Llc | Polymorphic forms of a hydrochloride salt of (S) -2-(1-(9H-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3H) -one |
EP3094646B1 (en) | 2014-01-13 | 2020-04-15 | Valerion Therapeutics, LLC | Internalizing moieties |
BR112016017248A8 (en) | 2014-01-24 | 2018-04-17 | Ngm Biopharmaceuticals Inc | antibody or fragment thereof, binding agent, transgenic animal, hybridoma, vector, pharmaceutical composition, fgf19 and / or fgf21-like signaling induction method, method for activating a klotho beta / fgf receptor complex, method for improving metabolism of glucose in an individual, method of detecting klotho beta, use of antibody or fragment thereof, use of pharmaceutical composition, treatment method and method for improving metabolic parameters |
WO2016039801A1 (en) | 2014-01-31 | 2016-03-17 | Boehringer Ingelheim International Gmbh | Novel anti-baff antibodies |
US9701743B2 (en) | 2014-02-20 | 2017-07-11 | Allergan, Inc. | Complement component C5 antibodies |
JP6643244B2 (en) | 2014-02-27 | 2020-02-12 | アラーガン、インコーポレイテッドAllergan,Incorporated | Complement factor Bb antibody |
AU2015225867B2 (en) | 2014-03-07 | 2020-02-06 | University Health Network | Methods and compositions for modifying the immune response |
SI3701971T1 (en) | 2014-03-14 | 2023-01-31 | Biomolecular Holdings LLC, | Compounds useful in preparing hybrid immunoglobulin containing non-peptidyl linkage |
EP3954713A3 (en) | 2014-03-28 | 2022-03-30 | Xencor, Inc. | Bispecific antibodies that bind to cd38 and cd3 |
FR3020063A1 (en) | 2014-04-16 | 2015-10-23 | Gamamabs Pharma | ANTI-HER4 HUMAN ANTIBODY |
EP3131929B1 (en) | 2014-04-16 | 2022-06-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies for the prevention or the treatment of bleeding episodes |
MX371033B (en) | 2014-05-28 | 2020-01-13 | Mederis Diabetes Llc | Improved peptide pharmaceuticals for insulin resistance. |
PT3148581T (en) | 2014-05-30 | 2020-01-06 | Henlix Biotech Co Ltd | Anti-epidermal growth factor receptor (egfr) antibodies |
PT3628680T (en) | 2014-06-12 | 2021-10-07 | Ra Pharmaceuticals Inc | Modulation of complement activity |
CN106459005A (en) | 2014-06-13 | 2017-02-22 | 吉利德科学公司 | Phosphatidylinositol 3-kinase inhibitors |
US10562946B2 (en) | 2014-06-20 | 2020-02-18 | Genentech, Inc. | Chagasin-based scaffold compositions, methods, and uses |
AR101669A1 (en) | 2014-07-31 | 2017-01-04 | Amgen Res (Munich) Gmbh | ANTIBODY CONSTRUCTS FOR CDH19 AND CD3 |
JP6749312B2 (en) | 2014-07-31 | 2020-09-02 | アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH | Optimized interspecific bispecific single chain antibody constructs |
WO2016016415A1 (en) | 2014-07-31 | 2016-02-04 | Amgen Research (Munich) Gmbh | Bispecific single chain antibody construct with enhanced tissue distribution |
MX2017002380A (en) | 2014-08-22 | 2017-09-15 | Sorrento Therapeutics Inc | Antigen binding proteins that bind cxcr3. |
EA201790470A1 (en) | 2014-08-27 | 2017-07-31 | Эмджен Инк. | VARIANTS OF THE TISSUE INHIBITOR OF METALLOPROTEINAS TYPE THREE (TIPP-3), COMPOSITIONS AND METHODS |
WO2016049036A1 (en) | 2014-09-22 | 2016-03-31 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
EP3209778B1 (en) | 2014-10-24 | 2019-04-03 | Astrazeneca AB | Combination |
EP4183806A3 (en) | 2014-11-12 | 2023-08-02 | Seagen Inc. | Glycan-interacting compounds and methods of use |
US9879087B2 (en) | 2014-11-12 | 2018-01-30 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
JP2017537619A (en) | 2014-11-21 | 2017-12-21 | ノースウェスタン ユニバーシティ | Sequence-specific intracellular uptake of spherical nucleic acid nanoparticle complexes |
BR112017011166A2 (en) | 2014-11-26 | 2018-02-27 | Xencor, Inc. | heterodimeric antibodies that bind to cd3 and cd38 |
CA2967426A1 (en) | 2014-11-26 | 2016-06-02 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and tumor antigens |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
CN111018987B (en) | 2014-12-05 | 2023-11-21 | 鸿运华宁(杭州)生物医药有限公司 | Antibody capable of specifically binding to human endothelin receptor and application thereof |
CA2968352A1 (en) | 2014-12-08 | 2016-06-16 | Dana-Farber Cancer Institute, Inc. | Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents |
EP3230441A4 (en) | 2014-12-12 | 2018-10-03 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scaav |
US10239942B2 (en) | 2014-12-22 | 2019-03-26 | Pd-1 Acquisition Group, Llc | Anti-PD-1 antibodies |
WO2016105450A2 (en) | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
CN104524169A (en) * | 2014-12-25 | 2015-04-22 | 庞凤梅 | Traditional Chinese medicinal preparation for treating senile cough and asthma |
PT3240801T (en) | 2014-12-31 | 2021-02-18 | Checkmate Pharmaceuticals Inc | Combination tumor immunotherapy |
ES2824167T3 (en) | 2015-01-23 | 2021-05-11 | Sanofi Sa | Anti-CD3 antibodies, anti-CD123 antibodies, and bispecific antibodies that specifically bind to CD3 and / or CD123 |
JP6640229B2 (en) | 2015-01-28 | 2020-02-05 | ラ ファーマシューティカルズ インコーポレイテッドRa Pharmaceuticals,Inc. | Modulators of complement activity |
US10266584B2 (en) | 2015-02-09 | 2019-04-23 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Antibodies specific to glycoprotein (GP) of Ebolavirus and uses for the treatment and diagnosis of ebola virus infection |
JP6917902B2 (en) | 2015-02-13 | 2021-08-11 | ソレント・セラピューティクス・インコーポレイテッド | Antibody drug that binds to CTLA4 |
US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
US9951144B2 (en) | 2015-04-08 | 2018-04-24 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind CD38 |
MX2017012966A (en) | 2015-04-10 | 2018-06-06 | Amgen Inc | Interleukin-2 muteins for the expansion of t-regulatory cells. |
EP4276116A3 (en) | 2015-04-17 | 2024-01-17 | Amgen Research (Munich) GmbH | Bispecific antibody constructs for cdh3 and cd3 |
US20160347848A1 (en) | 2015-05-28 | 2016-12-01 | Medimmune Limited | Therapeutic combinations and methods for treating neoplasia |
EP3307253A4 (en) | 2015-06-12 | 2018-11-21 | Georgia State University Research Foundation, Inc. | Compositions and methods for treating opioid tolerance |
CN107849126B (en) | 2015-07-29 | 2022-04-08 | 阿勒根公司 | Heavy chain-only anti-ANG-2 antibodies |
TWI829617B (en) | 2015-07-31 | 2024-01-21 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for flt3 and cd3 |
TWI744242B (en) | 2015-07-31 | 2021-11-01 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for egfrviii and cd3 |
TWI717375B (en) | 2015-07-31 | 2021-02-01 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for cd70 and cd3 |
TWI793062B (en) | 2015-07-31 | 2023-02-21 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for dll3 and cd3 |
TWI796283B (en) | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for msln and cd3 |
WO2017030909A1 (en) | 2015-08-14 | 2017-02-23 | Allergan, Inc. | Heavy chain only antibodies to pdgf |
WO2017040566A1 (en) | 2015-09-01 | 2017-03-09 | Boehringer Ingelheim International Gmbh | Use of anti-cd40 antibodies for treatment of lupus nephritis |
TWI799366B (en) | 2015-09-15 | 2023-04-21 | 美商建南德克公司 | Cystine knot scaffold platform |
EP3352760A4 (en) | 2015-09-21 | 2019-03-06 | Aptevo Research and Development LLC | Cd3 binding polypeptides |
JP2018535655A (en) | 2015-09-29 | 2018-12-06 | アムジエン・インコーポレーテツド | ASGR inhibitor |
EA201890790A1 (en) | 2015-09-29 | 2018-10-31 | Селджин Корпорейшн | CONNECTING PD-1 PROTEINS AND METHODS OF THEIR APPLICATION |
US20180280474A1 (en) | 2015-10-01 | 2018-10-04 | Amgen Inc. | Treatment of bile acid disorders |
WO2017062966A1 (en) | 2015-10-09 | 2017-04-13 | Florida State University Research Foundation, Inc. | Antibodies specific for 4,6-diamino-5-(formyulamino) pyrimidine and uses thereof |
US11207393B2 (en) | 2015-10-16 | 2021-12-28 | President And Fellows Of Harvard College | Regulatory T cell PD-1 modulation for regulating T cell effector immune responses |
IL258768B2 (en) | 2015-11-12 | 2023-11-01 | Siamab Therapeutics Inc | Glycan-interacting compounds and methods of use |
AU2016365423A1 (en) | 2015-12-04 | 2018-07-12 | The Regents Of The University Of California | Novel antibodies for the treatment of cancers |
EP3387013B1 (en) | 2015-12-07 | 2022-06-08 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and psma |
MX2018007352A (en) | 2015-12-16 | 2019-05-16 | Ra Pharmaceuticals Inc | Modulators of complement activity. |
JP6883590B2 (en) | 2016-01-29 | 2021-06-09 | ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. | Antigen-binding protein that binds to PD-L1 |
KR20180103084A (en) | 2016-02-03 | 2018-09-18 | 암젠 리서치 (뮌헨) 게엠베하 | BCMA and CD3 bispecific T cell engrafting antibody constructs |
EP3411404B1 (en) | 2016-02-03 | 2022-11-09 | Amgen Research (Munich) GmbH | Psma and cd3 bispecific t cell engaging antibody constructs |
EA039859B1 (en) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Bispecific antibody constructs binding egfrviii and cd3 |
JP7157981B2 (en) | 2016-03-07 | 2022-10-21 | チャールストンファーマ, エルエルシー | anti-nucleolin antibody |
CN109328069B (en) | 2016-04-15 | 2023-09-01 | 亿一生物医药开发(上海)有限公司 | Use of IL-22 in the treatment of necrotizing enterocolitis |
JOP20170091B1 (en) | 2016-04-19 | 2021-08-17 | Amgen Res Munich Gmbh | Administration of a bispecific construct binding to CD33 and CD3 for use in a method for the treatment of myeloid leukemia |
EP3448415A4 (en) | 2016-04-29 | 2019-11-06 | Araim Pharmaceuticals, Inc. | Tissue protective peptides for preventing and treating diseases and disorders associated with tissue damage |
KR20180133198A (en) | 2016-05-04 | 2018-12-13 | 암젠 인크 | Interleukin-2 mutein for proliferation of T-regulatory cells |
TWI826351B (en) | 2016-05-31 | 2023-12-21 | 大陸商鴻運華寧(杭州)生物醫藥有限公司 | R antibodies, their pharmaceutical compositions and uses |
MX2018015592A (en) | 2016-06-14 | 2019-04-24 | Xencor Inc | Bispecific checkpoint inhibitor antibodies. |
CA3029328A1 (en) | 2016-06-28 | 2018-01-04 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
WO2018013917A1 (en) | 2016-07-15 | 2018-01-18 | Takeda Pharmaceutical Company Limited | Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies |
TWI790206B (en) | 2016-07-18 | 2023-01-21 | 法商賽諾菲公司 | Bispecific antibody-like binding proteins specifically binding to cd3 and cd123 |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
ES2965087T3 (en) | 2016-09-02 | 2024-04-10 | Soares Christopher J | Use of CGRP receptor antagonists in the treatment of glaucoma |
JP2019534858A (en) | 2016-09-09 | 2019-12-05 | ジェネンテック, インコーポレイテッド | Selective peptide inhibitor of FRIZZLED |
EP3512885B1 (en) | 2016-09-16 | 2024-02-21 | Shanghai Henlius Biotech, Inc. | Anti-pd-1 antibodies |
US10766958B2 (en) | 2016-09-19 | 2020-09-08 | Celgene Corporation | Methods of treating vitiligo using PD-1 binding antibodies |
WO2018053405A1 (en) | 2016-09-19 | 2018-03-22 | Celgene Corporation | Methods of treating immune disorders using pd-1 binding proteins |
JP2019537621A (en) | 2016-10-04 | 2019-12-26 | フェアバンクス ファーマシューティカルズ,インコーポレイテッド | Anti-FSTL3 antibodies and uses thereof |
AU2017342559B2 (en) | 2016-10-14 | 2022-03-24 | Xencor, Inc. | Bispecific heterodimeric fusion proteins containing IL-15/IL-15Ralpha Fc-fusion proteins and PD-1 antibody fragments |
IL266023B1 (en) | 2016-10-14 | 2024-03-01 | Neomatrix Therapeutics Inc | Peptides Derived from Fibronectin with Improved Bioactivity and Reduced Susceptibility to Neutrophil Elastase Degradation for Use in Treating Wounds |
US11286295B2 (en) | 2016-10-20 | 2022-03-29 | Sanofi | Anti-CHIKV monoclonal antibodies directed against the E2 structural protein |
JP7136468B2 (en) | 2016-11-08 | 2022-09-13 | ユニバーシティ オブ マイアミ | Anti-Secretogranin III (SCG3) Antibodies and Uses Thereof |
EP3541847A4 (en) | 2016-11-17 | 2020-07-08 | Seattle Genetics, Inc. | Glycan-interacting compounds and methods of use |
CA3043333A1 (en) | 2016-12-07 | 2018-06-14 | Molecular Templates, Inc. | Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation |
MX2019006527A (en) | 2016-12-07 | 2019-08-01 | Ra Pharmaceuticals Inc | Modulators of complement activity. |
TWI788323B (en) | 2017-01-19 | 2023-01-01 | 丹麥商諾佛 儂迪克股份有限公司 | Apoc-ii mimetic peptides |
JOP20190189A1 (en) | 2017-02-02 | 2019-08-01 | Amgen Res Munich Gmbh | Low ph pharmaceutical composition comprising t cell engaging antibody constructs |
WO2018152496A1 (en) | 2017-02-17 | 2018-08-23 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Compositions and methods for the diagnosis and treatment of zika virus infection |
MA47812A (en) | 2017-03-03 | 2021-04-14 | Seagen Inc | COMPOUNDS INTERACTING WITH GLYCAN AND METHODS OF USE |
GB201703876D0 (en) | 2017-03-10 | 2017-04-26 | Berlin-Chemie Ag | Pharmaceutical combinations |
CN110382544B (en) | 2017-03-16 | 2023-12-22 | 先天制药公司 | Compositions and methods for treating cancer |
CN110461877A (en) | 2017-03-27 | 2019-11-15 | 勃林格殷格翰国际有限公司 | The anti-antibody combined treatment of IL-36R |
US10729741B2 (en) | 2017-03-27 | 2020-08-04 | Neomatrix Therapeutics Inc. | Methods of treating burns with i.v. cP12 in a window from 2 to 6 hours after injury |
EP3615569A1 (en) | 2017-04-25 | 2020-03-04 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Antibodies and methods for the diagnosis and treatment of epstein barr virus infection |
WO2018204907A1 (en) | 2017-05-05 | 2018-11-08 | Amgen Inc. | Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration |
US10793634B2 (en) | 2017-06-09 | 2020-10-06 | Boehringer Ingelheim International Gmbh | Anti-TrkB antibodies |
JP2020529832A (en) | 2017-06-30 | 2020-10-15 | ゼンコア インコーポレイテッド | Targeted heterodimer Fc fusion protein containing IL-15 / IL-15Rα and antigen binding domain |
CN111436193A (en) | 2017-07-07 | 2020-07-21 | 百深公司 | Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant VWF |
KR20200037251A (en) | 2017-07-07 | 2020-04-08 | 박스알타 인코퍼레이티드 | Treatment of patients with severe von Willebrand disease undergoing atmospheric surgery by administration of recombinant VWF |
CN111094334A (en) | 2017-07-19 | 2020-05-01 | 美国卫生与公众服务部 | Antibodies and methods for diagnosis and treatment of hepatitis B virus infection |
SG11202001311VA (en) | 2017-08-22 | 2020-03-30 | Sanabio Llc | Soluble interferon receptors and uses thereof |
US11673963B2 (en) | 2017-11-02 | 2023-06-13 | Oxford Biotherapeutics Ltd | CRTAM antibodies and methods of treating cancer |
EP3706793A1 (en) | 2017-11-08 | 2020-09-16 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-pd-1 sequences |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
JP7285267B2 (en) | 2017-11-14 | 2023-06-01 | アーセルクス インコーポレイテッド | D domain-containing polypeptides and uses thereof |
EP3724229A1 (en) | 2017-12-11 | 2020-10-21 | Amgen Inc. | Continuous manufacturing process for bispecific antibody products |
WO2019125732A1 (en) | 2017-12-19 | 2019-06-27 | Xencor, Inc. | Engineered il-2 fc fusion proteins |
TW201940518A (en) | 2017-12-29 | 2019-10-16 | 美商安進公司 | Bispecific antibody construct directed to MUC17 and CD3 |
US11440957B2 (en) | 2017-12-29 | 2022-09-13 | Alector Llc | Anti-TMEM106B antibodies and methods of use thereof |
EP3735295A1 (en) | 2018-01-03 | 2020-11-11 | Mederis Diabetes, LLC | Improved peptide pharmaceuticals for treatment of nash and other disorders |
PT3743088T (en) | 2018-01-26 | 2022-12-05 | Hoffmann La Roche | Compositions and methods of use |
MA51676A (en) | 2018-01-26 | 2021-05-05 | Hoffmann La Roche | IL-22 FC FUSION PROTEINS AND METHODS OF USE |
US11472874B2 (en) | 2018-01-31 | 2022-10-18 | Alector Llc | Anti-MS4A4A antibodies and methods of use thereof |
EP3752195A4 (en) | 2018-02-14 | 2021-11-17 | Viela Bio, Inc. | Antibodies to feline mcdonough sarcoma (fms)-like tyrosine kinase 3 receptor ligand (flt3l) and uses thereof for treating autoimmune and inflammatory diseases |
MX2020008502A (en) | 2018-02-21 | 2020-09-25 | Genentech Inc | DOSING FOR TREATMENT WITH IL-22 Fc FUSION PROTEINS. |
BR112020014591A2 (en) | 2018-03-14 | 2020-12-01 | Beijing Xuanyi Pharmasciences Co., Ltd. | anticlaudin antibodies 18.2 |
CN117126279A (en) | 2018-03-20 | 2023-11-28 | 鸿运华宁(杭州)生物医药有限公司 | GIPR antibody and fusion protein of GIPR antibody and GLP-1, and pharmaceutical composition and application thereof |
AU2019240135A1 (en) | 2018-03-21 | 2020-10-22 | Takeda Pharmaceutical Company Limited | Separation of VWF and VWF propeptide by chromatographic methods |
AU2019247415A1 (en) | 2018-04-04 | 2020-10-22 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
WO2019195561A2 (en) | 2018-04-06 | 2019-10-10 | BioLegend, Inc. | Anti-tetraspanin 33 agents and compositions and methods for making and using the same |
CN110357959B (en) | 2018-04-10 | 2023-02-28 | 鸿运华宁(杭州)生物医药有限公司 | GCGR antibody, fusion protein of GCGR antibody and GLP-1, and pharmaceutical composition and application of GCGR antibody and fusion protein |
AU2019256529A1 (en) | 2018-04-18 | 2020-11-26 | Xencor, Inc. | TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and TIM-3 antigen binding domains |
CA3097593A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
BR112020022035A2 (en) | 2018-04-30 | 2021-02-02 | Takeda Pharmaceutical Company Limited | type 1 (cb1) cannabinoid receptor binding proteins and uses thereof |
KR20210005097A (en) | 2018-04-30 | 2021-01-13 | 메디뮨 리미티드 | Conjugates that target and remove aggregates |
WO2019213416A1 (en) | 2018-05-02 | 2019-11-07 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection |
CA3098710A1 (en) | 2018-05-25 | 2019-11-28 | Alector Llc | Anti-sirpa antibodies and methods of use thereof |
CN110655577A (en) | 2018-06-13 | 2020-01-07 | 鸿运华宁(杭州)生物医药有限公司 | APJ antibody and fusion protein thereof with Elabela, and pharmaceutical composition and application thereof |
GB201809746D0 (en) | 2018-06-14 | 2018-08-01 | Berlin Chemie Ag | Pharmaceutical combinations |
EA202092518A1 (en) | 2018-06-18 | 2021-08-23 | Иннейт Фарма | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER |
MX2020013885A (en) | 2018-06-29 | 2021-03-09 | Boehringer Ingelheim Int | Anti-cd40 antibodies for use in treating autoimmune disease. |
CN112384532A (en) | 2018-06-29 | 2021-02-19 | 艾利妥 | anti-SIRP-beta 1 antibodies and methods of use thereof |
WO2020010079A2 (en) | 2018-07-02 | 2020-01-09 | Amgen Inc. | Anti-steap1 antigen-binding protein |
CA3060547A1 (en) | 2018-07-13 | 2020-01-13 | Alector Llc | Anti-sortilin antibodies and methods of use thereof |
WO2020021061A1 (en) | 2018-07-26 | 2020-01-30 | Pieris Pharmaceuticals Gmbh | Humanized anti-pd-1 antibodies and uses thereof |
JP2021532140A (en) | 2018-07-30 | 2021-11-25 | アムジェン リサーチ (ミュニック) ゲゼルシャフト ミット ベシュレンクテル ハフツング | Long-term administration of bispecific antibody constructs that bind to CD33 and CD3 |
MA53330A (en) | 2018-08-03 | 2021-06-09 | Amgen Inc | ANTIBODY CONSTRUCTIONS FOR CLDN18.2 AND CD3 |
MA53493A (en) | 2018-08-31 | 2021-07-07 | Alx Oncology Inc | POLYPEPTIDES LURES |
US10894824B2 (en) | 2018-09-24 | 2021-01-19 | Aerpio Pharmaceuticals, Inc. | Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF |
CN113365697A (en) | 2018-09-25 | 2021-09-07 | 百进生物科技公司 | anti-TLR9 agents and compositions and methods of making and using the same |
AU2019349958A1 (en) | 2018-09-28 | 2021-05-06 | Kyowa Kirin Co., Ltd. | IL-36 antibodies and uses thereof |
JP2022503959A (en) | 2018-10-03 | 2022-01-12 | ゼンコア インコーポレイテッド | IL-12 heterodimer FC-fusion protein |
JP2022512636A (en) | 2018-10-11 | 2022-02-07 | アムジエン・インコーポレーテツド | Downstream processing of bispecific antibody constructs |
MX2021008081A (en) | 2019-01-04 | 2021-08-05 | Resolve Therapeutics Llc | Treatment of sjogren's disease with nuclease fusion proteins. |
EP3918323A4 (en) | 2019-01-30 | 2022-12-28 | TrueBinding, Inc. | Anti-gal3 antibodies and uses thereof |
EA202192140A1 (en) | 2019-02-01 | 2021-12-15 | Такеда Фармасьютикал Компани Лимитед | METHODS OF PREVENTIVE TREATMENT WITH RECOMBINANT VWF (rVWF) |
US20220080053A1 (en) | 2019-02-07 | 2022-03-17 | Sanofi | Use of anti-ceacam5 immunoconjugates for treating lung cancer |
EP3693023A1 (en) | 2019-02-11 | 2020-08-12 | Sanofi | Use of anti-ceacam5 immunoconjugates for treating lung cancer |
WO2020180726A1 (en) | 2019-03-01 | 2020-09-10 | Xencor, Inc. | Heterodimeric antibodies that bind enpp3 and cd3 |
KR20220004979A (en) | 2019-03-27 | 2022-01-12 | 유엠씨 우트레크트 홀딩 비.브이. | Engineered IGA Antibodies and Methods of Use |
JP2022528721A (en) | 2019-04-09 | 2022-06-15 | アブクロ,インク. | Killer cell lectin-like receptor subfamily G member 1 (KLRG1) -removing antibody |
CA3130449A1 (en) | 2019-04-30 | 2020-11-05 | Gigagen, Inc. | Recombinant polyclonal proteins and methods of use thereof |
JOP20210300A1 (en) | 2019-05-09 | 2023-01-30 | Boehringer Ingelheim Int | Anti-sema3a antibodies and their uses for treating eye or ocular diseases |
TW202045711A (en) | 2019-06-13 | 2020-12-16 | 美商安進公司 | Automated biomass-based perfusion control in the manufacturing of biologics |
TW202115112A (en) | 2019-06-27 | 2021-04-16 | 德商百靈佳殷格翰國際股份有限公司 | Anti-angpt2 antibodies |
US20220372137A1 (en) | 2019-07-03 | 2022-11-24 | Oxford Biotherapeutics Ltd | Antibodies and methods of use |
CN112239507A (en) | 2019-07-17 | 2021-01-19 | 鸿运华宁(杭州)生物医药有限公司 | Fusion protein of ETA antibody and TGF-beta Trap, and pharmaceutical composition and application thereof |
CN112300279A (en) | 2019-07-26 | 2021-02-02 | 上海复宏汉霖生物技术股份有限公司 | Methods and compositions directed to anti-CD 73 antibodies and variants |
CA3145885A1 (en) | 2019-07-31 | 2021-02-04 | Jeonghoon Sun | Anti-ms4a4a antibodies and methods of use thereof |
US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
DE102019121007A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigen binding proteins that specifically bind to MAGE-A |
MX2022001866A (en) | 2019-08-13 | 2022-03-11 | Amgen Inc | Interleukin-2 muteins for the expansion of t-regulatory cells. |
MX2022002981A (en) | 2019-09-10 | 2022-04-06 | Amgen Inc | Purification method for bispecific antigen-binding polypeptides with enhanced protein l capture dynamic binding capacity. |
JP2022547556A (en) | 2019-09-11 | 2022-11-14 | 武田薬品工業株式会社 | Therapies involving the complex of von Willebrand factor and complement C1Q |
CN112521501A (en) | 2019-09-18 | 2021-03-19 | 鸿运华宁(杭州)生物医药有限公司 | GIPR antibody and fusion protein thereof with GLP-1, and pharmaceutical composition and application thereof |
TW202126685A (en) | 2019-09-24 | 2021-07-16 | 德商百靈佳殷格翰國際股份有限公司 | Anti-nrp1a antibodies and their uses for treating eye or ocular diseases |
CR20220244A (en) | 2019-11-04 | 2022-06-28 | Alector Llc | Siglec-9 ecd fusion molecules and methods of use thereof |
CA3156683A1 (en) | 2019-11-13 | 2021-05-20 | Amgen Inc. | Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules |
JP2023505169A (en) | 2019-12-03 | 2023-02-08 | エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Interferon-associated antigen binding protein for use in treating hepatitis B infection |
US20230242655A1 (en) | 2019-12-03 | 2023-08-03 | Evotec International Gmbh | Interferon-associated antigen binding proteins and uses thereof |
JP2023505256A (en) | 2019-12-05 | 2023-02-08 | ソレント・セラピューティクス・インコーポレイテッド | Compositions and methods comprising anti-CD47 antibodies in combination with tumor-targeting antibodies |
BR112022011570A2 (en) | 2019-12-13 | 2022-12-13 | Alector Llc | ANTI-MERTK ANTIBODIES AND METHODS OF THEIR USE |
JP2023507115A (en) | 2019-12-17 | 2023-02-21 | アムジエン・インコーポレーテツド | Dual interleukin-2/TNF receptor agonist for use in therapy |
EP4090365A1 (en) | 2020-01-15 | 2022-11-23 | Immatics Biotechnologies GmbH | Antigen binding proteins specifically binding prame |
EP4090681A1 (en) | 2020-01-17 | 2022-11-23 | Biolegend, Inc. | Anti-tlr7 agents and compositions and methods for making and using the same |
WO2021150824A1 (en) | 2020-01-22 | 2021-07-29 | Amgen Research (Munich) Gmbh | Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof |
AR121268A1 (en) | 2020-02-04 | 2022-05-04 | Takeda Pharmaceuticals Co | TREATMENT OF MENORRAGIA IN PATIENTS WITH SEVERE VON WILLEBRAND DISEASE BY ADMINISTRATION OF RECOMBINANT VWF |
CA3168986A1 (en) | 2020-02-26 | 2021-09-02 | Sorrento Therapeutics, Inc. | Activatable antigen binding proteins with universal masking moieties |
US20230146593A1 (en) | 2020-03-12 | 2023-05-11 | Amgen Inc. | Method for treatment and prophylaxis of crs in patients comprising a combination of bispecific antibodies binding to cds x cancer cell and tnf alpha or il-6 inhibitor |
WO2021195089A1 (en) | 2020-03-23 | 2021-09-30 | Sorrento Therapeutics, Inc. | Fc-coronavirus antigen fusion proteins, and nucleic acids, vectors, compositions and methods of use thereof |
EP4126937A1 (en) | 2020-03-31 | 2023-02-08 | Alector LLC | Anti-mertk antibodies and methods of use thereof |
WO2021207662A1 (en) | 2020-04-10 | 2021-10-14 | Genentech, Inc. | Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome |
BR112022020753A2 (en) | 2020-04-15 | 2022-12-20 | Voyager Therapeutics Inc | TAU-BINDING COMPOUNDS |
EP4138884A1 (en) | 2020-04-20 | 2023-03-01 | Sorrento Therapeutics, Inc. | Pulmonary administration of ace2 polypeptides |
WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
MX2022014636A (en) | 2020-05-19 | 2023-02-23 | Amgen Inc | Mageb2 binding constructs. |
CN115956087A (en) | 2020-05-26 | 2023-04-11 | 勃林格殷格翰国际有限公司 | anti-PD-1 antibodies |
JP2023527972A (en) | 2020-05-29 | 2023-07-03 | アムジエン・インコーポレーテツド | Reduced Adverse Effect Administration of Bispecific Constructs that Bind CD33 and CD3 |
CA3177152A1 (en) | 2020-06-12 | 2021-12-16 | David Scott Johnson | Recombinant polyclonal proteins targeting covid-19 and methods of use thereof |
JP2023532266A (en) | 2020-06-23 | 2023-07-27 | ジアンスー カニョン ファーマシューティカル カンパニー リミテッド | Anti-CD38 antibody and use thereof |
CN116209677A (en) | 2020-06-26 | 2023-06-02 | 索伦托药业有限公司 | anti-PD 1 antibodies and uses thereof |
EP4171614A1 (en) | 2020-06-29 | 2023-05-03 | Resolve Therapeutics, LLC | Treatment of sjogren's syndrome with nuclease fusion proteins |
WO2022031834A1 (en) | 2020-08-05 | 2022-02-10 | Gigagen, Inc. | Recombinant polyclonal proteins targeting zika and methods of use thereof |
BR112023001733A2 (en) | 2020-09-04 | 2023-03-28 | Merck Patent Gmbh | ANTI-CEACAM5 AND CONJUGATE ANTIBODIES AND THEIR USES |
US20220089759A1 (en) | 2020-09-21 | 2022-03-24 | Boehringer Ingelheim International Gmbh | Use of anti-cd40 antibodies for treatment of inflammatory conditions |
US20220127344A1 (en) | 2020-10-23 | 2022-04-28 | Boehringer Ingelheim International Gmbh | Anti-sema3a antibodies and their uses for treating a thrombotic disease of the retina |
WO2022093641A1 (en) | 2020-10-30 | 2022-05-05 | BioLegend, Inc. | Anti-nkg2a agents and compositions and methods for making and using the same |
WO2022093640A1 (en) | 2020-10-30 | 2022-05-05 | BioLegend, Inc. | Anti-nkg2c agents and compositions and methods for making and using the same |
JP2023547662A (en) | 2020-11-06 | 2023-11-13 | アムジェン リサーチ (ミュニック) ゲゼルシャフト ミット ベシュレンクテル ハフツング | Polypeptide constructs that selectively bind to CLDN6 and CD3 |
AU2021374839A1 (en) | 2020-11-06 | 2023-06-08 | Amgen Inc. | Multitargeting bispecific antigen-binding molecules of increased selectivity |
BR112023008670A2 (en) | 2020-11-06 | 2024-02-06 | Amgen Inc | POLYPEPTIDE CONSTRUCTS LINKED TO CD3 |
WO2022096704A1 (en) | 2020-11-06 | 2022-05-12 | Amgen Inc. | Antigen binding domain with reduced clipping rate |
AU2021403010A1 (en) | 2020-12-16 | 2023-07-13 | Voyager Therapeutics, Inc. | Tau binding compounds |
JP2024502832A (en) | 2020-12-31 | 2024-01-23 | アラマー バイオサイエンシーズ, インコーポレイテッド | Binding agent molecules with high affinity and/or specificity and methods for their production and use |
WO2022159575A1 (en) | 2021-01-20 | 2022-07-28 | Bioentre Llc | Ctla4-binding proteins and methods of treating cancer |
CN117440966A (en) | 2021-01-28 | 2024-01-23 | 塔勒姆治疗有限责任公司 | anti-SARS-CoV-2 spike glycoprotein antibody and therapeutic use thereof |
EP4288457A2 (en) | 2021-02-05 | 2023-12-13 | Boehringer Ingelheim International GmbH | Anti-il1rap antibodies |
EP4305067A1 (en) | 2021-03-09 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
WO2022192586A1 (en) | 2021-03-10 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
AU2022238571A1 (en) | 2021-03-18 | 2023-09-14 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
WO2022197947A1 (en) | 2021-03-18 | 2022-09-22 | Alector Llc | Anti-tmem106b antibodies and methods of use thereof |
EP4314063A1 (en) | 2021-03-23 | 2024-02-07 | Alector LLC | Anti-tmem106b antibodies for treating and preventing coronavirus infections |
WO2022204514A1 (en) | 2021-03-26 | 2022-09-29 | Abcuro, Inc. | Anti-klrg1 antibodies |
WO2022204529A1 (en) | 2021-03-26 | 2022-09-29 | Abcuro, Inc. | Anti-klrg1 antibodies |
CN115141276A (en) | 2021-03-31 | 2022-10-04 | 鸿运华宁(杭州)生物医药有限公司 | Antibody capable of being specifically combined with human endothelin receptor and application thereof in treatment of diabetic nephropathy and chronic nephropathy |
WO2022212836A1 (en) | 2021-04-01 | 2022-10-06 | Pyxis Oncology, Inc. | Gpnmb antibodies and methods of use |
AR125290A1 (en) | 2021-04-02 | 2023-07-05 | Amgen Inc | MAGEB2 JOINING CONSTRUCTIONS |
EP4334358A1 (en) | 2021-05-06 | 2024-03-13 | Amgen Research (Munich) GmbH | Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases |
IL308741A (en) | 2021-06-04 | 2024-01-01 | Boehringer Ingelheim Int | Anti-sirp-alpha antibodies |
WO2022261183A2 (en) | 2021-06-08 | 2022-12-15 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating and/or identifying an agent for treating intestinal cancers |
EP4351732A1 (en) | 2021-06-09 | 2024-04-17 | Evotec International GmbH | Interferon-associated antigen binding proteins for use for the treatment or prevention of coronavirus infection |
EP4355783A1 (en) | 2021-06-16 | 2024-04-24 | Alector LLC | Monovalent anti-mertk antibodies and methods of use thereof |
WO2022266223A1 (en) | 2021-06-16 | 2022-12-22 | Alector Llc | Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof |
WO2023009498A1 (en) | 2021-07-26 | 2023-02-02 | Abcuro, Inc. | Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies |
WO2023069919A1 (en) | 2021-10-19 | 2023-04-27 | Alector Llc | Anti-cd300lb antibodies and methods of use thereof |
WO2023097119A2 (en) | 2021-11-29 | 2023-06-01 | Dana-Farber Cancer Institute, Inc. | Methods and compositions to modulate riok2 |
TW202339804A (en) | 2021-12-02 | 2023-10-16 | 法商賽諾菲公司 | Cea assay for patient selection in cancer therapy |
WO2023099682A1 (en) | 2021-12-02 | 2023-06-08 | Sanofi | Ceacam5 adc–anti-pd1/pd-l1 combination therapy |
AR128065A1 (en) | 2021-12-22 | 2024-03-20 | Cdr Life Ag | ANTI-C3 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF AND THEIR USES TO TREAT OPHTHALMIC OR EYE DISEASES |
WO2023131901A1 (en) | 2022-01-07 | 2023-07-13 | Johnson & Johnson Enterprise Innovation Inc. | Materials and methods of il-1beta binding proteins |
WO2023170240A1 (en) | 2022-03-09 | 2023-09-14 | Merck Patent Gmbh | Anti-ceacam5 antibodies and conjugates and uses thereof |
WO2023172968A1 (en) | 2022-03-09 | 2023-09-14 | Merck Patent Gmbh | Anti-gd2 antibodies, immunoconjugates and therapeutic uses thereof |
WO2023218027A1 (en) | 2022-05-12 | 2023-11-16 | Amgen Research (Munich) Gmbh | Multichain multitargeting bispecific antigen-binding molecules of increased selectivity |
WO2023240287A1 (en) | 2022-06-10 | 2023-12-14 | Bioentre Llc | Combinations of ctla4 binding proteins and methods of treating cancer |
WO2023250388A1 (en) | 2022-06-22 | 2023-12-28 | Voyager Therapeutics, Inc. | Tau binding compounds |
WO2024013727A1 (en) | 2022-07-15 | 2024-01-18 | Janssen Biotech, Inc. | Material and methods for improved bioengineered pairing of antigen-binding variable regions |
WO2024020051A1 (en) | 2022-07-19 | 2024-01-25 | BioLegend, Inc. | Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same |
WO2024026447A1 (en) | 2022-07-29 | 2024-02-01 | Alector Llc | Anti-gpnmb antibodies and methods of use thereof |
WO2024040114A2 (en) | 2022-08-18 | 2024-02-22 | BioLegend, Inc. | Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same |
WO2024059675A2 (en) | 2022-09-14 | 2024-03-21 | Amgen Inc. | Bispecific molecule stabilizing composition |
WO2024081918A1 (en) | 2022-10-14 | 2024-04-18 | Talem Therapeutics Llc | Anti-trkb/cd3 antibodies and uses thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE343210B (en) * | 1967-12-20 | 1972-03-06 | Pharmacia Ab | |
US4167446A (en) * | 1973-03-15 | 1979-09-11 | Bayer Aktiengesellschaft | Water soluble carrier-bound penicillinacylase |
US3876501A (en) * | 1973-05-17 | 1975-04-08 | Baxter Laboratories Inc | Binding enzymes to activated water-soluble carbohydrates |
US3947352A (en) * | 1974-05-31 | 1976-03-30 | Pedro Cuatrecasas | Polysaccharide matrices for use as adsorbents in affinity chromatography techniques |
JPS54113492A (en) * | 1978-02-24 | 1979-09-05 | Sanyo Chem Ind Ltd | Preparation of glucoprotein derivative |
DE3271827D1 (en) * | 1981-05-01 | 1986-07-31 | Medical Research Inst Of San F | Method for isolating alpha-1-antitrypsin |
US4379087A (en) * | 1982-06-17 | 1983-04-05 | Cutter Laboratories, Inc. | Method of preparing alpha-1-proteinase inhibitor |
US4439358A (en) * | 1982-06-17 | 1984-03-27 | Miles Laboratories, Inc. | Method of preparing alpha-1-proteinase inhibitor |
JPS5959629A (en) * | 1982-09-27 | 1984-04-05 | Nippon Chem Res Kk | Sustained release composition |
-
1983
- 1983-12-27 US US06/565,810 patent/US4496689A/en not_active Expired - Lifetime
-
1984
- 1984-10-15 CA CA000465464A patent/CA1242664A/en not_active Expired
- 1984-10-26 JP JP59224243A patent/JPH0696541B2/en not_active Expired - Lifetime
- 1984-12-17 EP EP84115620A patent/EP0147761B1/en not_active Expired - Lifetime
- 1984-12-17 AT AT84115620T patent/ATE56025T1/en not_active IP Right Cessation
- 1984-12-17 DE DE8484115620T patent/DE3483094D1/en not_active Expired - Lifetime
- 1984-12-19 ES ES538807A patent/ES8605826A1/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
ES8605826A1 (en) | 1986-04-01 |
ES538807A0 (en) | 1986-04-01 |
EP0147761A2 (en) | 1985-07-10 |
EP0147761A3 (en) | 1986-07-30 |
EP0147761B1 (en) | 1990-08-29 |
JPH0696541B2 (en) | 1994-11-30 |
ATE56025T1 (en) | 1990-09-15 |
US4496689A (en) | 1985-01-29 |
JPS60178823A (en) | 1985-09-12 |
DE3483094D1 (en) | 1990-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1242664A (en) | COVALENTLY ATTACHED COMPLEX OF .alpha.-1-PROTEINASE INHIBITOR WITH A WATER SOLUBLE POLYMER | |
US4656254A (en) | Method of preparing alpha-1-proteinase inhibitor and antithrombin III | |
EP0221426B1 (en) | Method of preparing alpha-1-proteinase inhibitor | |
EP0097274B1 (en) | Method for separating alpha-1-proteinase inhibitor from blood plasma fractions | |
US5969040A (en) | Factor IX -- polymeric conjugates | |
EP0058993B1 (en) | Process for heat treatment of aqueous solution containing cold insoluble globulin | |
US4470969A (en) | Process for producing a concentrate of coagulation factors VII and VIIa | |
EP1762576B1 (en) | Process for separating alpha-1-proteinase inhibitor from Cohn Fraction IV1+IV4 paste | |
US4379087A (en) | Method of preparing alpha-1-proteinase inhibitor | |
CA2293806C (en) | Alpha 1-antitrypsin preparation as well as a method for producing the same | |
AU549584B2 (en) | Heat stabilization of plasma proteins | |
JP3650937B2 (en) | Process for the preparation of an inter-α-trypsin inhibitor concentrate for use in therapy, and the concentrate so obtained | |
EP0137356B1 (en) | Covalently bound heparin - antithrombin-iii complex, method for its preparation and its use for treating thromboembolism | |
US4473553A (en) | Process for producing a lipoprotein-poor concentrate of coagulation factors VII and VIIa | |
JPS59222421A (en) | Manufacture of antithrombic iii heparin concentrate | |
US4637932A (en) | Process for producing a concentrate enriched in coagulation factors VII and VIIa | |
EP0694562B1 (en) | Preparation of alpha-1-antichymotrypsin | |
EP0339919B1 (en) | Method for purifying antithrombin-III and antithrombin-III preparation containing said antithrombin-III | |
Hörl et al. | In vitro inhibition of protein catabolism by alpha2-macroglobulin in plasma from a patient with posttraumatic acute renal failure | |
Ohtani et al. | Purification of a capillary permeability increasing-enzyme from the venom of Agkistrodon caliginosus (Kankoku-Mamushi) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKEX | Expiry |